Kinase inhibitors and uses thereof
Inhibiting RIPK1 kinase activity with developed compounds addresses chronic inflammation and dysregulation, offering therapeutic benefits for diseases like neurodegeneration and cancer by modulating inflammatory responses and cell death pathways.
Patent Information
- Application Number
- CA3063934
- Authority / Receiving Office
- CA · CA
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2018-04-30
- Filing Date
- 2018-05-17
- Publication Date
- 2026-11-10
- Estimated Expiration
- 2038-05-17
AI Technical Summary
Chronic inflammation and dysregulation of receptor-interacting protein kinase 1 (RIPK1) signaling contribute to various human diseases, including neurodegeneration, rheumatoid arthritis, autoimmune diseases, and cancer, necessitating effective therapeutic interventions.
Development of compounds that inhibit RIPK1 kinase activity to modulate inflammatory responses and cell death pathways, formulated as pharmaceutical compositions for treating associated diseases.
The compounds effectively inhibit RIPK1, providing therapeutic benefits by reducing inflammation and cell death, thereby addressing the underlying mechanisms of these diseases.
Abstract
Description
KINASE INHIBITORS AND USES THEREOF CROSS-REFERENCES TO RELATED APPLICATIONS
[0001] The present application claims priority to U.S. Provisional Pat. Appl. No. 62 / 507,698, filed May 17, 2017, and U.S. Provisional Pat. Appl. No. 62 / 664,895, filed April 30, 2018. BACKGROUND
[0002] Although inflammation can be a protective mechanism in response to harmful stimuli such as invasion of pathogens and tissue damages, chronic inflammation is an important underlying factor in many human diseases such as neurodegeneration, rheumatoid arthritis, autoimmune and inflammatory diseases, and cancer. Similarly, the activation of cell death pathways, such as necrosis and apoptosis which are useful in eliminating infected or damaged cells, is also an important underlying mechanism for human diseases, including acute and chronic neurodegenerative diseases.
[0003] Receptor-interacting protein kinase 1 (UniProtKB Q13546) is a key regulator of inflammation, apoptosis and necroptosis. Receptor-interacting protein kinase 1 has an important role in modulating inflammatory responses mediated by nuclear-factor kappa-light chain enhancer of activated B cells (NF-kB). More recent research has shown that its kinase activity controls necroptosis, a form of necrotic cell death, which was traditionally thought to be passive and unregulated, and is characterized by a unique morphology. Further, receptor- interacting protein kinase 1 is part of a pro-apoptotic complex indicating its activity in regulating apoptosis.
[0004] The receptor-interacting protein kinase 1 is subject to complex and intricate regulatory mechanisms, including ubiquitylation, deubiquitylation, and phosphorylation. These regulatory events collectively determine whether a cell will survive and activate an inflammatory response or die through apoptosis or necroptosis. Dysregulation of receptor- interacting protein kinase 1 signaling can lead to excessive inflammation or cell death, and conversely, research has shown that inhibition of receptor interacting protein kinase 1 can be effective therapies for diseases involving inflammation or cell death. DESCRIPTION
[0005] In one aspect, provided herein are compounds that are useful as inhibitors of receptor-interacting protein kinase 1.
[0006] In another apect provided are methods for making the compounds and intermediates thereof.
[0007] In a related aspect, provided herein is a pharmaceutical composition comprising a compound as described herein and a pharmaceutically acceptable excipient.
[0008] In another aspect, provided herein is a method of inhibiting a receptor-interacting protein kinase 1. Further provided are methods for treating a receptor-interacting protein kinase 1-mediated disease or disorder comprising administering a therapeutically effective amount of a compound or a pharmaceutical composition as described herein to a subject in need thereof. The disclosure also provides uses of the compounds or compositions thereof in the manufacture of a medicament for the treatment of a disease, disorder or condition that is mediated by (or mediated, at least in part, by) receptor-interacting protein kinase. I. Definitions
[0009] As used herein, the term "alkyl," by itself or as part of another substituent, refers to a straight or branched, saturated, aliphatic radical having the number of carbon atoms indicated. Alkyl can include any number of carbons, such as C<com:Sub>1-2< / com:Sub>, C<com:Sub>1-3< / com:Sub>, C<com:Sub>1-4< / com:Sub>, C<com:Sub>1-5< / com:Sub>, C<com:Sub>1-6< / com:Sub>, C<com:Sub>1-7< / com:Sub>, C<com:Sub>1-8< / com:Sub>, C<com:Sub>1-9< / com:Sub>, C<com:Sub>1-10< / com:Sub>, C<com:Sub>2-3< / com:Sub>, C<com:Sub>2-4< / com:Sub>, C<com:Sub>2-5< / com:Sub>, C<com:Sub>2-6< / com:Sub>, C<com:Sub>3-4< / com:Sub>, C<com:Sub>3-5< / com:Sub>, C<com:Sub>3-6< / com:Sub>, C<com:Sub>4-5< / com:Sub>, C<com:Sub>4-6< / com:Sub> and C<com:Sub>5-6< / com:Sub>. For example, C<com:Sub>1-6< / com:Sub> alkyl includes, but is not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, hexyl, etc. Alkyl can also refer to alkyl groups having up to 20 carbons atoms, such as, but not limited to heptyl, octyl, nonyl, decyl, etc. Alkyl groups can be substituted or unsubstituted. Unless otherwise specified, "substituted alkyl" groups can be substituted with one or more halo, hydroxy, amino, alkylamino, amido, acyl, nitro, cyano, and / or alkoxy groups.
[0010] As used herein, the term "alkoxy," by itself or as part of another substituent, refers to a group having the formula -OR, wherein R is alkyl.
[0011] As used herein, the term "cycloalkyl," by itself or as part of another substituent, refers to a saturated or partially unsaturated, monocyclic, fused bicyclic or bridged polycyclic ring assembly containing from 3 to 12 ring atoms, or the number of atoms indicated. Cycloalkyl can include any number of carbons, such as C<com:Sub>3-6< / com:Sub>, C<com:Sub>4-6< / com:Sub>, C<com:Sub>5-6< / com:Sub>, C<com:Sub>3-8< / com:Sub>, C<com:Sub>4-8< / com:Sub>, C<com:Sub>5-8< / com:Sub>, C<com:Sub>6-8< / com:Sub>, C<com:Sub>3-9< / com:Sub>, C<com:Sub>3-10< / com:Sub>, C<com:Sub>3-11< / com:Sub>, and C<com:Sub>3-12< / com:Sub>. Saturated monocyclic cycloalkyl rings include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cyclooctyl. Saturated bicyclic and polycyclic cycloalkyl rings include, for example, norbornane, [2.2.2] bicyclooctane, decahydronaphthalene, and adamantane. Cycloalkyl groups can also be partially unsaturated, having one or more double or triple bonds in the ring. Representative cycloalkyl groups that are partially unsaturated include, but are not limited to, cyclobutene, cyclopentene, cyclohexene, cyclohexadiene (1,3- and 1,4-isomers), cycloheptene, cycloheptadiene, cyclooctene, cyclooctadiene (1,3-, 1,4- and 1,5-isomers), norbornene, and norbornadiene. When cycloalkyl is a saturated monocyclic C<com:Sub>3-8< / com:Sub> cycloalkyl, exemplary groups include, but are not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl. When cycloalkyl is a saturated monocyclic <com:Math><semantics>C3−6<annotation encoding="application / x-tex">C_{3-6}< / annotation>< / semantics>< / com:Math> cycloalkyl, exemplary groups include, but are not limited to cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. Cycloalkyl groups can be substituted or unsubstituted. Unless otherwise specified, "substituted cycloalkyl" groups can be substituted with one or more halo, hydroxy, amino, alkylamino, amido, acyl, nitro, cyano, and / or alkoxy groups. The term "lower cycloalkyl" refers to a cycloalkyl radical having from three to seven carbons including, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl.
[0012] As used herein, the term "heteroalkyl," by itself or as part of another substituent, refers to an alkyl group of any suitable length and having from 1 to 3 heteroatoms such as N, O and S, provided that the attachment of the substituent is at a carbon atom. For example, heteroalkyl can include ethers, thioethers and alkyl-amines. Additional heteroatoms can also be useful, including, but not limited to, B, Al, Si and P. The heteroatoms can be oxidized to form moieties such as, but not limited to, <com:Math><semantics>−S(O)<annotation encoding="application / x-tex">-S(O)< / annotation>< / semantics>< / com:Math>- and <com:Math><semantics>−S(O)2<annotation encoding="application / x-tex">-S(O)_2< / annotation>< / semantics>< / com:Math>-. The heteroatom portion of the heteroalkyl can replace a hydrogen of the alkyl group to form a hydroxy, thio, or amino group. Alternatively, the heteroatom portion can be inserted between two carbon atoms.
[0013] As used herein, the term "alkenyl," by itself or as part of another substituent, refers to a straight chain or branched hydrocarbon having at least 2 carbon atoms and at least one double bond. Alkenyl can include any number of carbons, such as C<com:Sub>2< / com:Sub>, C<com:Sub>2-3< / com:Sub>, C<com:Sub>2-4< / com:Sub>, C<com:Sub>2-5< / com:Sub>, C<com:Sub>2-6< / com:Sub>, C2-7, C2-8, C2-9, C2-10, C3, C3-4, C3-5, C3-6, C4, C4-5, C4-6, C5, C5-6, and C6. Alkenyl groups can have any suitable number of double bonds, including, but not limited to, 1, 2, 3, 4, 5 or more. Examples of alkenyl groups include, but are not limited to, vinyl (ethenyl), propenyl, isopropenyl, 1-butenyl, 2-butenyl, isobutenyl, butadienyl, 1-pentenyl, 2-pentenyl, isopentenyl, 1,3-pentadienyl, 1,4-pentadienyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 1,3-hexadienyl, 1,4-hexadienyl, 1,5-hexadienyl, 2,4-hexadienyl, or 1,3,5-hexatrienyl. Alkenyl groups can be substituted or unsubstituted. Unless otherwise specified, "substituted alkenyl" groups can be substituted with one or more halo, hydroxy, amino, alkylamino, amido, acyl, nitro, cyano, and / or alkoxy groups.
[0014] As used herein, the term "alkynyl," by itself or as part of another substituent refers, to either a straight chain or branched hydrocarbon having at least 2 carbon atoms and at least one triple bond. Alkynyl can include any number of carbons, such as C<com:Sub>2< / com:Sub>, C<com:Sub>2-3< / com:Sub>, C<com:Sub>2-4< / com:Sub>, C<com:Sub>2-5< / com:Sub>, C<com:Sub>2-6< / com:Sub>, C2-7, C2-8, C2-9, C2-10, C3, C3-4, C3-5, C3-6, C4, C4-5, C4-6, C5, C5-6, and C6. Examples of alkynyl groups include, but are not limited to, acetylenyl, propynyl, 1-butynyl, 2-butynyl, isobutynyl, sec-butynyl, butadiynyl, 1-pentynyl, 2-pentynyl, isopentynyl, 1,3-pentadiynyl, 1,4-pentadiynyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, 1,3-hexadiynyl, 1,4-hexadiynyl, 1,5-hexadiynyl, 2,4-hexadiynyl, or 1,3,5-hexatriynyl. Alkynyl groups can be substituted or unsubstituted. Unless otherwise specified, "substituted alkynyl" groups can be substituted with one or more halo, hydroxy, amino, alkylamino, amido, acyl, nitro, cyano, and / or alkoxy groups.
[0015] As used herein, the terms "halo" and "halogen," by themselves or as part of another substituent, refer to a fluorine, chlorine, bromine, or iodine atom.
[0016] As used herein, the term "haloalkyl," by itself or as part of another substituent, refers to an alkyl group where some or all of the hydrogen atoms are replaced with halogen atoms. As for alkyl groups, haloalkyl groups can have any suitable number of carbon atoms, such as C<com:Sub>1-6< / com:Sub>. For example, haloalkyl includes trifluoromethyl, fluoromethyl, etc. In some instances, the term "perfluoro" can be used to define a compound or radical where all the hydrogens are replaced with fluorine. For example, perfluoromethyl refers to 1,1,1-trifluoromethyl.
[0017] As used herein, the term "aryl," by itself or as part of another substituent, refers to an aromatic ring system having any suitable number of carbon ring atoms and any suitable number of rings. Aryl groups can include any suitable number of carbon ring atoms, such as C<com:Sub>6< / com:Sub>, C<com:Sub>7< / com:Sub>, C<com:Sub>8< / com:Sub>, C<com:Sub>9< / com:Sub>, C<com:Sub>10< / com:Sub>, C<com:Sub>11< / com:Sub>, C<com:Sub>12< / com:Sub>, C<com:Sub>13< / com:Sub>, C<com:Sub>14< / com:Sub>, C<com:Sub>15< / com:Sub> or C<com:Sub>16< / com:Sub>, as well as C<com:Sub>6-10< / com:Sub>, C<com:Sub>6-12< / com:Sub>, or C<com:Sub>6-14< / com:Sub>. Aryl groups can be monocyclic, fused to form bicyclic (e.g., benzocyclohexyl) or tricyclic groups, or linked by a bond to form a biaryl group. Representative aryl groups include phenyl, naphthyl and biphenyl. Other aryl groups include benzyl, having a methylene linking group. Some aryl groups have from 6 to 12 ring members, such as phenyl, naphthyl or biphenyl. Other aryl groups have from 6 to 10 ring members, such as phenyl or naphthyl. Some other aryl groups have 6 ring members, such as phenyl. Aryl groups can be substituted or unsubstituted. Unless otherwise specified, "substituted aryl" groups can be substituted with one or more halo, hydroxy, amino, alkylamino, amido, acyl, nitro, cyano, and / or alkoxy groups.
[0018] As used herein, the term "heteroaryl," by itself or as part of another substituent, refers to a monocyclic or fused bicyclic or tricyclic aromatic ring assembly containing 5 to 16 ring atoms, where from 1 to 5 of the ring atoms are heteroatoms such as N, O or S. Additional heteroatoms can also be useful, including, but not limited to, B, Al, Si and P. The heteroatoms can be oxidized to form moieties such as, but not limited to, <com:Math><semantics>−S(O)<annotation encoding="application / x-tex">-S(O)< / annotation>< / semantics>< / com:Math>- and <com:Math><semantics>−S(O)2<annotation encoding="application / x-tex">-S(O)_2< / annotation>< / semantics>< / com:Math>-. Heteroaryl groups can include any number of ring atoms, such as C<com:Sub>5-6< / com:Sub>, C<com:Sub>3-8< / com:Sub>, C<com:Sub>4-8< / com:Sub>, C<com:Sub>6-8< / com:Sub>, C<com:Sub>3-9< / com:Sub>, C<com:Sub>3-10< / com:Sub>, C<com:Sub>3-11< / com:Sub>, or C<com:Sub>3-12< / com:Sub>, wherein at least one of the carbon atoms is replaced by a heteroatom. Any suitable number of heteroatoms can be included in the heteroaryl groups, such as 1, 2, 3, 4; or 5, or 1 to 2, 1 to 3, 1 to 4, 1 to 5, 2 to 3, 2 to 4, 2 to 5, 3 to 4, or 3 to 5. For example, heteroaryl groups can be C<com:Sub>5-8< / com:Sub> heteroaryl, wherein 1 to 4 carbon ring atoms are replaced with heteroatoms; or C<com:Sub>5-8< / com:Sub> heteroaryl, wherein 1 to 3 carbon ring atoms are replaced with heteroatoms; or C<com:Sub>5-6< / com:Sub> heteroaryl, wherein 1 to 4 carbon ring atoms are replaced with heteroatoms; or C<com:Sub>5-6< / com:Sub> heteroaryl, wherein 1 to 3 carbon ring atoms are replaced with heteroatoms. The heteroaryl group can include groups such as pyrrole, pyridine, imidazole, pyrazole, triazole, tetrazole, pyrazine, pyrimidine, pyridazine, triazine (1,2,3-, 1,2,4- and 1,3,5-isomers), thiophene, furan, thiazole, isothiazole, oxazole, and isoxazole. The heteroaryl groups can also be fused to aromatic ring systems, such as a phenyl ring, to form members including, but not limited to, benzopyrroles such as indole and isoindole, benzopyridines such as quinoline and isoquinoline, benzopyrazine (quinoxaline), benzopyrimidine (quinazoline), benzopyridazines such as phthalazine and cinnoline, benzothiophene, and benzofuran. Other heteroaryl groups include heteroaryl rings linked by a bond, such as bipyridine. Heteroaryl groups can be substituted or unsubstituted. Unless otherwise specified, "substituted heteroaryl" groups can be substituted with one or more halo, hydroxy, amino, alkylamino, amido, acyl, nitro, cyano, and / or alkoxy groups.
[0019] The heteroaryl groups can be linked via any position on the ring. For example, pyrrole includes 1-, 2- and 3-pyrrole, pyridine includes 2-, 3- and 4-pyridine, imidazole includes 1-, 2-, 4- and 5-imidazole, pyrazole includes 1-, 3-, 4- and 5-pyrazole, triazole includes 1-, 4- and 5-triazole, tetrazole includes 1- and 5-tetrazole, pyrimidine includes 2-, 4-, 5- and 6- pyrimidine, pyridazine includes 3- and 4-pyridazine, 1,2,3-triazine includes 4- and 5-triazine, 1,2,4-triazine includes 3-, 5- and 6-triazine, 1,3,5-triazine includes 2-triazine, thiophene includes 2- and 3-thiophene, furan includes 2- and 3-furan, thiazole includes 2-, 4- and 5-thiazole, isothiazole includes 3-, 4- and 5-isothiazole, oxazole includes 2-, 4- and 5- oxazole, isoxazole includes 3-, 4- and 5-isoxazole, indole includes 1-, 2- and 3-indole, isoindole includes 1- and 2-isoindole, quinoline includes 2-, 3- and 4-quinoline, isoquinoline includes 1-, 3- and 4-isoquinoline, quinazoline includes 2- and 4-quinoazoline, cinnoline includes 3- and 4-cinnoline, benzothiophene includes 2- and 3-benzothiophene, and benzofuran includes 2- and 3-benzofuran.
[0020] Some heteroaryl groups include those having from 5 to 10 ring members and from 1 to 3 ring atoms including N, O or S, such as pyrrole, pyridine, imidazole, pyrazole, triazole, pyrazine, pyrimidine, pyridazine, triazine (1,2,3-, 1,2,4- and 1,3,5-isomers), thiophene, furan, thiazole, isothiazole, oxazole, isoxazole, indole, isoindole, quinoline, isoquinoline, quinoxaline, quinazoline, phthalazine, cinnoline, benzothiophene, and benzofuran. Other heteroaryl groups include those having from 5 to 8 ring members and from 1 to 3 heteroatoms, such as pyrrole, pyridine, imidazole, pyrazole, triazole, pyrazine, pyrimidine, pyridazine, triazine (1,2,3-, 1,2,4- and 1,3,5-isomers), thiophene, furan, thiazole, isothiazole, oxazole, and isoxazole. Some other heteroaryl groups include those having from 9 to 12 ring members and from 1 to 3 heteroatoms, such as indole, isoindole, quinoline, isoquinoline, quinoxaline, quinazoline, phthalazine, cinnoline, benzothiophene, benzofuran and bipyridine. Still other heteroaryl groups include those having from 5 to 6 ring members and from 1 to 2 ring atoms including N, O or S, such as pyrrole, pyridine, imidazole, pyrazole, pyrazine, pyrimidine, pyridazine, thiophene, furan, thiazole, isothiazole, oxazole, and isoxazole.
[0021] Some heteroaryl groups include from 5 to 10 ring members and only nitrogen heteroatoms, such as pyrrole, pyridine, imidazole, pyrazole, triazole, pyrazine, pyrimidine, pyridazine, triazine (1,2,3-, 1,2,4- and 1,3,5-isomers), indole, isoindole, quinoline, isoquinoline, quinoxaline, quinazoline, phthalazine, and cinnoline. Other heteroaryl groups include from 5 to 10 ring members and only oxygen heteroatoms, such as furan and benzofuran. Some other heteroaryl groups include from 5 to 10 ring members and only sulfur heteroatoms, such as thiophene and benzothiophene. Still other heteroaryl groups include from 5 to 10 ring members and at least two heteroatoms, such as imidazole, pyrazole, triazole, pyrazine, pyrimidine, pyridazine, triazine (1,2,3-, 1,2,4- and 1,3,5-isomers), thiazole, isothiazole, oxazole, isoxazole, quinoxaline, quinazoline, phthalazine, and cinnoline.
[0022] As used herein the term "heterocyclyl," by itself or as part of another substituent, refers to a saturated ring system having from 3 to 12 ring members and from 1 to 4 heteroatoms of N, O and S. Additional heteroatoms can also be useful, including, but not limited to, B, Al, Si and P. The heteroatoms can be oxidized to form moieties such as, but not limited to, -S(O)- and -S(O)<com:Sub>2< / com:Sub>-. Heterocyclyl groups can include any number of ring atoms, such as, C<com:Sub>3-6< / com:Sub>, C<com:Sub>4-6< / com:Sub>, C<com:Sub>5-6< / com:Sub>, C<com:Sub>3-8< / com:Sub>, C<com:Sub>4-8< / com:Sub>, C<com:Sub>5-8< / com:Sub>, C<com:Sub>6-8< / com:Sub>, C<com:Sub>3-9< / com:Sub>, C<com:Sub>3-10< / com:Sub>, C<com:Sub>3-11< / com:Sub>, or C<com:Sub>3-12< / com:Sub>, wherein at least one of the carbon atoms is replaced by a heteroatom. Any suitable number of carbon ring atoms can be replaced with heteroatoms in the heterocyclyl groups, such as 1, 2, 3, or 4, or 1 to 2, 1 to 3, 1 to 4, 2 to 3, 2 to 4, or 3 to 4. The heterocyclyl group can include groups such as aziridine, azetidine, pyrrolidine, piperidine, azepane, azocane, quinuclidine, pyrazolidine, imidazolidine, piperazine (1,2-, 1,3- and 1,4-isomers), oxirane, oxetane, tetrahydrofuran, oxane (tetrahydropyran), oxepane, thiirane, thietane, thiolane (tetrahydrothiophene), thiane (tetrahydrothiopyran), oxazolidine, isoxazolidine, thiazolidine, isothiazolidine, dioxolane, dithiolane, morpholine, thiomorpholine, dioxane, or dithiane. The heterocyclyl groups can also be fused to aromatic or non-aromatic ring systems to form members including, but not limited to, indoline. Heterocyclyl groups can be unsubstituted or substituted. Unless otherwise specified, "substituted heterocyclyl" groups can be substituted with one or more halo, hydroxy, amino, oxo (=O), alkylamino, amido, acyl, nitro, cyano, and / or alkoxy.
[0023] The heterocyclyl groups can be linked via any position on the ring. For example, aziridine can be 1- or 2-aziridine, azetidine can be 1- or 2- azetidine, pyrrolidine can be 1-, 2- or 3-pyrrolidine, piperidine can be 1-, 2-, 3- or 4-piperidine, pyrazolidine can be 1-, 2-, 3-, or 4-pyrazolidine, imidazolidine can be 1-, 2-, 3- or 4-imidazolidine, piperazine can be 1-, 2-, 3- or 4-piperazine, tetrahydrofuran can be 1- or 2-tetrahydrofuran, oxazolidine can be 2-, 3-, 4- or 5-oxazolidine, isoxazolidine can be 2-, 3-, 4- or 5-isoxazolidine, thiazolidine can be 2-, 3-, 4- or 5-thiazolidine, isothiazolidine can be 2-, 3-, 4- or 5- isothiazolidine, and morpholine can be 2-, 3- or 4-morpholine.
[0024] When heterocyclyl includes 3 to 8 ring members and 1 to 3 heteroatoms, representative members include, but are not limited to, pyrrolidine, piperidine, tetrahydrofuran, oxane, tetrahydrothiophene, thiane, pyrazolidine, imidazolidine, piperazine, oxazolidine, isoxazolidine, thiazolidine, isothiazolidine, morpholine, thiomorpholine, dioxane and dithiane. Heterocyclyl can also form a ring having 5 to 6 ring members and 1 to 2 heteroatoms, with representative members including, but not limited to, pyrrolidine, piperidine, tetrahydrofuran, tetrahydrothiophene, pyrazolidine, imidazolidine, piperazine, oxazolidine, isoxazolidine, thiazolidine, isothiazolidine, and morpholine.
[0025] As used herein, the term "carbonyl," by itself or as part of another substituent, refers to <com:Math><semantics>−C(O)<annotation encoding="application / x-tex">-C(O)< / annotation>< / semantics>< / com:Math>-, i.e., a carbon atom double-bonded to oxygen and bound to two other groups in the moiety having the carbonyl.
[0026] As used herein, the term "amino" refers to a moiety –NR<com:Sub>2< / com:Sub>, wherein each R group is H or alkyl. An amino moiety can be ionized to form the corresponding ammonium cation. "Dialkylamino" refers to an amino moiety wherein each R group is alkyl.
[0027] As used herein, the term "hydroxy" refers to the moiety –OH.
[0028] As used herein, the term "cyano" refers to a carbon atom triple-bonded to a nitrogen atom (i.e., the moiety <com:Math><semantics>−C≡N<annotation encoding="application / x-tex">-C \equiv N< / annotation>< / semantics>< / com:Math>).
[0029] As used herein, the term "carboxy" refers to the moiety -C(O)OH. A carboxy moiety can be ionized to form the corresponding carboxylate anion.
[0030] As used herein, the term "amido" refers to a moiety <com:Math><semantics>−NRC(O)R<annotation encoding="application / x-tex">-NRC(O)R< / annotation>< / semantics>< / com:Math> or <com:Math><semantics>−C(O)NR2<annotation encoding="application / x-tex">-C(O)NR_2< / annotation>< / semantics>< / com:Math>, wherein each R group is H or alkyl.
[0031] As used herein, the term "nitro" refers to the moiety –NO<com:Sub>2< / com:Sub>.
[0032] As used herein, the term "oxo" refers to an oxygen atom that is double-bonded to a compound (i.e., <com:Math><semantics>O=<annotation encoding="application / x-tex">O=< / annotation>< / semantics>< / com:Math>).
[0033] As used herein, the term "pharmaceutically acceptable excipient" refers to a substance that aids the administration of an active agent to a subject. By "pharmaceutically acceptable," it is meant that the excipient is compatible with the other ingredients of the formulation and is not deleterious to the recipient thereof. Pharmaceutical excipients useful in the present disclosure include, but are not limited to, binders, fillers, disintegrants, lubricants, glidants, coatings, sweeteners, flavors and colors.
[0034] As used herein, the term "salt" refers to acid or base salts of the compounds of the disclosed herein. Illustrative examples of pharmaceutically acceptable salts are mineral acid (hydrochloric acid, hydrobromic acid, phosphoric acid, and the like) salts, organic acid (acetic acid, propionic acid, glutamic acid, citric acid and the like) salts, quaternary ammonium (methyl iodide, ethyl iodide, and the like) salts. It is understood that the pharmaceutically acceptable salts are non-toxic.
[0035] Pharmaceutically acceptable salts of the acidic compounds disclosed herein are salts formed with bases, namely cationic salts such as alkali and alkaline earth metal salts, such as sodium, lithium, potassium, calcium, magnesium, as well as ammonium salts, such as ammonium, trimethyl-ammonium, diethylammonium, and tris-(hydroxymethyl)-methyl- ammonium salts.
[0036] Similarly acid addition salts, such as of mineral acids, organic carboxylic and organic sulfonic acids, e.g., hydrochloric acid, methanesulfonic acid, maleic acid, are also possible provided a basic group, such as pyridyl, constitutes part of the structure.
[0037] The neutral forms of the compounds can be regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner. The parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents, but otherwise the salts are equivalent to the parent form of the compound for the purposes of the present disclosure.
[0038] In addition to salt forms, described herein are compounds which are in a prodrug form. Prodrugs of the compounds described herein are those compounds that readily undergo chemical changes under physiological conditions to provide the compounds of the present disclosure. Additionally, prodrugs can be converted to the compounds of the present disclosure by chemical or biochemical methods in an ex vivo environment. For example, prodrugs can be slowly converted to the compounds of the present disclosure when placed in a transdermal patch reservoir with a suitable enzyme or chemical reagent.
[0039] Any compound or Formula given herein, is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds (i.e., "isotopic analogs"). Isotopically labeled compounds have structures depicted by the formulas given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number. Examples of isotopes that can be incorporated into the disclosed compounds include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, chlorine and iodine, such as <com:Sup>2< / com:Sup>H, <com:Sup>3< / com:Sup>H, <com:Sup>11< / com:Sup>C, <com:Sup>13< / com:Sup>C, <com:Sup>14< / com:Sup>C, <com:Sup>13< / com:Sup>N, <com:Sup>15< / com:Sup>N, <com:Sup>15< / com:Sup>O, <com:Sup>17< / com:Sup>O, <com:Sup>18< / com:Sup>O, <com:Sup>31< / com:Sup>P, <com:Sup>32< / com:Sup>P, <com:Sup>35< / com:Sup>S, <com:Sup>18< / com:Sup>F, <com:Sup>36< / com:Sup>Cl, <com:Sup>123< / com:Sup>I and <com:Sup>125< / com:Sup>I, respectively. Various isotopically labeled compounds of the present disclosure, for example those into which radioactive isotopes such as <com:Sup>3< / com:Sup>H, <com:Sup>13< / com:Sup>C and <com:Sup>14< / com:Sup>C are incorporated. Such isotopically labeled compounds may be useful in metabolic studies, reaction kinetic studies, detection or imaging techniques, such as positron emission tomography (PET) or single- photon emission computed tomography (SPECT) including drug or substrate tissue distribution assays or in radioactive treatment of patients.
[0040] The disclosure also includes "deuterated analogs" of compounds described herein in which from 1 to n hydrogens attached to a carbon atom is / are replaced by deuterium, in which n is the number of hydrogens in the molecule. Such compounds exhibit increased resistance to metabolism and are thus useful for increasing the half-life of any compound when administered to a mammal, particularly a human. See, for example, Foster, "Deuterium Isotope Effects in Studies of Drug Metabolism," Trends Pharmacol. Sci. 5(12):524-527 (1984). Such compounds are synthesized by means well known in the art, for example by employing starting materials in which one or more hydrogens have been replaced by deuterium.
[0041] Deuterium labeled or substituted therapeutic compounds of the disclosure may have improved DMPK (drug metabolism and pharmacokinetics) properties, relating to distribution, metabolism and excretion (ADME). Substitution with heavier isotopes such as deuterium may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life, reduced dosage requirements and / or an improvement in therapeutic index. An <com:Sup>18< / com:Sup>F, <com:Sup>3< / com:Sup>H, <com:Sup>11< / com:Sup>C labeled compound may be useful for PET or SPECT or other imaging studies. Isotopically labeled compounds of this disclosure and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the schemes or in the examples and preparations described below by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent. It is understood that deuterium in this context is regarded as a substituent in a compound described herein.
[0042] The concentration of such a heavier isotope, specifically deuterium, may be defined by an isotopic enrichment factor. In the compounds of this disclosure any atom not specifically designated as a particular isotope is meant to represent any stable isotope of that atom. Unless otherwise stated, when a position is designated specifically as "H" or "hydrogen", the position is understood to have hydrogen at its natural abundance isotopic composition. Accordingly, in the compounds of this disclosure any atom specifically designated as a deuterium (D) is meant to represent deuterium.
[0043] "Treatment" or "treating" is an approach for obtaining beneficial or desired results including clinical results. Beneficial or desired clinical results may include one or more of the following: a) inhibiting the disease or condition (e.g., decreasing one or more symptoms resulting from the disease or condition, and / or diminishing the extent of the disease or condition); b) slowing or arresting the development of one or more clinical symptoms associated with the disease or condition (e.g., stabilizing the disease or condition, preventing or delaying the worsening or progression of the disease or condition, and / or preventing or delaying the spread (e.g., metastasis) of the disease or condition); and / or c) relieving the disease, that is, causing the regression of clinical symptoms (e.g., ameliorating the disease state, providing partial or total remission of the disease or condition, enhancing effect of another medication, delaying the progression of the disease, increasing the quality of life, and / or prolonging survival.
[0044] "Prevention" or "preventing" means any treatment of a disease or condition that causes the clinical symptoms of the disease or condition not to develop. Compounds may, in some embodiments, be administered to a subject (including a human) who is at risk or has a family history of the disease or condition.
[0045] "Subject" refers to an animal, such as a mammal (including a human), that has been or will be the object of treatment, observation or experiment. The methods described herein may be useful in human therapy and / or veterinary applications. In some embodiments, the subject is a mammal. In one embodiment, the subject is a human.
[0046] The term "therapeutically effective amount" or "effective amount" of a compound described herein or a pharmaceutically acceptable salt, tautomer, stereoisomer, mixture of stereoisomers, prodrug, or deuterated analog thereof means an amount sufficient to effect treatment when administered to a subject, to provide a therapeutic benefit such as amelioration of symptoms or slowing of disease progression. For example, a therapeutically effective amount may be an amount sufficient to decrease a symptom of a disease or condition of as described herein. The therapeutically effective amount may vary depending on the subject, and disease or condition being treated, the weight and age of the subject, the severity of the disease or condition, and the manner of administering, which can readily be determined by one of ordinary skill in the art. II. Kinase Inhibitors
[0047] In one aspect, provided is a compound according to Formula A: [Image disponible dans le document PDF, Image available in the PDF document] (A), or a pharmaceutically acceptable salt, solvate, prodrug, isotopic analog, or isomer thereof, wherein <com:Math><semantics>W1<annotation encoding="application / x-tex">W^1< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>W2<annotation encoding="application / x-tex">W^2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>W3<annotation encoding="application / x-tex">W^3< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>W4<annotation encoding="application / x-tex">W^4< / annotation>< / semantics>< / com:Math> are independently N or <com:Math><semantics>CR7<annotation encoding="application / x-tex">CR^7< / annotation>< / semantics>< / com:Math>; R<com:Sup>1a< / com:Sup>, R<com:Sup>1b< / com:Sup>, and R<com:Sup>1c< / com:Sup> are independently hydrogen, [Image disponible dans le document PDF, Image available in the PDF document] C<com:Sub>2-8< / com:Sub> alkynyl, C<com:Sub>1-8< / com:Sub> heteroalkyl, C<com:Sub>3-8< / com:Sub> cycloalkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, C<com:Sub>1-8< / com:Sub> alkoxy, C<com:Sub>1-8< / com:Sub> haloalkoxy, 4- to 12-membered heterocyclyl, C<com:Sub>6-10< / com:Sub> aryl, 5- to 12- membered heteroaryl, <com:Math><semantics>−N(R1d)2<annotation encoding="application / x-tex">-N(R^{1d})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(O)R1e<annotation encoding="application / x-tex">-C(O)R^{1e}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(O)OR1d<annotation encoding="application / x-tex">-C(O)OR^{1d}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(O)N(R1d)2<annotation encoding="application / x-tex">-C(O)N(R^{1d})_2< / annotation>< / semantics>< / com:Math>, [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] -NR<com:Sup>1d< / com:Sup>S(O)<com:Sub>2< / com:Sub>N(R<com:Sup>1d< / com:Sup>)<com:Sub>2< / com:Sub>, wherein each of R<com:Sup>1a< / com:Sup>, R<com:Sup>1b< / com:Sup>, and R<com:Sup>1c< / com:Sup> is optionally and independently substituted with one or more (e.g., one to eight) <com:Math><semantics>R5<annotation encoding="application / x-tex">R^5< / annotation>< / semantics>< / com:Math> and at least one of R<com:Sup>1a< / com:Sup>, R<com:Sup>1b< / com:Sup>, and R<com:Sup>1c< / com:Sup> is other than hydrogen; or R<com:Sup>1b< / com:Sup> and R<com:Sup>1c< / com:Sup> are optionally taken together to form C<com:Sub>3-10< / com:Sub> cycloalkyl or 4- to 12- membered heterocyclyl, each of which is optionally substituted with one or more (e.g., one to eight) <com:Math><semantics>ℝ5<annotation encoding="application / x-tex">\mathbb{R}^5< / annotation>< / semantics>< / com:Math>; or R<com:Sup>1a< / com:Sup>, R<com:Sup>1b< / com:Sup>, and R<com:Sup>1c< / com:Sup> are optionally taken together to form C<com:Sub>5-10< / com:Sub> cycloalkyl or 5- to 12-membered heterocyclyl, each which is optionally substituted with one or more (e.g., one to eight) <com:Math><semantics>R5<annotation encoding="application / x-tex">R^5< / annotation>< / semantics>< / com:Math>; or <com:Math><semantics>R1a<annotation encoding="application / x-tex">R^{1a}< / annotation>< / semantics>< / com:Math> is absent and <com:Math><semantics>R1b<annotation encoding="application / x-tex">R^{1b}< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>R1c<annotation encoding="application / x-tex">R^{1c}< / annotation>< / semantics>< / com:Math> are taken together to form <com:Math><semantics>C6−10<annotation encoding="application / x-tex">C_{6-10}< / annotation>< / semantics>< / com:Math> aryl or 5- to 12-membered heteroaryl or 5- to 12-membered heterocyclyl, each of which is optionally substituted with one or more (e.g., one to eight) <com:Math><semantics>R5<annotation encoding="application / x-tex">R^5< / annotation>< / semantics>< / com:Math>; each R<com:Sup>1d< / com:Sup> is independently hydrogen, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, C<com:Sub>3-10< / com:Sub> cycloalkyl, or 4- to 12-membered heterocyclyl, or two R<com:Sup>1d< / com:Sup> on the same atom are optionally taken together to form a 4- to 8-membered heterocyclyl optionally substituted by oxo, halo, or C<com:Sub>1-6< / com:Sub> alkyl, wherein said alkyl is optionally substituted with one or more (e.g., one to eight) <com:Math><semantics>R5<annotation encoding="application / x-tex">R^5< / annotation>< / semantics>< / com:Math>; each R<com:Sup>1e< / com:Sup> is independently C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, C<com:Sub>3-10< / com:Sub> cycloalkyl, or 4- to 12-membered heterocyclyl; <com:Math><semantics>R2a<annotation encoding="application / x-tex">R^{2a}< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>R2b<annotation encoding="application / x-tex">R^{2b}< / annotation>< / semantics>< / com:Math> are independently hydrogen, halogen, <com:Math><semantics>C1−8<annotation encoding="application / x-tex">C_{1-8}< / annotation>< / semantics>< / com:Math> alkyl, <com:Math><semantics>C1−8<annotation encoding="application / x-tex">C_{1-8}< / annotation>< / semantics>< / com:Math> haloalkyl, C<com:Sub>2-8< / com:Sub> alkenyl, or C<com:Sub>2-8< / com:Sub> alkynyl, or <com:Math><semantics>R2a<annotation encoding="application / x-tex">R^{2a}< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>R2b<annotation encoding="application / x-tex">R^{2b}< / annotation>< / semantics>< / com:Math> are optionally taken together to form <com:Math><semantics>C3−6<annotation encoding="application / x-tex">C_{3-6}< / annotation>< / semantics>< / com:Math> cycloalkyl or 4- to 6-membered heterocyclyl, each of which is optionally substituted with one or more (e.g., one to eight) R<com:Sup>6< / com:Sup>; R<com:Sup>3a< / com:Sup> and R<com:Sup>3b< / com:Sup> are independently hydrogen, halogen, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>2-8< / com:Sub> alkenyl, C<com:Sub>2-8< / com:Sub> alkynyl, C<com:Sub>1-8< / com:Sub> haloalkyl, C<com:Sub>3-6< / com:Sub> cycloalkyl, or 4- to 6-membered heterocyclyl, wherein said cycloalkyl and said heterocyclyl are optionally substituted with one or more (e.g., one to eight) <com:Math><semantics>R6<annotation encoding="application / x-tex">R^6< / annotation>< / semantics>< / com:Math>, or R<com:Sup>3a< / com:Sup> and R<com:Sup>3b< / com:Sup> are optionally taken together to form oxo, C<com:Sub>3-6< / com:Sub> cycloalkyl, or 4- to 6-membered heterocyclyl, wherein said cycloalkyl and said heterocyclyl are optionally substituted with one or more (e.g., one to eight) <com:Math><semantics>R6<annotation encoding="application / x-tex">R^6< / annotation>< / semantics>< / com:Math>; Y is O, C(O), S, S(O), S(O)<com:Sub>2< / com:Sub>, <com:Math><semantics>CR4aR4b<annotation encoding="application / x-tex">CR^{4a}R^{4b}< / annotation>< / semantics>< / com:Math>, or <com:Math><semantics>NR4c<annotation encoding="application / x-tex">NR^{4c}< / annotation>< / semantics>< / com:Math>. R<com:Sup>4a< / com:Sup> and R<com:Sup>4b< / com:Sup> are independently hydrogen, halogen, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>2-8< / com:Sub> alkenyl, C<com:Sub>2-8< / com:Sub> alkynyl, C<com:Sub>1-8< / com:Sub> haloalkyl, C<com:Sub>3-6< / com:Sub> cycloalkyl, or 4- to 6-membered heterocyclyl, wherein said cycloalkyl and said heterocyclyl are optionally substituted with one or more (e.g., one to eight) <com:Math><semantics>R6<annotation encoding="application / x-tex">R^6< / annotation>< / semantics>< / com:Math>, or R<com:Sup>4a< / com:Sup> and R<com:Sup>4b< / com:Sup> are optionally taken together to form C<com:Sub>3-6< / com:Sub> cycloalkyl or 4- to 6-membered heterocyclyl, wherein said cycloalkyl and said heterocyclyl are optionally substituted with one or more <com:Math><semantics>(e.g.,onetoeight)R6<annotation encoding="application / x-tex">(e.g., one to eight) R^6< / annotation>< / semantics>< / com:Math>, or R<com:Sup>4a< / com:Sup> and R<com:Sup>1b< / com:Sup> are optionally taken together to form 4- to 12-membered heterocyclyl, which is optionally substituted with one or more (e.g., one to eight) R<com:Sup>6< / com:Sup>, or <com:Math><semantics>ℝ4a<annotation encoding="application / x-tex">\mathbb{R}^{4a}< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>ℝ3a<annotation encoding="application / x-tex">\mathbb{R}^{3a}< / annotation>< / semantics>< / com:Math> are optionally taken together to form <com:Math><semantics>ℂ3−8<annotation encoding="application / x-tex">\mathbb{C}_{3-8}< / annotation>< / semantics>< / com:Math> cycloalkyl or 4- to 12-membered heterocyclyl, each of which is optionally substituted with one or more (e.g., one to eight) <com:Math><semantics>R6<annotation encoding="application / x-tex">R^6< / annotation>< / semantics>< / com:Math>, or R<com:Sup>4c< / com:Sup> is hydrogen, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, C<com:Sub>3-10< / com:Sub> cycloalkyl, or 4- to 12-membered heterocyclyl; each R<com:Sup>5< / com:Sup> is independently halogen, -CN, -OH, -SF<com:Sub>5< / com:Sub>, -SCF<com:Sub>3< / com:Sub>, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>2-8< / com:Sub> alkenyl, C<com:Sub>2-8< / com:Sub> alkynyl, C<com:Sub>1-8< / com:Sub> haloalkyl, C<com:Sub>1-8< / com:Sub> heteroalkyl, C<com:Sub>3-8< / com:Sub> cycloalkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, C<com:Sub>1-8< / com:Sub> alkoxy, C<com:Sub>1-8< / com:Sub> haloalkoxy, 4- to 12-membered heterocyclyl, C<com:Sub>6-10< / com:Sub> aryl, 5- to 12-membered heteroaryl, (4- to 12-membered [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] substituted with one or more (e.g., one to eight) R<com:Sup>5c< / com:Sup>, or two <com:Math><semantics>ℝ5<annotation encoding="application / x-tex">\mathbb{R}^5< / annotation>< / semantics>< / com:Math> are optionally taken together to form oxo; each R<com:Sup>5a< / com:Sup> is independently hydrogen, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, C<com:Sub>3-10< / com:Sub> cycloalkyl, or 4- to 12-membered heterocyclyl, and each R<com:Sup>5b< / com:Sup> is independently C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, C<com:Sub>3-10< / com:Sub> cycloalkyl, 4- to 12-membered heterocyclyl, or 5- to 12-membered heteroaryl; each R<com:Sup>5c< / com:Sup> is independently halogen, cyano, C<com:Sub>1-8< / com:Sub> haloalkyl, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>1-8< / com:Sub> alkoxy, <com:Math><semantics>C1−8<annotation encoding="application / x-tex">C_{1-8}< / annotation>< / semantics>< / com:Math> haloalkoxy, <com:Math><semantics>(C1−8<annotation encoding="application / x-tex">(C_{1-8}< / annotation>< / semantics>< / com:Math> alkoxy)<com:Math><semantics>(C1−8<annotation encoding="application / x-tex">(C_{1-8}< / annotation>< / semantics>< / com:Math> alkoxy), hydroxyl, <com:Math><semantics>SR5d<annotation encoding="application / x-tex">SR^{5d}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>N(R5d)2<annotation encoding="application / x-tex">N(R^{5d})_2< / annotation>< / semantics>< / com:Math>, N(R<com:Sup>5d< / com:Sup>)<com:Sub>2< / com:Sub>(C<com:Sub>1-8< / com:Sub> alkoxy), C<com:Sub>3-10< / com:Sub> cycloalkyl, and 4- to 12-membered heterocyclyl, or two R<com:Sup>5c< / com:Sup> are optionally taken together to form oxo; each R<com:Sup>5d< / com:Sup> is independently hydrogen, C<com:Sub>1-8< / com:Sub> alkyl, or C<com:Sub>1-8< / com:Sub> haloalkyl; each R<com:Sup>6< / com:Sup> is halogen, -CN, -OH, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>1-8< / com:Sub> heteroalkyl, C<com:Sub>3-8< / com:Sub> cycloalkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, C<com:Sub>1-8< / com:Sub> alkoxy, 4- to 12-membered heterocyclyl, C<com:Sub>6-10< / com:Sub> aryl, [Image disponible dans le document PDF, Image available in the PDF document] <com:Math><semantics>−C(O)OR6a<annotation encoding="application / x-tex">-C(O)OR^{6a}< / annotation>< / semantics>< / com:Math>, or two <com:Math><semantics>ℝ6<annotation encoding="application / x-tex">\mathbb{R}^6< / annotation>< / semantics>< / com:Math> are taken together to form oxo; each R<com:Sup>6a< / com:Sup> is independently hydrogen, C<com:Sub>1-8< / com:Sub> alkyl, or C<com:Sub>1-8< / com:Sub> haloalkyl, or two R<com:Sup>6a< / com:Sup> on the same atom are optionally taken together to form 4- to 6-membered heterocyclyl; each R<com:Sup>6b< / com:Sup> is independently C<com:Sub>1-8< / com:Sub> alkyl or C<com:Sub>1-8< / com:Sub> haloalkyl; each R<com:Sup>7< / com:Sup> is independently hydrogen, halogen, -CN, -N<com:Sub>3< / com:Sub>, -NO<com:Sub>2< / com:Sub>, -SF<com:Sub>5< / com:Sub>, -SCF<com:Sub>3< / com:Sub>, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>2-8< / com:Sub> alkenyl, C<com:Sub>2-8< / com:Sub> alkynyl, C<com:Sub>1-8< / com:Sub> heteroalkyl, C<com:Sub>3-8< / com:Sub> cycloalkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, 4- to 12-membered heterocyclyl, C<com:Sub>6-10< / com:Sub> aryl, 5- to 12-membered [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] -NR<com:Sup>7a< / com:Sup>S(O)<com:Sub>2< / com:Sub>N(R<com:Sup>7a< / com:Sup>)<com:Sub>2< / com:Sub>, each of which is optionally and independently substituted with one or more (e.g., one to eight) <com:Math><semantics>ℝ8<annotation encoding="application / x-tex">\mathbb{R}^8< / annotation>< / semantics>< / com:Math>; each R<com:Sup>7a< / com:Sup> is independently hydrogen, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, C<com:Sub>3-10< / com:Sub> cycloalkyl, or 4- to 12-membered heterocyclyl, or two R<com:Sup>7a< / com:Sup> on the same atom are optionally taken together to form a 4- to 8-membered heterocyclyl optionally substituted by oxo, halo, or C<com:Sub>1-6< / com:Sub> alkyl, wherein said alkyl is optionally substituted with one or more (e.g., one to eight) <com:Math><semantics>ℝ8<annotation encoding="application / x-tex">\mathbb{R}^8< / annotation>< / semantics>< / com:Math>; each R<com:Sup>7b< / com:Sup> is independently C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, C<com:Sub>3-10< / com:Sub> cycloalkyl, or 4- to 12-membered heterocyclyl; each R<com:Sup>8< / com:Sup> is halogen, -CN, -OH, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>2-8< / com:Sub> alkenyl, C<com:Sub>2-8< / com:Sub> alkynyl, C<com:Sub>1-8< / com:Sub> heteroalkyl, C<com:Sub>3-8< / com:Sub> cycloalkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, C<com:Sub>1-8< / com:Sub> alkoxy, 4- to 12-membered heterocyclyl, <com:Math><semantics>C6−10<annotation encoding="application / x-tex">C_{6-10}< / annotation>< / semantics>< / com:Math> aryl, 5- to 12-membered heteroaryl, <com:Math><semantics>−N(R8a)2<annotation encoding="application / x-tex">-N(R^{8a})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(O)R8b<annotation encoding="application / x-tex">-C(O)R^{8b}< / annotation>< / semantics>< / com:Math>, or <com:Math><semantics>−C(O)OR8a<annotation encoding="application / x-tex">-C(O)OR^{8a}< / annotation>< / semantics>< / com:Math>, or two R<com:Sup>8< / com:Sup> are optionally taken together to form oxo; each R<com:Sup>8a< / com:Sup> is independently hydrogen, C<com:Sub>1-8< / com:Sub> alkyl, or C<com:Sub>1-8< / com:Sub> haloalkyl; each R<com:Sup>8b< / com:Sup> is independently C<com:Sub>1-8< / com:Sub> alkyl or C<com:Sub>1-8< / com:Sub> haloalkyl; Z is <com:Math><semantics>C(R9)2<annotation encoding="application / x-tex">C(R^9)_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C(O)<annotation encoding="application / x-tex">C(O)< / annotation>< / semantics>< / com:Math>, O, S, <com:Math><semantics>S(O)<annotation encoding="application / x-tex">S(O)< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>S(O)2<annotation encoding="application / x-tex">S(O)_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>S(O)NR9<annotation encoding="application / x-tex">S(O)NR^9< / annotation>< / semantics>< / com:Math>, or <com:Math><semantics>NR9<annotation encoding="application / x-tex">NR^9< / annotation>< / semantics>< / com:Math>; each R<com:Sup>9< / com:Sup> is independently hydrogen, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>2-8< / com:Sub> alkenyl, C<com:Sub>2-8< / com:Sub> alkynyl, <com:Math><semantics>C1−8<annotation encoding="application / x-tex">C_{1-8}< / annotation>< / semantics>< / com:Math> haloalkyl, <com:Math><semantics>C3−8<annotation encoding="application / x-tex">C_{3-8}< / annotation>< / semantics>< / com:Math> cycloalkyl, 4- to 8-membered heterocyclyl, or <com:Math><semantics>−C(O)R9a<annotation encoding="application / x-tex">-C(O)R^{9a}< / annotation>< / semantics>< / com:Math>; and R<com:Sup>9a< / com:Sup> is C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, C<com:Sub>3-8< / com:Sub> cycloalkyl, or 4- to 12-membered heterocyclyl, or R<com:Sup>9< / com:Sup> and R<com:Sup>3a< / com:Sup> are optionally taken together to form C<com:Sub>3-8< / com:Sub> cycloalkyl or 4- to 12-membered heterocyclyl, each of which is optionally substituted with one or more (e.g., one to eight) R<com:Sup>6< / com:Sup>.
[0048] In one aspect, provided is a compound according to Formula B: [Image disponible dans le document PDF, Image available in the PDF document] (B), or a pharmaceutically acceptable salt, solvate, prodrug, isotopic analog, or isomer thereof, wherein <com:Math><semantics>W1<annotation encoding="application / x-tex">W^1< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>W2<annotation encoding="application / x-tex">W^2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>W3<annotation encoding="application / x-tex">W^3< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>W4<annotation encoding="application / x-tex">W^4< / annotation>< / semantics>< / com:Math> are independently N or <com:Math><semantics>CR7<annotation encoding="application / x-tex">CR^7< / annotation>< / semantics>< / com:Math>; R<com:Sup>1a< / com:Sup>, R<com:Sup>1b< / com:Sup>, and R<com:Sup>1c< / com:Sup> are independently hydrogen, halogen, -CN, -N<com:Sub>3< / com:Sub>, -NO<com:Sub>2< / com:Sub>, -OH, -SF<com:Sub>5< / com:Sub>, -SCF<com:Sub>3< / com:Sub>, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>2-8< / com:Sub> alkenyl, C<com:Sub>2-8< / com:Sub> alkynyl, C<com:Sub>1-8< / com:Sub> heteroalkyl, C<com:Sub>3-8< / com:Sub> cycloalkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, C<com:Sub>1-8< / com:Sub> alkoxy, C<com:Sub>1-8< / com:Sub> haloalkoxy, 4- to 12-membered heterocyclyl, C<com:Sub>6-10< / com:Sub> aryl, 5- to 12- membered heteroaryl, <com:Math><semantics>−N(R1d)2<annotation encoding="application / x-tex">-N(R^{1d})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(O)R1e<annotation encoding="application / x-tex">-C(O)R^{1e}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(O)OR1d<annotation encoding="application / x-tex">-C(O)OR^{1d}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(O)N(R1d)2<annotation encoding="application / x-tex">-C(O)N(R^{1d})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NR1dC(O)R1e<annotation encoding="application / x-tex">-NR^{1d}C(O)R^{1e}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NR1dC(O)N(R1d)2<annotation encoding="application / x-tex">-NR^{1d}C(O)N(R^{1d})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NR1dC(O)OR1d<annotation encoding="application / x-tex">-NR^{1d}C(O)OR^{1d}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−OC(O)N(R1d)2<annotation encoding="application / x-tex">-OC(O)N(R^{1d})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−OC(O)OR1d<annotation encoding="application / x-tex">-OC(O)OR^{1d}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−SR1d<annotation encoding="application / x-tex">-SR^{1d}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(O)R1e<annotation encoding="application / x-tex">-S(O)R^{1e}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(O)2R1e<annotation encoding="application / x-tex">-S(O)_2R^{1e}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(O)3R1d<annotation encoding="application / x-tex">-S(O)_3R^{1d}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(O)N(R1d)2<annotation encoding="application / x-tex">-S(O)N(R^{1d})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(O)2N(R1d)2<annotation encoding="application / x-tex">-S(O)_2N(R^{1d})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NR1dS(O)R1e<annotation encoding="application / x-tex">-NR^{1d}S(O)R^{1e}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NR1dS(O)2R1e<annotation encoding="application / x-tex">-NR^{1d}S(O)_2R^{1e}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NR1dS(O)N(R1d)2<annotation encoding="application / x-tex">-NR^{1d}S(O)N(R^{1d})_2< / annotation>< / semantics>< / com:Math>, or -NR<com:Sup>1d< / com:Sup>S(O)<com:Sub>2< / com:Sub>N(R<com:Sup>1d< / com:Sup>)<com:Sub>2< / com:Sub>, wherein each of R<com:Sup>1a< / com:Sup>, R<com:Sup>1b< / com:Sup>, and R<com:Sup>1c< / com:Sup> is optionally and independently substituted with one or more (e.g., one to eight) <com:Math><semantics>R5<annotation encoding="application / x-tex">R^5< / annotation>< / semantics>< / com:Math> and at least one of R<com:Sup>1a< / com:Sup>, R<com:Sup>1b< / com:Sup>, and R<com:Sup>1c< / com:Sup> is other than hydrogen; or R<com:Sup>1b< / com:Sup> and R<com:Sup>1c< / com:Sup> are optionally taken together to form C<com:Sub>3-10< / com:Sub> cycloalkyl or 4- to 12-membered heterocyclyl, each of which is optionally substituted with one or more (e.g., one to eight) <com:Math><semantics>R5<annotation encoding="application / x-tex">R^5< / annotation>< / semantics>< / com:Math>; or R<com:Sup>1a< / com:Sup>, R<com:Sup>1b< / com:Sup>, and R<com:Sup>1c< / com:Sup> are optionally taken together to form C<com:Sub>5-10< / com:Sub> cycloalkyl, which is optionally substituted with one or more (e.g., one to eight) R<com:Sup>5< / com:Sup>; or R<com:Sup>1a< / com:Sup> is absent and R<com:Sup>1b< / com:Sup> and R<com:Sup>1c< / com:Sup> are taken together to form C<com:Sub>6-10< / com:Sub> aryl or 5- to 12-membered heteroaryl, each of which is optionally substituted with one or more (e.g., one to eight) <com:Math><semantics>R5<annotation encoding="application / x-tex">R^5< / annotation>< / semantics>< / com:Math>; each R<com:Sup>1d< / com:Sup> is independently hydrogen, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, C<com:Sub>3-10< / com:Sub> cycloalkyl, or 4- to 12-membered heterocyclyl, or two R<com:Sup>1d< / com:Sup> on the same atom are optionally taken together to form a 4- to 8-membered heterocyclyl optionally substituted by oxo, halo, or C<com:Sub>1-6< / com:Sub> alkyl, wherein said alkyl is optionally substituted with one or more (e.g., one to eight) <com:Math><semantics>R5<annotation encoding="application / x-tex">R^5< / annotation>< / semantics>< / com:Math>; each R<com:Sup>1e< / com:Sup> is independently C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, C<com:Sub>3-10< / com:Sub> cycloalkyl, or 4- to 12- membered heterocyclyl; <com:Math><semantics>ℝ2a<annotation encoding="application / x-tex">\mathbb{R}^{2a}< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>ℝ2b<annotation encoding="application / x-tex">\mathbb{R}^{2b}< / annotation>< / semantics>< / com:Math> are independently hydrogen, halogen, <com:Math><semantics>ℂ1−8<annotation encoding="application / x-tex">\mathbb{C}_{1-8}< / annotation>< / semantics>< / com:Math> alkyl, <com:Math><semantics>ℂ1−8<annotation encoding="application / x-tex">\mathbb{C}_{1-8}< / annotation>< / semantics>< / com:Math> haloalkyl, C<com:Sub>2-8< / com:Sub> alkenyl, or C<com:Sub>2-8< / com:Sub> alkynyl, or R<com:Sup>2a< / com:Sup> and R<com:Sup>2b< / com:Sup> are optionally taken together to form C<com:Sub>3-6< / com:Sub> cycloalkyl or 4- to 6-membered heterocyclyl, each of which is optionally substituted with one or more (e.g., one to eight) <com:Math><semantics>R6<annotation encoding="application / x-tex">R^6< / annotation>< / semantics>< / com:Math>; R<com:Sup>3a< / com:Sup> and R<com:Sup>3b< / com:Sup> are independently hydrogen, halogen, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>2-8< / com:Sub> alkenyl, C<com:Sub>2-8< / com:Sub> alkynyl, C<com:Sub>1-8< / com:Sub> haloalkyl, C<com:Sub>3-6< / com:Sub> cycloalkyl, or 4- to 6-membered heterocyclyl, wherein said cycloalkyl and said heterocyclyl are optionally substituted with one or more (e.g., one to eight) <com:Math><semantics>R6<annotation encoding="application / x-tex">R^6< / annotation>< / semantics>< / com:Math>, or R<com:Sup>3a< / com:Sup> and R<com:Sup>3b< / com:Sup> are optionally taken together to form oxo, C<com:Sub>3-6< / com:Sub> cycloalkyl, or 4- to 6- membered heterocyclyl, wherein said cycloalkyl and said heterocyclyl are optionally substituted with one or more (e.g., one to eight) <com:Math><semantics>ℝ6<annotation encoding="application / x-tex">\mathbb{R}^6< / annotation>< / semantics>< / com:Math>; Y is O, C(O), S, S(O), S(O)<com:Sub>2< / com:Sub>, <com:Math><semantics>CR4aR4b<annotation encoding="application / x-tex">CR^{4a}R^{4b}< / annotation>< / semantics>< / com:Math>, or <com:Math><semantics>NR4c<annotation encoding="application / x-tex">NR^{4c}< / annotation>< / semantics>< / com:Math>. R<com:Sup>4a< / com:Sup> and R<com:Sup>4b< / com:Sup> are independently hydrogen, halogen, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>2-8< / com:Sub> alkenyl, C<com:Sub>2-8< / com:Sub> alkynyl, C<com:Sub>1-8< / com:Sub> haloalkyl, C<com:Sub>3-6< / com:Sub> cycloalkyl, or 4- to 6-membered heterocyclyl, wherein said cycloalkyl and said heterocyclyl are optionally substituted with one or more (e.g., one to eight) <com:Math><semantics>R6<annotation encoding="application / x-tex">R^6< / annotation>< / semantics>< / com:Math>, or R<com:Sup>4a< / com:Sup> and R<com:Sup>4b< / com:Sup> are optionally taken together to form C<com:Sub>3-6< / com:Sub> cycloalkyl or 4- to 6-membered heterocyclyl, wherein said cycloalkyl and said heterocyclyl are optionally substituted with one or more <com:Math><semantics>(e.g.,onetoeight)R6<annotation encoding="application / x-tex">(e.g., one to eight) R^6< / annotation>< / semantics>< / com:Math>, or R<com:Sup>4a< / com:Sup> and R<com:Sup>1b< / com:Sup> are optionally taken together to form 4- to 12-membered heterocyclyl, which is optionally substituted with one or more <com:Math><semantics>(e.g.,onetoeight)R6<annotation encoding="application / x-tex">(e.g., one to eight) R^6< / annotation>< / semantics>< / com:Math>, or R<com:Sup>4a< / com:Sup> and R<com:Sup>3a< / com:Sup> are optionally taken together to form C<com:Sub>3-8< / com:Sub> cycloalkyl or 4- to 12- membered heterocyclyl, each of which is optionally substituted with one or more (e.g., one to eight) <com:Math><semantics>R6<annotation encoding="application / x-tex">R^6< / annotation>< / semantics>< / com:Math>, or R<com:Sup>4c< / com:Sup> is hydrogen, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, C<com:Sub>3-10< / com:Sub> cycloalkyl, or 4- to 12-membered heterocyclyl; each R<com:Sup>5< / com:Sup> is halogen, -CN, -OH, -SF<com:Sub>5< / com:Sub>, -SCF<com:Sub>3< / com:Sub>, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>2-8< / com:Sub> alkenyl, C<com:Sub>2-8< / com:Sub> alkynyl, C<com:Sub>1-8< / com:Sub> heteroalkyl, C<com:Sub>3-8< / com:Sub> cycloalkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, C<com:Sub>1-8< / com:Sub> alkoxy, 4- to 12- membered heterocyclyl, C<com:Sub>6-10< / com:Sub> aryl, 5- to 12-membered heteroaryl, -N(R<com:Sup>5a< / com:Sup>)<com:Sub>2< / com:Sub>, <com:Math><semantics>−C(O)R5b<annotation encoding="application / x-tex">-C(O)R^{5b}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(O)OR5a<annotation encoding="application / x-tex">-C(O)OR^{5a}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(O)N(R5a)2<annotation encoding="application / x-tex">-C(O)N(R^{5a})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NR5aC(O)R5b<annotation encoding="application / x-tex">-NR^{5a}C(O)R^{5b}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NR5aC(O)N(R5a)2<annotation encoding="application / x-tex">-NR^{5a}C(O)N(R^{5a})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NR5aC(O)OR5a<annotation encoding="application / x-tex">-NR^{5a}C(O)OR^{5a}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−OC(O)N(R5a)2<annotation encoding="application / x-tex">-OC(O)N(R^{5a})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−OC(O)OR5a<annotation encoding="application / x-tex">-OC(O)OR^{5a}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−SR5a<annotation encoding="application / x-tex">-SR^{5a}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(O)R5b<annotation encoding="application / x-tex">-S(O)R^{5b}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(O)2R5b<annotation encoding="application / x-tex">-S(O)_2R^{5b}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(O)3R5a<annotation encoding="application / x-tex">-S(O)_3R^{5a}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(O)N(R5a)2<annotation encoding="application / x-tex">-S(O)N(R^{5a})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(O)2N(R5a)2<annotation encoding="application / x-tex">-S(O)_2N(R^{5a})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NR5aS(O)R5b<annotation encoding="application / x-tex">-NR^{5a}S(O)R^{5b}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NR5aS(O)2R5b<annotation encoding="application / x-tex">-NR^{5a}S(O)_2R^{5b}< / annotation>< / semantics>< / com:Math>, -NR<com:Sup>5a< / com:Sup>S(O)N(R<com:Sup>5a< / com:Sup>)<com:Sub>2< / com:Sub>, or -NR<com:Sup>5a< / com:Sup>S(O)<com:Sub>2< / com:Sub>N(R<com:Sup>5a< / com:Sup>)<com:Sub>2< / com:Sub>, each of which is optionally substituted with one or more (e.g., one to eight) <com:Math><semantics>R5c<annotation encoding="application / x-tex">R^{5c}< / annotation>< / semantics>< / com:Math>, or two R<com:Sup>5< / com:Sup> are optionally taken together to form oxo; each R<com:Sup>5a< / com:Sup> is independently hydrogen, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, C<com:Sub>3-10< / com:Sub> cycloalkyl, or 4- to 12-membered heterocyclyl, and each R<com:Sup>5b< / com:Sup> is independently C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, C<com:Sub>3-10< / com:Sub> cycloalkyl, or 4- to 12- membered heterocyclyl; each R<com:Sup>5c< / com:Sup> is independently halogen, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>1-8< / com:Sub> alkoxy, C<com:Sub>3-10< / com:Sub> cycloalkyl, and 4- to 12-membered heterocyclyl, or two <com:Math><semantics>R5c<annotation encoding="application / x-tex">R^{5c}< / annotation>< / semantics>< / com:Math> are optionally taken together to form oxo; each R<com:Sup>6< / com:Sup> is halogen, -CN, -OH, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>1-8< / com:Sub> heteroalkyl, C<com:Sub>3-8< / com:Sub> cycloalkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, C<com:Sub>1-8< / com:Sub> alkoxy, 4- to 12-membered heterocyclyl, C<com:Sub>6-10< / com:Sub> aryl, 5- to 12-membered heteroaryl, <com:Math><semantics>−N(R6a)2<annotation encoding="application / x-tex">-N(R^{6a})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(O)R6b<annotation encoding="application / x-tex">-C(O)R^{6b}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(O)N(R6a)2<annotation encoding="application / x-tex">-C(O)N(R^{6a})_2< / annotation>< / semantics>< / com:Math>, or <com:Math><semantics>−C(O)OR6a<annotation encoding="application / x-tex">-C(O)OR^{6a}< / annotation>< / semantics>< / com:Math>, or two <com:Math><semantics>R6<annotation encoding="application / x-tex">R^6< / annotation>< / semantics>< / com:Math> are taken together to form oxo; each R<com:Sup>6a< / com:Sup> is independently hydrogen, C<com:Sub>1-8< / com:Sub> alkyl, or C<com:Sub>1-8< / com:Sub> haloalkyl, or two <com:Math><semantics>R6a<annotation encoding="application / x-tex">R^{6a}< / annotation>< / semantics>< / com:Math> on the same atom are optionally taken together to form 4- to 6-membered heterocyclyl; each R<com:Sup>6b< / com:Sup> is independently C<com:Sub>1-8< / com:Sub> alkyl or C<com:Sub>1-8< / com:Sub> haloalkyl; each R<com:Sup>7< / com:Sup> is independently hydrogen, halogen, -CN, -N<com:Sub>3< / com:Sub>, -NO<com:Sub>2< / com:Sub>, -SF<com:Sub>5< / com:Sub>, -SCF<com:Sub>3< / com:Sub>, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>2-8< / com:Sub> alkenyl, C<com:Sub>2-8< / com:Sub> alkynyl, C<com:Sub>1-8< / com:Sub> heteroalkyl, C<com:Sub>3-8< / com:Sub> cycloalkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, 4- to 12-membered heterocyclyl, C<com:Sub>6-10< / com:Sub> aryl, 5- to 12-membered heteroaryl, [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] <com:Math><semantics>−NR7aS(O)2R7b<annotation encoding="application / x-tex">-NR^{7a}S(O)_2R^{7b}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NR7aS(O)N(R7a)2<annotation encoding="application / x-tex">-NR^{7a}S(O)N(R^{7a})_2< / annotation>< / semantics>< / com:Math>, or <com:Math><semantics>−NR7aS(O)2N(R7a)2<annotation encoding="application / x-tex">-NR^{7a}S(O)_2N(R^{7a})_2< / annotation>< / semantics>< / com:Math>, each of which is optionally and independently substituted with one or more (e.g., one to eight) <com:Math><semantics>ℝ8<annotation encoding="application / x-tex">\mathbb{R}^8< / annotation>< / semantics>< / com:Math>; each R<com:Sup>7a< / com:Sup> is independently hydrogen, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, C<com:Sub>3-10< / com:Sub> cycloalkyl, or 4- to 12-membered heterocyclyl, or two <com:Math><semantics>R7a<annotation encoding="application / x-tex">R^{7a}< / annotation>< / semantics>< / com:Math> on the same atom are optionally taken together to form a 4- to 8-membered heterocyclyl optionally substituted by oxo, halo, or C<com:Sub>1-6< / com:Sub> alkyl, wherein said alkyl is optionally substituted with one or more (e.g., one to eight) <com:Math><semantics>ℝ8<annotation encoding="application / x-tex">\mathbb{R}^8< / annotation>< / semantics>< / com:Math>; each R<com:Sup>7b< / com:Sup> is independently C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, C<com:Sub>3-10< / com:Sub> cycloalkyl, or 4- to 12- membered heterocyclyl; each R<com:Sup>8< / com:Sup> is halogen, -CN, -OH, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>2-8< / com:Sub> alkenyl, C<com:Sub>2-8< / com:Sub> alkynyl, C<com:Sub>1-8< / com:Sub> heteroalkyl, C<com:Sub>3-8< / com:Sub> cycloalkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, C<com:Sub>1-8< / com:Sub> alkoxy, 4- to 12-membered heterocyclyl, C<com:Sub>6-10< / com:Sub> aryl, 5- to 12-membered heteroaryl, -N(R<com:Sup>8a< / com:Sup>)<com:Sub>2< / com:Sub>, -C(O)R<com:Sup>8b< / com:Sup>, or -C(O)OR<com:Sup>8a< / com:Sup>, or two R<com:Sup>8< / com:Sup> are optionally taken together to form oxo; each R<com:Sup>8a< / com:Sup> is independently hydrogen, C<com:Sub>1-8< / com:Sub> alkyl, or C<com:Sub>1-8< / com:Sub> haloalkyl; each R<com:Sup>8b< / com:Sup> is independently C<com:Sub>1-8< / com:Sub> alkyl or C<com:Sub>1-8< / com:Sub> haloalkyl; <com:Math><semantics>Z is C(R9)2,C(O),O,S,S(O),S(O)2,S(O)NR9, or NR9;<annotation encoding="application / x-tex">Z \text{ is } C(R^9)_2, C(O), O, S, S(O), S(O)_2, S(O)NR^9, \text{ or } NR^9;< / annotation>< / semantics>< / com:Math> each R<com:Sup>9< / com:Sup> is independently hydrogen, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>2-8< / com:Sub> alkenyl, C<com:Sub>2-8< / com:Sub> alkynyl, C<com:Sub>1-8< / com:Sub> haloalkyl, C<com:Sub>3-8< / com:Sub> cycloalkyl, 4- to 8-membered heterocyclyl, or –C(O)R<com:Sup>9a< / com:Sup>; and R<com:Sup>9a< / com:Sup> is C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, C<com:Sub>3-8< / com:Sub> cycloalkyl, or 4- to 12-membered heterocyclyl, or R<com:Sup>9< / com:Sup> and R<com:Sup>3a< / com:Sup> are optionally taken together to form C<com:Sub>3-8< / com:Sub> cycloalkyl or 4- to 12-membered heterocyclyl, each of which is optionally substituted with one or more (e.g., one to eight) R<com:Sup>6< / com:Sup>.
[0049] In one aspect, provided is a compound according to Formula I: [Image disponible dans le document PDF, Image available in the PDF document] (I), or a pharmaceutically acceptable salt, solvate, prodrug, isotopic analog, or isomer thereof, wherein <com:Math><semantics>W1<annotation encoding="application / x-tex">W^1< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>W3<annotation encoding="application / x-tex">W^3< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>W4<annotation encoding="application / x-tex">W^4< / annotation>< / semantics>< / com:Math> are <com:Math><semantics>CR7<annotation encoding="application / x-tex">CR^7< / annotation>< / semantics>< / com:Math>; <com:Math><semantics>W2<annotation encoding="application / x-tex">W^2< / annotation>< / semantics>< / com:Math> is N or <com:Math><semantics>CR7<annotation encoding="application / x-tex">CR^7< / annotation>< / semantics>< / com:Math>; provided that when <com:Math><semantics>W2<annotation encoding="application / x-tex">W^2< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>CR7<annotation encoding="application / x-tex">CR^7< / annotation>< / semantics>< / com:Math>, then either a) W<com:Sup>4< / com:Sup> is C-CN or b) <com:Math><semantics>R1a<annotation encoding="application / x-tex">R^{1a}< / annotation>< / semantics>< / com:Math> is not hydrogen and <com:Math><semantics>R1b<annotation encoding="application / x-tex">R^{1b}< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>R1c<annotation encoding="application / x-tex">R^{1c}< / annotation>< / semantics>< / com:Math> together form a piperidinyl ring substituted by <com:Math><semantics>(R5)n<annotation encoding="application / x-tex">(R^5)_n< / annotation>< / semantics>< / com:Math> and n is 0-9; R<com:Sup>1a< / com:Sup>, R<com:Sup>1b< / com:Sup>, and R<com:Sup>1c< / com:Sup> are independently hydrogen, halogen, -CN, -N<com:Sub>3< / com:Sub>, -NO<com:Sub>2< / com:Sub>, -OH, -SF<com:Sub>5< / com:Sub>, -SCF<com:Sub>3< / com:Sub>, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>2-8< / com:Sub> alkenyl, C<com:Sub>2-8< / com:Sub> alkynyl, C<com:Sub>1-8< / com:Sub> heteroalkyl, C<com:Sub>3-8< / com:Sub> cycloalkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, C<com:Sub>1-8< / com:Sub> alkoxy, C<com:Sub>1-8< / com:Sub> haloalkoxy, 4- to 12-membered heterocyclyl <com:Math><semantics>C6−10<annotation encoding="application / x-tex">C_{6-10}< / annotation>< / semantics>< / com:Math> aryl, 5- to 12-membered heteroaryl, <com:Math><semantics>−N(R1d)2<annotation encoding="application / x-tex">-N(R^{1d})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(O)R1e<annotation encoding="application / x-tex">-C(O)R^{1e}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(O)OR1d<annotation encoding="application / x-tex">-C(O)OR^{1d}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(O)N(R1d)2<annotation encoding="application / x-tex">-C(O)N(R^{1d})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NR1dC(O)R1e<annotation encoding="application / x-tex">-NR^{1d}C(O)R^{1e}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NR1dC(O)N(R1d)2<annotation encoding="application / x-tex">-NR^{1d}C(O)N(R^{1d})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NR1dC(O)OR1d<annotation encoding="application / x-tex">-NR^{1d}C(O)OR^{1d}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−OC(O)N(R1d)2<annotation encoding="application / x-tex">-OC(O)N(R^{1d})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−OC(O)OR1d<annotation encoding="application / x-tex">-OC(O)OR^{1d}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−SR1d<annotation encoding="application / x-tex">-SR^{1d}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(O)R1e<annotation encoding="application / x-tex">-S(O)R^{1e}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(O)2R1e<annotation encoding="application / x-tex">-S(O)_2R^{1e}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(O)3R1d<annotation encoding="application / x-tex">-S(O)_3R^{1d}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(O)N(R1d)2<annotation encoding="application / x-tex">-S(O)N(R^{1d})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(O)2N(R1d)2<annotation encoding="application / x-tex">-S(O)_2N(R^{1d})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NR1dS(O)R1e<annotation encoding="application / x-tex">-NR^{1d}S(O)R^{1e}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NR1dS(O)2R1e<annotation encoding="application / x-tex">-NR^{1d}S(O)_2R^{1e}< / annotation>< / semantics>< / com:Math>, -NR<com:Sup>1d< / com:Sup>S(O)N(R<com:Sup>1d< / com:Sup>)<com:Sub>2< / com:Sub>, or -NR<com:Sup>1d< / com:Sup>S(O)<com:Sub>2< / com:Sub>N(R<com:Sup>1d< / com:Sup>)<com:Sub>2< / com:Sub>, wherein each of R<com:Sup>1a< / com:Sup>, R<com:Sup>1b< / com:Sup>, and R<com:Sup>1c< / com:Sup> is optionally and independently substituted with one to eight R<com:Sup>5< / com:Sup> and at least one of R<com:Sup>1a< / com:Sup>, R<com:Sup>1b< / com:Sup>, and R<com:Sup>1c< / com:Sup> is other than hydrogen; or R<com:Sup>1b< / com:Sup> and R<com:Sup>1c< / com:Sup> are optionally taken together to form C<com:Sub>3-10< / com:Sub> cycloalkyl or 4- to 12- membered heterocyclyl, each of which is optionally substituted with one to eight R<com:Sup>5< / com:Sup>; or R<com:Sup>1a< / com:Sup>, R<com:Sup>1b< / com:Sup>, and R<com:Sup>1c< / com:Sup> are optionally taken together to form C<com:Sub>5-10< / com:Sub> cycloalkyl or 6- to 8- membered heterocyclyl, each of which is optionally substituted with one to eight R<com:Sup>5< / com:Sup>; or R<com:Sup>1a< / com:Sup> is absent and R<com:Sup>1b< / com:Sup> and R<com:Sup>1c< / com:Sup> are taken together to form C<com:Sub>6-10< / com:Sub> aryl or 5- to 12- membered heteroaryl, each of which is optionally substituted with one to eight <com:Math><semantics>ℝ5<annotation encoding="application / x-tex">\mathbb{R}^5< / annotation>< / semantics>< / com:Math>; each R<com:Sup>1d< / com:Sup> is independently hydrogen, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, C<com:Sub>3-10< / com:Sub> cycloalkyl, or 4- to 12-membered heterocyclyl, or two R<com:Sup>1d< / com:Sup> on the same atom are optionally taken together to form a 4- to 8-membered heterocyclyl optionally substituted by oxo, halo, or C<com:Sub>1-6< / com:Sub> alkyl, wherein said alkyl is optionally substituted with one to eight <com:Math><semantics>R5<annotation encoding="application / x-tex">R^5< / annotation>< / semantics>< / com:Math>; each R<com:Sup>1e< / com:Sup> is independently C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, C<com:Sub>3-10< / com:Sub> cycloalkyl, or 4- to 12- membered heterocyclyl; R<com:Sup>2a< / com:Sup> and R<com:Sup>2b< / com:Sup> are independently hydrogen, halogen, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, C<com:Sub>2-8< / com:Sub> alkenyl, or C<com:Sub>2-8< / com:Sub> alkynyl, or <com:Math><semantics>R2a<annotation encoding="application / x-tex">R^{2a}< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>R2b<annotation encoding="application / x-tex">R^{2b}< / annotation>< / semantics>< / com:Math> are optionally taken together to form <com:Math><semantics>C3−6<annotation encoding="application / x-tex">C_{3-6}< / annotation>< / semantics>< / com:Math> cycloalkyl or 4- to 6-membered heterocyclyl, each of which is optionally substituted with one to eight R<com:Sup>6< / com:Sup>; R<com:Sup>3a< / com:Sup> and R<com:Sup>3b< / com:Sup> are independently hydrogen, halogen, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>2-8< / com:Sub> alkenyl, C<com:Sub>2-8< / com:Sub> alkynyl, C<com:Sub>1-8< / com:Sub> haloalkyl, C<com:Sub>3-6< / com:Sub> cycloalkyl, or 4- to 6-membered heterocyclyl, wherein said cycloalkyl and said heterocyclyl are optionally substituted with one to eight R<com:Sup>6< / com:Sup>, or R<com:Sup>3a< / com:Sup> and R<com:Sup>3b< / com:Sup> are optionally taken together to form oxo, C<com:Sub>3-6< / com:Sub> cycloalkyl, or 4- to 6-membered heterocyclyl, wherein said cycloalkyl and said heterocyclyl are optionally substituted with one to eight R<com:Sup>6< / com:Sup>; Y is O, C(O), S, S(O), S(O)<com:Sub>2< / com:Sub>, <com:Math><semantics>CR4aR4b<annotation encoding="application / x-tex">CR^{4a}R^{4b}< / annotation>< / semantics>< / com:Math>, or <com:Math><semantics>NR4c<annotation encoding="application / x-tex">NR^{4c}< / annotation>< / semantics>< / com:Math>; R<com:Sup>4a< / com:Sup> and R<com:Sup>4b< / com:Sup> are independently hydrogen, halogen, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>2-8< / com:Sub> alkenyl, C<com:Sub>2-8< / com:Sub> alkynyl, C<com:Sub>1-8< / com:Sub> haloalkyl, C<com:Sub>3-6< / com:Sub> cycloalkyl, or 4- to 6-membered heterocyclyl, wherein said cycloalkyl and said heterocyclyl are optionally substituted with one to eight R<com:Sup>6< / com:Sup>, or R<com:Sup>4a< / com:Sup> and R<com:Sup>4b< / com:Sup> are optionally taken together to form C<com:Sub>3-6< / com:Sub> cycloalkyl or 4- to 6-membered heterocyclyl, wherein said cycloalkyl and said heterocyclyl are optionally substituted with one to eight <com:Math><semantics>R6<annotation encoding="application / x-tex">R^6< / annotation>< / semantics>< / com:Math>, or R<com:Sup>4a< / com:Sup> and R<com:Sup>1b< / com:Sup> are optionally taken together to form 4- to 12-membered heterocyclyl, which is optionally substituted with one to eight R<com:Sup>6< / com:Sup>, or R<com:Sup>4a< / com:Sup> and R<com:Sup>3a< / com:Sup> are optionally taken together to form C<com:Sub>3-8< / com:Sub> cycloalkyl or 4- to 12-membered heterocyclyl, each of which is optionally substituted with one to eight <com:Math><semantics>R6<annotation encoding="application / x-tex">R^6< / annotation>< / semantics>< / com:Math>, or R<com:Sup>4c< / com:Sup> is hydrogen, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, C<com:Sub>3-10< / com:Sub> cycloalkyl, or 4- to 12-membered heterocyclyl; each R<com:Sup>5< / com:Sup> is independently halogen, -CN, -OH, -SF<com:Sub>5< / com:Sub>, -SCF<com:Sub>3< / com:Sub>, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>2-8< / com:Sub> alkenyl, C<com:Sub>2-8< / com:Sub> alkynyl, C<com:Sub>1-8< / com:Sub> heteroalkyl, C<com:Sub>3-8< / com:Sub> cycloalkyl, C<com:Sub>1-8< / com:Sub> alkoxy, 4- to 12-membered heterocyclyl, C<com:Sub>6-10< / com:Sub> aryl, 5- to 12-membered heteroaryl, (4- to 12-membered heterocyclyl)-(<com:Math><semantics>C1−8<annotation encoding="application / x-tex">C_{1-8}< / annotation>< / semantics>< / com:Math> heteroalkyl), (<com:Math><semantics>C6−10<annotation encoding="application / x-tex">C_{6-10}< / annotation>< / semantics>< / com:Math> aryl)(<com:Math><semantics>C1−8<annotation encoding="application / x-tex">C_{1-8}< / annotation>< / semantics>< / com:Math> heteroalkyl), (5- to 12-membered heteroaryl)(C<com:Sub>1-8< / com:Sub> heteroalkyl), -N(R<com:Sup>5a< / com:Sup>)<com:Sub>2< / com:Sub>, -C(O)R<com:Sup>5b< / com:Sup>, <com:Math><semantics>−C(O)OR5a<annotation encoding="application / x-tex">-C(O)OR^{5a}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(O)N(R5a)2<annotation encoding="application / x-tex">-C(O)N(R^{5a})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NR5aC(O)R5b<annotation encoding="application / x-tex">-NR^{5a}C(O)R^{5b}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NR5aC(O)N(R5a)2<annotation encoding="application / x-tex">-NR^{5a}C(O)N(R^{5a})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NR5aC(O)OR5a<annotation encoding="application / x-tex">-NR^{5a}C(O)OR^{5a}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−OC(O)N(R5a)2<annotation encoding="application / x-tex">-OC(O)N(R^{5a})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−OC(O)OR5a<annotation encoding="application / x-tex">-OC(O)OR^{5a}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−SR5a<annotation encoding="application / x-tex">-SR^{5a}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(O)R5b<annotation encoding="application / x-tex">-S(O)R^{5b}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(O)2R5b<annotation encoding="application / x-tex">-S(O)_2R^{5b}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(O)3R5a<annotation encoding="application / x-tex">-S(O)_3R^{5a}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(O)N(R5a)2<annotation encoding="application / x-tex">-S(O)N(R^{5a})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(O)2N(R5a)2<annotation encoding="application / x-tex">-S(O)_2N(R^{5a})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NR5aS(O)R5b<annotation encoding="application / x-tex">-NR^{5a}S(O)R^{5b}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NR5aS(O)2R5b<annotation encoding="application / x-tex">-NR^{5a}S(O)_2R^{5b}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NR5aS(O)N(R5a)2<annotation encoding="application / x-tex">-NR^{5a}S(O)N(R^{5a})_2< / annotation>< / semantics>< / com:Math>, or <com:Math><semantics>−NR5aS(O)2N(R5a)2<annotation encoding="application / x-tex">-NR^{5a}S(O)_2N(R^{5a})_2< / annotation>< / semantics>< / com:Math>, each of which is optionally substituted with one to eight R<com:Sup>5c< / com:Sup>, or two R<com:Sup>5< / com:Sup> are optionally taken together to form oxo; each R<com:Sup>5a< / com:Sup> is independently hydrogen, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, C<com:Sub>3-10< / com:Sub> cycloalkyl, or 4- to 12-membered heterocyclyl, and each R<com:Sup>5b< / com:Sup> is independently C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, C<com:Sub>3-10< / com:Sub> cycloalkyl, 4- to 12-membered heterocyclyl, or 5- to 12-membered heteroaryl; each R<com:Sup>5c< / com:Sup> is independently halogen, cyano, C<com:Sub>1-8< / com:Sub> haloalkyl, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>1-8< / com:Sub> alkoxy, C<com:Sub>1-8< / com:Sub> haloalkoxy, (C<com:Sub>1-8< / com:Sub> alkoxy)(C<com:Sub>1-8< / com:Sub> alkoxy), hydroxyl, SR<com:Sup>5d< / com:Sup>, N(R<com:Sup>5d< / com:Sup>)<com:Sub>2< / com:Sub>, N(R<com:Sup>5d< / com:Sup>)<com:Sub>2< / com:Sub>(C<com:Sub>1-8< / com:Sub> alkoxy), C<com:Sub>3-10< / com:Sub> cycloalkyl, or 4- to 12-membered heterocyclyl, or two R<com:Sup>5c< / com:Sup> are optionally taken together to form oxo; each R<com:Sup>5d< / com:Sup> is independently hydrogen, C<com:Sub>1-8< / com:Sub> alkyl, or C<com:Sub>1-8< / com:Sub> haloalkyl; each R<com:Sup>6< / com:Sup> is halogen, -CN, -OH, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>1-8< / com:Sub> heteroalkyl, C<com:Sub>3-8< / com:Sub> cycloalkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, C<com:Sub>1-8< / com:Sub> alkoxy, 4- to 12-membered heterocyclyl, C<com:Sub>6-10< / com:Sub> aryl, 5- to 12-membered heteroaryl, <com:Math><semantics>−N(R6a)2<annotation encoding="application / x-tex">-N(R^{6a})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(O)R6b<annotation encoding="application / x-tex">-C(O)R^{6b}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(O)N(R6a)2<annotation encoding="application / x-tex">-C(O)N(R^{6a})_2< / annotation>< / semantics>< / com:Math>, or <com:Math><semantics>−C(O)OR6a<annotation encoding="application / x-tex">-C(O)OR^{6a}< / annotation>< / semantics>< / com:Math>, or two R<com:Sup>6< / com:Sup> are taken together to form oxo; each R<com:Sup>6a< / com:Sup> is independently hydrogen, C<com:Sub>1-8< / com:Sub> alkyl, or C<com:Sub>1-8< / com:Sub> haloalkyl, or two <com:Math><semantics>R6a<annotation encoding="application / x-tex">R^{6a}< / annotation>< / semantics>< / com:Math> on the same atom are optionally taken together to form 4- to 6-membered heterocyclyl; each <com:Math><semantics>R6b<annotation encoding="application / x-tex">R^{6b}< / annotation>< / semantics>< / com:Math> is independently <com:Math><semantics>C1−8<annotation encoding="application / x-tex">C_{1-8}< / annotation>< / semantics>< / com:Math> alkyl or <com:Math><semantics>C1−8<annotation encoding="application / x-tex">C_{1-8}< / annotation>< / semantics>< / com:Math> haloalkyl; each R<com:Sup>7< / com:Sup> is independently hydrogen, halogen, -CN, -N<com:Sub>3< / com:Sub>, -NO<com:Sub>2< / com:Sub>, -SF<com:Sub>5< / com:Sub>, -SCF<com:Sub>3< / com:Sub>, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>2-8< / com:Sub> alkenyl, C<com:Sub>2-8< / com:Sub> alkynyl, C<com:Sub>1-8< / com:Sub> heteroalkyl, C<com:Sub>3-8< / com:Sub> cycloalkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, 4- to 12-membered heterocyclyl, C<com:Sub>6-10< / com:Sub> aryl, 5- to 12-membered [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] -NR<com:Sup>7a< / com:Sup>S(O)<com:Sub>2< / com:Sub>N(R<com:Sup>7a< / com:Sup>)<com:Sub>2< / com:Sub>, each of which is optionally and independently substituted with one to eight <com:Math><semantics>ℝ8<annotation encoding="application / x-tex">\mathbb{R}^8< / annotation>< / semantics>< / com:Math>; each R<com:Sup>7a< / com:Sup> is independently hydrogen, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, C<com:Sub>3-10< / com:Sub> cycloalkyl, or 4- to 12-membered heterocyclyl, or two <com:Math><semantics>R7a<annotation encoding="application / x-tex">R^{7a}< / annotation>< / semantics>< / com:Math> on the same atom are optionally taken together to form a 4- to 8-membered heterocyclyl optionally substituted by oxo, halo, or C<com:Sub>1-6< / com:Sub> alkyl, wherein said alkyl is optionally substituted with one to eight R<com:Sup>8< / com:Sup>; each R<com:Sup>7b< / com:Sup> is independently C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, C<com:Sub>3-10< / com:Sub> cycloalkyl, or 4- to 12-membered heterocyclyl; each R<com:Sup>8< / com:Sup> is halogen, -CN, -OH, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>2-8< / com:Sub> alkenyl, C<com:Sub>2-8< / com:Sub> alkynyl, C<com:Sub>1-8< / com:Sub> heteroalkyl, C<com:Sub>3-8< / com:Sub> cycloalkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, C<com:Sub>1-8< / com:Sub> alkoxy, 4- to 12-membered heterocyclyl, C<com:Sub>6-10< / com:Sub> aryl, 5- to 12-membered heteroaryl, -N(R<com:Sup>8a< / com:Sup>)<com:Sub>2< / com:Sub>, -C(O)R<com:Sup>8b< / com:Sup>, or -C(O)OR<com:Sup>8a< / com:Sup>, or two R<com:Sup>8< / com:Sup> are optionally taken together to form oxo; each R<com:Sup>8a< / com:Sup> is independently hydrogen, C<com:Sub>1-8< / com:Sub> alkyl, or C<com:Sub>1-8< / com:Sub> haloalkyl; each R<com:Sup>8b< / com:Sup> is independently C<com:Sub>1-8< / com:Sub> alkyl or C<com:Sub>1-8< / com:Sub> haloalkyl; <com:Math><semantics>Z is C(R9)2,C(O),O,S,S(O),S(O)2,S(O)NR9, or NR9;<annotation encoding="application / x-tex">Z \text{ is } C(R^9)_2, C(O), O, S, S(O), S(O)_2, S(O)NR^9, \text{ or } NR^9;< / annotation>< / semantics>< / com:Math> provided that when Z is N, then <com:Math><semantics>R3a<annotation encoding="application / x-tex">R^{3a}< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>R3b<annotation encoding="application / x-tex">R^{3b}< / annotation>< / semantics>< / com:Math> are not oxo; each R<com:Sup>9< / com:Sup> is independently hydrogen, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>2-8< / com:Sub> alkenyl, C<com:Sub>2-8< / com:Sub> alkynyl, C<com:Sub>1-8< / com:Sub> haloalkyl, C<com:Sub>3-8< / com:Sub> cycloalkyl, 4- to 8-membered heterocyclyl, or -C(O)R<com:Sup>9a< / com:Sup>; and R<com:Sup>9a< / com:Sup> is C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, C<com:Sub>3-8< / com:Sub> cycloalkyl, or 4- to 12-membered heterocyclyl, or R<com:Sup>9< / com:Sup> and R<com:Sup>3a< / com:Sup> are optionally taken together to form C<com:Sub>3-8< / com:Sub> cycloalkyl or 4- to 12-membered heterocyclyl, each of which is optionally substituted with one to eight R<com:Sup>6< / com:Sup>.
[0050] In some embodiments, when <com:Math><semantics>R2a<annotation encoding="application / x-tex">R^{2a}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>R2b<annotation encoding="application / x-tex">R^{2b}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>R3a<annotation encoding="application / x-tex">R^{3a}< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>R3b<annotation encoding="application / x-tex">R^{3b}< / annotation>< / semantics>< / com:Math> are hydrogen and two of <com:Math><semantics>R1a<annotation encoding="application / x-tex">R^{1a}< / annotation>< / semantics>< / com:Math>, R<com:Sup>1b< / com:Sup>, and R<com:Sup>1c< / com:Sup> form piperidinyl or pyrrolidinyl in compounds of Formula A, Formula B, or Formula I, said piperidinyl or pyrrolidinyl is substituted with at least one R<com:Sup>1d< / com:Sup> group.
[0051] In some embodiments, when <com:Math><semantics>R2a<annotation encoding="application / x-tex">R^{2a}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>R2b<annotation encoding="application / x-tex">R^{2b}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>R3a<annotation encoding="application / x-tex">R^{3a}< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>R3b<annotation encoding="application / x-tex">R^{3b}< / annotation>< / semantics>< / com:Math> are hydrogen, <com:Math><semantics>R1a<annotation encoding="application / x-tex">R^{1a}< / annotation>< / semantics>< / com:Math> is unsubstituted methyl, R<com:Sup>1b< / com:Sup> is unsubstituted methyl, chloromethyl, or unsubstituted ethyl, and R<com:Sup>1c< / com:Sup> is methyl in compounds of Formula A, Formula B, and Formula I, said R<com:Sup>1c< / com:Sup> is substituted with <com:Math><semantics>1−3R1d<annotation encoding="application / x-tex">1-3 R^{1d}< / annotation>< / semantics>< / com:Math>.
[0052] In some embodiments, when R<com:Sup>2a< / com:Sup>, R<com:Sup>2b< / com:Sup>, R<com:Sup>3a< / com:Sup>, and R<com:Sup>3b< / com:Sup> are hydrogen, R<com:Sup>1a< / com:Sup> is unsubstituted aminomethyl or unsubstituted 2-aminoprop-2-yl, R1b is unsubstituted methyl or unsubstituted ethyl, and R<com:Sup>1c< / com:Sup> is methyl or ethyl in compounds of Formula A, Formula B, and Formula I, said R<com:Sup>1c< / com:Sup> is substituted with 1-4 R<com:Sup>1d< / com:Sup>.
[0053] In some embodiments, when <com:Math><semantics>R3a<annotation encoding="application / x-tex">R^{3a}< / annotation>< / semantics>< / com:Math> or <com:Math><semantics>R3b<annotation encoding="application / x-tex">R^{3b}< / annotation>< / semantics>< / com:Math> is methyl in compounds of Formula A, Formula B, and Formula I, at least two of R<com:Sup>1a< / com:Sup>, R<com:Sup>1b< / com:Sup>, and R<com:Sup>1c< / com:Sup> are C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>1-8< / com:Sub> heteroalkyl, C<com:Sub>3-8< / com:Sub> cycloalkyl, C<com:Sub>6-10< / com:Sub> aryl, 5- to 12-membered heterocyclyl, or 5- to 12-membered heteroaryl.
[0054] In some embodiments, W<com:Sup>2< / com:Sup> is N in compounds of Formula A, Formula B, and Formula I.
[0055] In some embodiments, Z is O; Y is CR<com:Sup>4a< / com:Sup>R<com:Sup>4b< / com:Sup>; R<com:Sup>2a< / com:Sup>, R<com:Sup>2b< / com:Sup>, R<com:Sup>3a< / com:Sup>, R<com:Sup>3b< / com:Sup>, R<com:Sup>4a< / com:Sup>, and R<com:Sup>4b< / com:Sup> are H; and R<com:Sup>1a< / com:Sup>, R<com:Sup>1b< / com:Sup>, R<com:Sup>1c< / com:Sup>, R<com:Sup>5< / com:Sup>, R<com:Sup>7< / com:Sup>, and R<com:Sup>8< / com:Sup> are as defined for Formula I, Formula A, or Formula B.
[0056] In some embodiments, provided herein are compounds of Formula Ia [Image disponible dans le document PDF, Image available in the PDF document] (Ia) wherein <com:Math><semantics>R1a<annotation encoding="application / x-tex">R^{1a}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>R2a<annotation encoding="application / x-tex">R^{2a}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>R2b<annotation encoding="application / x-tex">R^{2b}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>R3a<annotation encoding="application / x-tex">R^{3a}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>R3b<annotation encoding="application / x-tex">R^{3b}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>R5<annotation encoding="application / x-tex">R^{5}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>R7<annotation encoding="application / x-tex">R^{7}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>W1<annotation encoding="application / x-tex">W^{1}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>W2<annotation encoding="application / x-tex">W^{2}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>W3<annotation encoding="application / x-tex">W^{3}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>W4<annotation encoding="application / x-tex">W^{4}< / annotation>< / semantics>< / com:Math>, Y, and Z are as defined for Formula I, Formula A, or Formula B; and n is 0-9; provided that when <com:Math><semantics>W1<annotation encoding="application / x-tex">W^1< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>W2<annotation encoding="application / x-tex">W^2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>W3<annotation encoding="application / x-tex">W^3< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>W4<annotation encoding="application / x-tex">W^4< / annotation>< / semantics>< / com:Math> are <com:Math><semantics>CR7<annotation encoding="application / x-tex">CR^7< / annotation>< / semantics>< / com:Math>, then <com:Math><semantics>R1a<annotation encoding="application / x-tex">R^{1a}< / annotation>< / semantics>< / com:Math> is not hydrogen.
[0057] In some embodiments, provided herein are compounds of Formula Ia wherein at least one of R<com:Sup>5< / com:Sup> is 4- to 12-membered heterocyclyl or 5- to 12-membered heteroaryl, each of which is optionally substituted with one or more (e.g., one to eight) R<com:Sup>5c< / com:Sup>. In some embodiments, at least one of R<com:Sup>5< / com:Sup> is a 5- to 12-membered heteroaryl optionally substituted with one or more (e.g., one to eight) <com:Math><semantics>R5c<annotation encoding="application / x-tex">R^{5c}< / annotation>< / semantics>< / com:Math>. In some embodiments, at least one of <com:Math><semantics>R5<annotation encoding="application / x-tex">R^{5}< / annotation>< / semantics>< / com:Math> is attached to the piperidine nitrogen.
[0058] In some embodiments, provided herein are compounds of Formula Ib [Image disponible dans le document PDF, Image available in the PDF document] (Ib), wherein R<com:Sup>1a< / com:Sup>, R<com:Sup>1b< / com:Sup>, R<com:Sup>1c< / com:Sup>, R<com:Sup>2a< / com:Sup>, R<com:Sup>2b< / com:Sup>, R<com:Sup>3a< / com:Sup>, R<com:Sup>3b< / com:Sup>, W<com:Sup>1< / com:Sup>, W<com:Sup>2< / com:Sup>, W<com:Sup>3< / com:Sup>, Y, and Z are as defined for Formula I, Formula A, or Formula B.
[0059] In some embodiments, W<com:Sup>2< / com:Sup> is N in compounds of Formula I, Formula Ia, and Formula Ib, and W<com:Sup>1< / com:Sup>, W<com:Sup>3< / com:Sup>, W<com:Sup>4< / com:Sup> are CR<com:Sup>7< / com:Sup>. In some embodiments, W<com:Sup>2< / com:Sup> is N in compounds of Formula I, Formula Ia, and Formula Ib, and W<com:Sup>3< / com:Sup> is CH. In some embodiments, W<com:Sup>2< / com:Sup> is N in compounds of Formula I, Formula Ia, and Formula Ib, and each R<com:Sup>7< / com:Sup> is independently hydrogen, halogen, cyano, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, or C<com:Sub>1-8< / com:Sub> alkoxy. In some embodiments W<com:Sup>2< / com:Sup> is CR<com:Sup>7< / com:Sup> in compounds of Formula I, Formula Ia, and Formula Ib.
[0060] In some embodiments, provided herein are compounds according to Formula Ic, [Image disponible dans le document PDF, Image available in the PDF document] (Ic), wherein R<com:Sup>1d< / com:Sup>, R<com:Sup>1e< / com:Sup>, R<com:Sup>2a< / com:Sup>, R<com:Sup>2b< / com:Sup>, R<com:Sup>3a< / com:Sup>, R<com:Sup>3b< / com:Sup>, R<com:Sup>4a< / com:Sup>, R<com:Sup>5< / com:Sup>, R<com:Sup>6< / com:Sup>, W<com:Sup>1< / com:Sup>, W<com:Sup>2< / com:Sup>, W<com:Sup>3< / com:Sup>, W<com:Sup>4< / com:Sup>, Y, and Z are as defined for Formula I, Formula A, or Formula B; R<com:Sup>11a< / com:Sup> is haloalkyl; R<com:Sup>1b< / com:Sup> and R<com:Sup>1c< / com:Sup> are independently -CN, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>2-8< / com:Sub> alkenyl, C<com:Sub>2-8< / com:Sub> alkynyl, C<com:Sub>3-8< / com:Sub> cycloalkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, C<com:Sub>6-10< / com:Sub> aryl, 5- to 12-membered heteroaryl, -C(O)R<com:Sup>1e< / com:Sup>, -C(O)OR<com:Sup>1d< / com:Sup>, or -C(O)N(R<com:Sup>1d< / com:Sup>)<com:Sub>2< / com:Sub> wherein R<com:Sup>1b< / com:Sup> and R<com:Sup>1c< / com:Sup> are independently substituted with one or more (e.g., one to eight) <com:Math><semantics>ℝ5<annotation encoding="application / x-tex">\mathbb{R}^5< / annotation>< / semantics>< / com:Math>; or R<com:Sup>1b< / com:Sup> and R<com:Sup>1c< / com:Sup> are optionally taken together to form C<com:Sub>3-10< / com:Sub> cycloalkyl optionally substituted with one or more <com:Math><semantics>(e.g.,onetoeight)R5<annotation encoding="application / x-tex">(e.g., one to eight) R^5< / annotation>< / semantics>< / com:Math>; or R<com:Sup>1b< / com:Sup> and R<com:Sup>4a< / com:Sup> are optionally taken together to form 4- to 12-membered heterocyclyl, which is optionally substituted with one or more (e.g., one to eight) R<com:Sup>6< / com:Sup>; and provided that the compound is not: [Image disponible dans le document PDF, Image available in the PDF document] [1-(difluoromethyl)cyclopentyl](2,3- dihydro-3-methyl-1,4-benzoxazepin- 4(5H)-yl)-methanone [Image disponible dans le document PDF, Image available in the PDF document] (2,3-dihydro-1,1-dioxido-1,4- benzothiazepin-4(5H)-yl)[1- (trifluoromethyl)cyclopentyl]- methanone [Image disponible dans le document PDF, Image available in the PDF document] 2-(chloromethyl)-1-(2,3-dihydro-1,4- benzoxazepin-4(5H)-yl)-2-methyl-1- propanone or [Image disponible dans le document PDF, Image available in the PDF document] 2-(chloromethyl)-2-methyl-1-(1,3,4,5- tetrahydro-2H-2-benzazepin-2-yl)-1- propanone
[0061] In some embodiments, provided herein are compounds of Formula Ic wherein at least one of W<com:Sup>1< / com:Sup>, W<com:Sup>2< / com:Sup>, W<com:Sup>3< / com:Sup>, or W<com:Sup>4< / com:Sup> is nitrogen. In some embodiments, provided herein are compound of Formula Ic wherein R<com:Sup>11a< / com:Sup> is difluoromethyl.
[0062] In some embodiments, provided herein are compounds of Formula Id [Image disponible dans le document PDF, Image available in the PDF document] (Id), wherein R<com:Sup>1a< / com:Sup>, R<com:Sup>1d< / com:Sup>, R<com:Sup>1e< / com:Sup>, R<com:Sup>2a< / com:Sup>, R<com:Sup>2b< / com:Sup>, R<com:Sup>3a< / com:Sup>, R<com:Sup>3b< / com:Sup>, R<com:Sup>4a< / com:Sup>, R<com:Sup>5< / com:Sup>, R<com:Sup>6< / com:Sup>, W<com:Sup>1< / com:Sup>, W<com:Sup>2< / com:Sup>, W<com:Sup>3< / com:Sup>, W<com:Sup>4< / com:Sup>, Y, and Z are as defined for Formula I, Formula A, or Formula B; at least one of W<com:Sup>1< / com:Sup>, W<com:Sup>2< / com:Sup>, W<com:Sup>3< / com:Sup>, or W<com:Sup>4< / com:Sup> is nitrogen (e.g., W<com:Sup>1< / com:Sup>, W<com:Sup>3< / com:Sup>, and W<com:Sup>4< / com:Sup> are CR<com:Sup>7< / com:Sup> and W<com:Sup>2< / com:Sup> is N or <com:Math><semantics>CR7<annotation encoding="application / x-tex">CR^7< / annotation>< / semantics>< / com:Math>); R<com:Sup>1b< / com:Sup> and R<com:Sup>1c< / com:Sup> are independently -CN, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>2-8< / com:Sub> alkenyl, C<com:Sub>2-8< / com:Sub> alkynyl, C<com:Sub>3-8< / com:Sub> cycloalkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, C<com:Sub>6-10< / com:Sub> aryl, 5- to 12-membered heteroaryl, -C(O)R<com:Sup>1e< / com:Sup>, -C(O)OR<com:Sup>1d< / com:Sup>, or -C(O)N(R<com:Sup>1d< / com:Sup>)<com:Sub>2< / com:Sub> wherein R<com:Sup>1b< / com:Sup> and R<com:Sup>1c< / com:Sup> are independently substituted with one or more (e.g., one to eight) <com:Math><semantics>R5<annotation encoding="application / x-tex">R^5< / annotation>< / semantics>< / com:Math>; or R<com:Sup>1b< / com:Sup> and R<com:Sup>1c< / com:Sup> are optionally taken together to form C<com:Sub>3-10< / com:Sub> cycloalkyl optionally substituted with one or more (e.g., one to eight) R<com:Sup>5< / com:Sup>; or R<com:Sup>1b< / com:Sup> and R<com:Sup>4a< / com:Sup> are optionally taken together to form 4- to 12-membered heterocyclyl, which is optionally substituted with one or more (e.g., one to eight) R<com:Sup>6< / com:Sup>; or R<com:Sup>1a< / com:Sup>, R<com:Sup>1b< / com:Sup>, and R<com:Sup>1c< / com:Sup> are optionally taken together form a C<com:Sub>5-10< / com:Sub> cycloalkyl optionally substituted with one or more (e.g., one to eight) <com:Math><semantics>ℝ5<annotation encoding="application / x-tex">\mathbb{R}^5< / annotation>< / semantics>< / com:Math>; and provided that the compound is not: [Image disponible dans le document PDF, Image available in the PDF document] cyclopropyl[4-[[(2,4- dichloro-phenyl)methyl]- amino]-7,8-dihydro-2- (methylthio)-pyrimido[5,4- f][1,4]oxazepin-6(5H)-yl]- methanone or [Image disponible dans le document PDF, Image available in the PDF document] 1-[4-[6-(cyclopropyl- carbonyl)-4-[[(2,4- dichlorophenyl)- methyl[amino]-5,6,7,8- tetrahydropyrimido[5,4- f][1,4]oxazepin-2-yl]-1- piperazinyl]-2-(1- pyrrolidinyl)-ethanone
[0063] In some embodiments, provided herein are compounds of Formula Id wherein two or three of W<com:Sup>1< / com:Sup>, W<com:Sup>2< / com:Sup>, W<com:Sup>3< / com:Sup>, or W<com:Sup>4< / com:Sup> is CR<com:Sup>7< / com:Sup>, wherein R<com:Sup>7< / com:Sup> is independently hydrogen, halogen, -CN, -N<com:Sub>3< / com:Sub>, -NO<com:Sub>2< / com:Sub>, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>2-8< / com:Sub> alkenyl, C<com:Sub>2-8< / com:Sub> alkynyl, C<com:Sub>1-8< / com:Sub> heteroalkyl, C<com:Sub>3-8< / com:Sub> cycloalkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, C<com:Sub>6-10< / com:Sub> aryl, 5- to 12-membered heteroaryl, -OR<com:Sup>7a< / com:Sup>, -C(O)R<com:Sup>7b< / com:Sup>, -C(O)OR<com:Sup>7a< / com:Sup>, <com:Math><semantics>−C(O)N(R7a)2<annotation encoding="application / x-tex">-C(O)N(R^{7a})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−OC(O)N(R7a)2<annotation encoding="application / x-tex">-OC(O)N(R^{7a})_2< / annotation>< / semantics>< / com:Math>, or <com:Math><semantics>−OC(O)OR7a<annotation encoding="application / x-tex">-OC(O)OR^{7a}< / annotation>< / semantics>< / com:Math>, each of which is optionally and independently substituted with one or more (e.g., one to eight) <com:Math><semantics>ℝ8<annotation encoding="application / x-tex">\mathbb{R}^8< / annotation>< / semantics>< / com:Math>.
[0064] In some embodiments, provided herein are compounds of Formula Id wherein one of <com:Math><semantics>R1a<annotation encoding="application / x-tex">R^{1a}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>R1b<annotation encoding="application / x-tex">R^{1b}< / annotation>< / semantics>< / com:Math>, or <com:Math><semantics>R1c<annotation encoding="application / x-tex">R^{1c}< / annotation>< / semantics>< / com:Math> is difluoromethyl.
[0065] In some embodiments, provided herein are compounds of Formula Id wherein one of R<com:Sup>1a< / com:Sup>, R<com:Sup>1b< / com:Sup>, and R<com:Sup>1c< / com:Sup> is cyclopropyl.
[0066] In some embodiments, provided herein are compounds of Formula Ie [Image disponible dans le document PDF, Image available in the PDF document] (Ie) wherein R<com:Sup>1b< / com:Sup>, R<com:Sup>1c< / com:Sup>, R<com:Sup>2a< / com:Sup>, R<com:Sup>2b< / com:Sup>, R<com:Sup>3a< / com:Sup>, R<com:Sup>3b< / com:Sup>, R<com:Sup>5< / com:Sup>, R<com:Sup>7< / com:Sup>, W<com:Sup>1< / com:Sup>, W<com:Sup>2< / com:Sup>, W<com:Sup>3< / com:Sup>, W<com:Sup>4< / com:Sup>, Y, and Z are as defined for Formula I, Formula A, or Formula B; Cy is C<com:Sub>3-8< / com:Sub> cycloalkyl, 4- to 12-membered heterocyclyl, or 5- to 12-membered heteroaryl, wherein Cy is optionally substituted with one to six substituents independently selected from halo, C<com:Sub>1-8< / com:Sub> alkyl, and haloC<com:Sub>1-8< / com:Sub> alkyl; provided that when W<com:Sup>1< / com:Sup>, W<com:Sup>2< / com:Sup>, W<com:Sup>3< / com:Sup>, and W<com:Sup>4< / com:Sup> are CR<com:Sup>7< / com:Sup>, then Cy is cyclopropyl, at least one of <com:Math><semantics>R1b<annotation encoding="application / x-tex">R^{1b}< / annotation>< / semantics>< / com:Math> or <com:Math><semantics>R1c<annotation encoding="application / x-tex">R^{1c}< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>C1−8<annotation encoding="application / x-tex">C_{1-8}< / annotation>< / semantics>< / com:Math> alkyl optionally substituted with one or more (e.g., one to eight) R<com:Sup>5< / com:Sup>, and at least one R<com:Sup>7< / com:Sup> is not hydrogen.
[0067] In some embodiments, provided herein are compounds of Formula Ie wherein at least one of W<com:Sup>1< / com:Sup>, W<com:Sup>2< / com:Sup>, W<com:Sup>3< / com:Sup>, or W<com:Sup>4< / com:Sup> is nitrogen.
[0068] In some embodiments, provided herein are compounds of Formula Ie wherein Cy is <com:Math><semantics>C3−8<annotation encoding="application / x-tex">C_{3-8}< / annotation>< / semantics>< / com:Math> cycloalkyl optionally substituted with one or more (e.g., one to eight) <com:Math><semantics>R5<annotation encoding="application / x-tex">R^5< / annotation>< / semantics>< / com:Math>.
[0069] In some embodiments, provided herein are compounds according to Formula I, Formula A, Formula B, Formula Ia, Formula Ic, Formula Id, or Formula Ie, wherein W<com:Sup>1< / com:Sup> is N. In some embodiments, provided herein are compounds according to Formula I, Formula A, Formula B, Formula Ia, Formula Ic, Formula Id, or Formula Ie, wherein W<com:Sup>2< / com:Sup> is N. In some embodiments, provided herein are compounds according to Formula I, Formula A, Formula B, Formula Ia, Formula Ic, Formula Id, or Formula Ie, wherein W<com:Sup>3< / com:Sup> is N. In some embodiments, provided herein are compounds according to Formula I, Formula A, Formula B, Formula Ia, Formula Ic, Formula Id, or Formula Ie, wherein W<com:Sup>3< / com:Sup> and W<com:Sup>4< / com:Sup> are N and W<com:Sup>1< / com:Sup> and W<com:Sup>2< / com:Sup> are CR<com:Sup>7< / com:Sup>. In some embodiments, provided herein are compounds according to Formula I, Formula A, Formula B, Formula Ia, Formula Ic, Formula Id, or Formula Ie, wherein W<com:Sup>4< / com:Sup> is N and <com:Math><semantics>W1<annotation encoding="application / x-tex">W^1< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>W2<annotation encoding="application / x-tex">W^2< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>W3<annotation encoding="application / x-tex">W^3< / annotation>< / semantics>< / com:Math> are <com:Math><semantics>CR7<annotation encoding="application / x-tex">CR^7< / annotation>< / semantics>< / com:Math>.
[0070] In some embodiments, provided herein are compounds of Formula I, wherein: <com:Math><semantics>W2<annotation encoding="application / x-tex">W^2< / annotation>< / semantics>< / com:Math> is N; <com:Math><semantics>W1<annotation encoding="application / x-tex">W^1< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>W3<annotation encoding="application / x-tex">W^3< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>W4<annotation encoding="application / x-tex">W^4< / annotation>< / semantics>< / com:Math> are <com:Math><semantics>CR7<annotation encoding="application / x-tex">CR^7< / annotation>< / semantics>< / com:Math>; Z is O; [Image disponible dans le document PDF, Image available in the PDF document] <com:Math><semantics>R2a<annotation encoding="application / x-tex">R^{2a}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>R2b<annotation encoding="application / x-tex">R^{2b}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>R3a<annotation encoding="application / x-tex">R^{3a}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>R3b<annotation encoding="application / x-tex">R^{3b}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>R4a<annotation encoding="application / x-tex">R^{4a}< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>R4b<annotation encoding="application / x-tex">R^{4b}< / annotation>< / semantics>< / com:Math> are H; and R<com:Sup>1a< / com:Sup>, R<com:Sup>1b< / com:Sup>, and R<com:Sup>1c< / com:Sup>, R<com:Sup>5< / com:Sup>, R<com:Sup>7< / com:Sup>, and R<com:Sup>8< / com:Sup> are as defined as set forth above.
[0071] In some embodiments, provided herein are compounds according to Formula I, Formula A, Formula B, Formula Ia, Formula Ib, Formula Ic, Formula Id, or Formula Ie, wherein each R<com:Sup>7< / com:Sup> is independently hydrogen, halogen, cyano, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, or C<com:Sub>1-8< / com:Sub> alkoxy. In some embodiments, at least one R<com:Sup>7< / com:Sup> is halo, C<com:Sub>1-6< / com:Sub> alkyl, C<com:Sub>1-6< / com:Sub> alkoxy, cyano, or heteroaryl. In some embodiments, at least one R<com:Sup>7< / com:Sup> is chloro, fluoro, methyl, methoxy, cyano, bromo, triazolyl. In some embodiments, two of R<com:Sup>7< / com:Sup> is 7-chloro, 7-methyl, 8-methoxy, 9- fluoro, 6-fluoro, 6-fluoro-9-cyano, 7-fluoro-9-cyano, 9-cyano, 6-cyano, 8-cyano, 7-fluoro-, 9- bromo-7-fluoro-, or 9-triazol-2-yl.
[0072] In some embodiments at least one <com:Math><semantics>R7<annotation encoding="application / x-tex">R^7< / annotation>< / semantics>< / com:Math> is halo, <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> alkyl, <com:Math><semantics>C1−6<annotation encoding="application / x-tex">C_{1-6}< / annotation>< / semantics>< / com:Math> alkoxy, or cyano. In some embodiments, at least one R<com:Sup>7< / com:Sup> is chloro, fluoro, methyl, methoxy, cyano, or bromo. In some embodiments, one or two of R<com:Sup>7< / com:Sup> is 7-chloro, 7-methyl, 8-methoxy, 9-fluoro, 6-fluoro, 6- fluoro-9-cyano, 7-fluoro-9-cyano, 9-cyano, 6-cyano, 8-cyano, 7-fluoro-, or 9-bromo-7-fluoro-.
[0073] In some embodiments, provided herein are compounds according to Formula If: [Image disponible dans le document PDF, Image available in the PDF document] (If), wherein R<com:Sup>1d< / com:Sup>, R<com:Sup>1e< / com:Sup>, R<com:Sup>2a< / com:Sup>, R<com:Sup>2b< / com:Sup>, R<com:Sup>3a< / com:Sup>, R<com:Sup>3b< / com:Sup>, R<com:Sup>4a< / com:Sup>, R<com:Sup>5< / com:Sup>, R<com:Sup>6< / com:Sup>, R<com:Sup>7a< / com:Sup>, R<com:Sup>7b< / com:Sup>, R<com:Sup>8< / com:Sup>, Y, and Z are as defined for Formula I, Formula A, or Formula B; R<com:Sup>1a< / com:Sup>, R<com:Sup>1b< / com:Sup>, and R<com:Sup>1c< / com:Sup> are independently C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>2-8< / com:Sub> alkenyl, C<com:Sub>2-8< / com:Sub> alkynyl, C<com:Sub>1-8< / com:Sub> heteroalkyl, C<com:Sub>3-8< / com:Sub> cycloalkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, C<com:Sub>1-8< / com:Sub> alkoxy, C<com:Sub>1-8< / com:Sub> haloalkoxy, <com:Math><semantics>C6−10<annotation encoding="application / x-tex">C_{6-10}< / annotation>< / semantics>< / com:Math> aryl, 5- to 12-membered heteroaryl, <com:Math><semantics>−C(O)R1e<annotation encoding="application / x-tex">-C(O)R^{1e}< / annotation>< / semantics>< / com:Math>, or <com:Math><semantics>−C(O)N(R1d)2<annotation encoding="application / x-tex">-C(O)N(R^{1d})_2< / annotation>< / semantics>< / com:Math>, each of which is optionally and independently substituted with one or more (e.g., one to eight) R<com:Sup>5< / com:Sup>; or R<com:Sup>1b< / com:Sup> and R<com:Sup>1c< / com:Sup> are optionally taken together to form C<com:Sub>3-10< / com:Sub> cycloalkyl or 4- to 12-membered heterocyclyl, each of which is optionally and independently substituted with one or more <com:Math><semantics>(e.g.,onetoeight)R5<annotation encoding="application / x-tex">(e.g., one to eight) R^5< / annotation>< / semantics>< / com:Math>; or R<com:Sup>1b< / com:Sup> and R<com:Sup>4a< / com:Sup> are optionally taken together to form 4- to 12-membered heterocyclyl, which is optionally substituted with one or more (e.g., one to eight) R<com:Sup>6< / com:Sup>; or R<com:Sup>1a< / com:Sup>, R<com:Sup>1b< / com:Sup>, and R<com:Sup>1c< / com:Sup> are optionally taken together form a C<com:Sub>5-10< / com:Sub> cycloalkyl optionally substituted with one or more (e.g., one to eight) <com:Math><semantics>R5<annotation encoding="application / x-tex">R^5< / annotation>< / semantics>< / com:Math>; and each R<com:Sup>7< / com:Sup> is independently hydrogen, halogen, -CN, -SF<com:Sub>5< / com:Sub>, -SCF<com:Sub>3< / com:Sub>, C<com:Sub>2-8< / com:Sub> alkyl, C<com:Sub>2-8< / com:Sub> alkenyl, C<com:Sub>2-8< / com:Sub> alkynyl, C<com:Sub>3-8< / com:Sub> cycloalkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, 4- to 12-membered heterocyclyl, 5- to 12-membered [Image disponible dans le document PDF, Image available in the PDF document] <com:Math><semantics>−S(O)N(R7a)2<annotation encoding="application / x-tex">-S(O)N(R^{7a})_2< / annotation>< / semantics>< / com:Math>, or <com:Math><semantics>−S(O)2N(R7a)2<annotation encoding="application / x-tex">-S(O)_2N(R^{7a})_2< / annotation>< / semantics>< / com:Math>, each of which is optionally and independently substituted with one or more (e.g., one to eight) <com:Math><semantics>ℝ8<annotation encoding="application / x-tex">\mathbb{R}^8< / annotation>< / semantics>< / com:Math>; provided that at least one R<com:Sup>7< / com:Sup> is other than hydrogen.
[0074] In some embodiments, provided herein are compounds according to Formula If wherein each R<com:Sup>7< / com:Sup> is independently hydrogen, halogen, -CN, -SF<com:Sub>5< / com:Sub>, -SCF<com:Sub>3< / com:Sub>, C<com:Sub>2-8< / com:Sub> alkyl, C<com:Sub>2-8< / com:Sub> alkenyl, C<com:Sub>2-8< / com:Sub> alkynyl, C<com:Sub>3-8< / com:Sub> cycloalkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, 5- to 12-membered heteroaryl, <com:Math><semantics>−C(O)R7b<annotation encoding="application / x-tex">-C(O)R^{7b}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−SR7a<annotation encoding="application / x-tex">-SR^{7a}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(O)R7b<annotation encoding="application / x-tex">-S(O)R^{7b}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(O)2R7b<annotation encoding="application / x-tex">-S(O)_2R^{7b}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(O)3R7a<annotation encoding="application / x-tex">-S(O)_3R^{7a}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(O)N(R7a)2<annotation encoding="application / x-tex">-S(O)N(R^{7a})_2< / annotation>< / semantics>< / com:Math>, or <com:Math><semantics>−S(O)2N(R7a)2<annotation encoding="application / x-tex">-S(O)_2N(R^{7a})_2< / annotation>< / semantics>< / com:Math>, each of which is optionally and independently substituted with one or more (e.g., one to eight) R<com:Sup>8< / com:Sup>.
[0075] In some embodiments, provided herein are compounds according to Formula If wherein at least one R<com:Sup>7< / com:Sup> is halo, cyano, or 5- to 12-membered heteroaryl.
[0076] In some embodiments, provided herein are compounds according to Formula If wherein at least one <com:Math><semantics>ℝ7<annotation encoding="application / x-tex">\mathbb{R}^7< / annotation>< / semantics>< / com:Math> is chloro, fluoro, methyl, methoxy, cyano, bromo, triazolyl.
[0077] In some embodiments, provided herein are compounds according to Formula If wherein one or two of R<com:Sup>7< / com:Sup> is 7-chloro, 7-methyl, 8-methoxy, 9-fluoro, 6-fluoro, 6-fluoro-9- cyano, 7-fluoro-9-cyano, 9-cyano, 6-cyano, 8-cyano, 7-fluoro-, 9-bromo-7-fluoro-, or 9- triazol-2-yl.
[0078] In some embodiments, provided herein are compounds wherein Z is CH<com:Sub>2< / com:Sub>.
[0079] In some embodiments, provided herein are compounds wherein Z is O.
[0080] In some embodiments, provided herein are compounds wherein Y is CR<com:Sup>4a< / com:Sup>R<com:Sup>4b< / com:Sup>.
[0081] In some embodiments, provided herein are compounds according to Formula I, Formula A, or Formula B wherein R<com:Sup>1a< / com:Sup>, R<com:Sup>1b< / com:Sup>, and R<com:Sup>1c< / com:Sup> are independently hydrogen, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>1-8< / com:Sub> heteroalkyl, C<com:Sub>3-8< / com:Sub> cycloalkyl, C<com:Sub>6-10< / com:Sub> aryl, 4- to 12-membered heterocyclyl, or 5- to 12-membered heteroaryl.
[0082] In some embodiments, provided herein are compounds according to Formula I, Formula A, or Formula B wherein R<com:Sup>1a< / com:Sup> is hydrogen, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, and C<com:Sub>3-8< / com:Sub> cycloalkyl, wherein C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, and C<com:Sub>3-8< / com:Sub> cycloalkyl are optionally substituted with halogen or -CN.
[0083] In some embodiments, at least one of R<com:Sup>1a< / com:Sup>, R<com:Sup>1b< / com:Sup>, and R<com:Sup>1c< / com:Sup> is chloro, fluoro, methyl, -CD<com:Sub>3< / com:Sub>, ethyl, difluoromethyl, cyanomethyl, cyclopropyl, cyclopropylmethyl, trifluoromethyl, methoxy, trifluoromethoxymethyl, 2,2,2-trifluoroethyl, 1,1-difluoroethyl, 2- fluoroethyl, trifluoromethoxy, 1-cyanoethyl, fluoromethyl, 1-hydroxycyclopropyl, difluoromethylcyclo-propyl, cyanocyclopropyl, 3,3-difluorocyclobutyl, 1,1,2,2,2- pentafluoroethyl, 1-methylethyl, methylsulfanyl, methoxymethyl, 5-fluoropyrimidin-2- ylsulfanyl, azetidin-3-yl, pyrroldin-3-yl, cyano, or hydroxyl.
[0084] In some embodiments, at least one of R<com:Sup>1a< / com:Sup>, R<com:Sup>1b< / com:Sup>, and R<com:Sup>1c< / com:Sup> is chloro, methyl, -CD<com:Sub>3< / com:Sub>, ethyl, difluoromethyl, cyanomethyl, cyclopropyl, cyclopropylmethyl, trifluoromethyl, methoxy, trifluoromethoxymethyl, 2,2,2-trifluoroethyl, or 1,1-difluoroethyl. In some embodiments, R<com:Sup>1a< / com:Sup>, R<com:Sup>1b< / com:Sup>, and R<com:Sup>1c< / com:Sup> are taken together to form bicyclo[1.1.1]pentane, azabicyclo[4.1.0]heptane, azepan-4yl, 1,4-oxepane-7-yl, tetrahydropyran-2-yl, or 3,6- dihydro-2H-pyridin-4-yl. In some embodiments, R<com:Sup>1a< / com:Sup>, R<com:Sup>1b< / com:Sup>, and R<com:Sup>1c< / com:Sup> are taken together to form bicyclo[1.1.1]pentane.
[0085] In some embodiments, <com:Math><semantics>R1b<annotation encoding="application / x-tex">R^{1b}< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>R1c<annotation encoding="application / x-tex">R^{1c}< / annotation>< / semantics>< / com:Math> are taken together to form 4- to 12-membered heterocyclyl, each of which is optionally substituted with one or more (e.g., one to eight) R<com:Sup>5< / com:Sup>. R<com:Sup>1b< / com:Sup> and R<com:Sup>1c< / com:Sup> are taken together to form a 4, 5, 6, or 7 membered heterocyclyl containing a nitrogen ring atom and optionally substituted with one to eight <com:Math><semantics>ℝ5<annotation encoding="application / x-tex">\mathbb{R}^5< / annotation>< / semantics>< / com:Math>. In some embodiments, the heterocyclyl is substituted with one to four R<com:Sup>5< / com:Sup>. In some embodiments, at least one of R<com:Sup>5< / com:Sup> is C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, halogen, C<com:Sub>1-8< / com:Sub> haloalkyl, C<com:Sub>1-8< / com:Sub> alkoxy, -OH, or cyano. In some embodiments, at least one of R<com:Sup>5< / com:Sup> is methyl, ethyl, fluoro, chloro, difluoromethyl, fluoromethyl, methoxy, hydroxyl, C<com:Sub>1-8< / com:Sub> haloalkyl, halogen, C<com:Sub>1-8< / com:Sub> haloalkyl, C<com:Sub>1-8< / com:Sub> alkoxy, or cyano.
[0086] In some embodiments, at least one of R<com:Sup>5< / com:Sup> is 4- to 12-membered heterocyclyl or 5- to 12-membered heteroaryl, each of which is optionally substituted with one to eight R<com:Sup>5c< / com:Sup>. In some embodiments, at least one of R<com:Sup>5< / com:Sup> is a 5- to 12-membered heteroaryl optionally substituted with one to eight R<com:Sup>5c< / com:Sup>. For example, R<com:Sup>5< / com:Sup> can be pyrimidin-2-yl, pyrimidin-4-yl, pyrazin-2-yl, [1,2,4]triazolo[1,5-a]pyrazin-8-yl, [1,2,4]triazolo[1,5-c]pyrimidin-5-yl, pyrazolo[1,5-a][1,3,5]triazin-4-yl, pyrazolo[1,5-a]pyrimidin-7-yl, pyridazin-4-yl, quinazolin- 2-yl, imidazo[1,2-a]pyrazin-8-yl, pyrazolo[4,3-c]pyridin-6-yl, pyrrolo[3,2-d]pyrimidin-2-yl, imidazo[1,2-b]pyridazin-6-yl, pyrazolo[1,5-a]pyrimidin-7-yl, 6,7-dihydro-5H- cyclopenta[d]pyrimidin-2-yl, pyrid-2-yl, pyrid-3-yl, methoxypyridazin-3-yl, 5,7- dihydrofuro[3,4-d]pyrimidin-2-yl, purin-2-yl, quinazolin-2-yl, quinoxalin-2-yl, isoquinol-3- yl, quinol-2-yl, and 1,3,5-triazin-2-yl, or imidazo[2,1-f][1,2,4]triazin-4-yl, each of which can be optionally substituted with one to eight R<com:Sup>5c< / com:Sup>. In some embodiments, heterocyclyl in R<com:Sup>5< / com:Sup> is substituted with one to three R<com:Sup>5c< / com:Sup>. In some embodiments, R<com:Sup>5c< / com:Sup> is independently fluoro, methoxy, difluoromethoxy, methyl, methylamino, cyclopropylamino, 2,2-difluoroethoxy, methylsulfanyl, dimethylaminopropoxy, chloro, 2-methoxyethoxy, dimethylaminoethoxy, cyano, trifluoromethyl, ethoxy, difluoromethyl, cyclopropyl, and oxo.
[0087] In some embodiments, R<com:Sup>1b< / com:Sup> and R<com:Sup>1c< / com:Sup> are taken together to form 2,2-difluorocycobutyl, 3,3-difluorocycobutyl, (5-fluoropyrimidin-2-yl)piperidin-4-yl, tetrahydopyran-4-yl, tetrahydopyran-3-yl, tetrahydofuran-3-yl, cylcopropyl, or cyclobutyl.
[0088] Some embodiments provide compounds as described above wherein R<com:Sup>1a< / com:Sup> is hydrogen. In some embodiments, R<com:Sup>1a< / com:Sup> is chloro, fluoro, methyl, ethyl, difluoromethyl, fluoromethyl, cyano, or hydroxyl.
[0089] In some embodiments, provided herein are compounds according to Formula I, Formula A, or Formula B wherein <com:Math><semantics>R2a<annotation encoding="application / x-tex">R^{2a}< / annotation>< / semantics>< / com:Math> is hydrogen and <com:Math><semantics>R2b<annotation encoding="application / x-tex">R^{2b}< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>C1−8<annotation encoding="application / x-tex">C_{1-8}< / annotation>< / semantics>< / com:Math> alkyl.
[0090] In some embodiments, provided herein are compounds according to Formula I, Formula A, or Formula B wherein R<com:Sup>2a< / com:Sup> and R<com:Sup>2b< / com:Sup> are hydrogen.
[0091] In some embodiments, provided herein are compounds according to Formula I, Formula A, or Formula B wherein Z is O, R<com:Sup>1b< / com:Sup> and R<com:Sup>1c< / com:Sup> are C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, or C<com:Sub>3-8< / com:Sub> cycloalkyl, each of which is optionally substituted with halogen and / or -CN. In some embodiments, Z is CH<com:Sub>2< / com:Sub>, R<com:Sup>1b< / com:Sup> and R<com:Sup>1c< / com:Sup> are C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, or C<com:Sub>3-8< / com:Sub> cycloalkyl, each of which is optionally substituted with halogen and / or -CN.
[0092] In some embodiments, provided herein are compounds according to Formula I, Formula A, or Formula B wherein Z is O; R<com:Sup>2a< / com:Sup> and R<com:Sup>2b< / com:Sup> are hydrogen; and R<com:Sup>1b< / com:Sup> and R<com:Sup>1c< / com:Sup> are C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, or C<com:Sub>3-8< / com:Sub> cycloalkyl, each of which is optionally substituted with halogen and / or -CN. In some embodiments, Z is CH<com:Sub>2< / com:Sub>; R<com:Sup>2a< / com:Sup> and R<com:Sup>2b< / com:Sup> are hydrogen; and R<com:Sup>1b< / com:Sup> and R<com:Sup>1c< / com:Sup> are C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, or C<com:Sub>3-8< / com:Sub> cycloalkyl, each of which is optionally substituted with halogen and / or -CN.
[0093] In some embodiments, provided herein are compounds according to Formula I, Formula A, or Formula B wherein Z is O; R<com:Sup>2a< / com:Sup> is hydrogen; R<com:Sup>2b< / com:Sup> is C<com:Sub>1-4< / com:Sub> alkyl; and R<com:Sup>1b< / com:Sup> and R<com:Sup>1c< / com:Sup> are C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, or C<com:Sub>3-8< / com:Sub> cycloalkyl, each of which is optionally substituted with halogen and / or -CN. In some such embodiments, R<com:Sup>2b< / com:Sup> is methyl. In some embodiments, Z is CH<com:Sub>2< / com:Sub>; R<com:Sup>2a< / com:Sup> is hydrogen; R<com:Sup>2b< / com:Sup> is C<com:Sub>1-4< / com:Sub> alkyl; and R<com:Sup>1b< / com:Sup> and R<com:Sup>1c< / com:Sup> are C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, or C<com:Sub>3-8< / com:Sub> cycloalkyl, each of which is optionally substituted with halogen and / or -CN. In some such embodiments, <com:Math><semantics>R2b<annotation encoding="application / x-tex">R^{2b}< / annotation>< / semantics>< / com:Math> is methyl.
[0094] In some embodiments, provided herein are compounds according to Formula I, Formula A, or Formula B wherein R<com:Sup>1b< / com:Sup> and R<com:Sup>1c< / com:Sup> are independently selected C<com:Sub>1-8< / com:Sub> alkyl. For example, R<com:Sup>1b< / com:Sup> and R<com:Sup>1c< / com:Sup> can independently be methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, branched pentyl, n-hexyl, branched hexyl, n-heptyl, branched heptyl, n-octyl, or branched octyl. In some embodiments, R<com:Sup>1b< / com:Sup> and R<com:Sup>1c< / com:Sup> are independently selected C<com:Sub>1-4< / com:Sub> alkyl. In some embodiments, R<com:Sup>1b< / com:Sup> and R<com:Sup>1c< / com:Sup> are each methyl.
[0095] In some embodiments, provided herein are compounds according to Formula I, Formula A, or Formula B wherein R<com:Sup>1b< / com:Sup> and R<com:Sup>1c< / com:Sup> are independently selected C<com:Sub>1-4< / com:Sub> alkyl, and R<com:Sup>1a< / com:Sup> is C<com:Sub>1-4< / com:Sub> alkyl, halo-C<com:Sub>1-4< / com:Sub> alkyl, cyano-C<com:Sub>1-4< / com:Sub> alkyl, or cyclopropyl. In some embodiments, R<com:Sup>1b< / com:Sup> and <com:Math><semantics>R1c<annotation encoding="application / x-tex">R^{1c}< / annotation>< / semantics>< / com:Math> are independently selected <com:Math><semantics>C1−4<annotation encoding="application / x-tex">C_{1-4}< / annotation>< / semantics>< / com:Math> alkyl, and <com:Math><semantics>R1a<annotation encoding="application / x-tex">R^{1a}< / annotation>< / semantics>< / com:Math> is methyl, ethyl, difluoromethyl, cyanomethyl, 1,1-difluoroethyl, 2,2-difluoroethyl, or cyclopropyl.
[0096] In some embodiments, provided herein are compounds according to Formula I, Formula A, or Formula B wherein <com:Math><semantics>R1b<annotation encoding="application / x-tex">R^{1b}< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>R1c<annotation encoding="application / x-tex">R^{1c}< / annotation>< / semantics>< / com:Math> are each methyl, and <com:Math><semantics>R1a<annotation encoding="application / x-tex">R^{1a}< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>C1−4<annotation encoding="application / x-tex">C_{1-4}< / annotation>< / semantics>< / com:Math> alkyl, halo-C<com:Sub>1-4< / com:Sub> alkyl, cyano-C<com:Sub>1-4< / com:Sub> alkyl, or cyclopropyl. In some embodiments, R<com:Sup>1b< / com:Sup> and R<com:Sup>1c< / com:Sup> are each methyl, and R<com:Sup>1a< / com:Sup> is methyl, ethyl, difluoromethyl, cyanomethyl, 1,1-difluoroethyl, 2,2- difluoroethyl, or cyclopropyl.
[0097] In some embodiments, provided herein are compounds according to Formula I, Formula A, or Formula B wherein R<com:Sup>1b< / com:Sup> and R<com:Sup>1c< / com:Sup> are C<com:Sub>1-8< / com:Sub> haloalkyl or C<com:Sub>3-8< / com:Sub> cycloalkyl. For example, R<com:Sup>1b< / com:Sup> and R<com:Sup>1c< / com:Sup> can independently be chloromethyl, dichloromethyl, trichloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, 2,2,2-trichloroethyl, 2,2,2-trifluoroethyl, pentachloroethyl, pentafluoroethyl, 1,1,1,3,3,3-hexachloropropyl, 1,1,1,3,3,3- hexafluoropropyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl. In some embodiments, R<com:Sup>1b< / com:Sup> and R<com:Sup>1c< / com:Sup> are independently C<com:Sub>1-4< / com:Sub> haloalkyl or <com:Math><semantics>C3−6<annotation encoding="application / x-tex">C_{3-6}< / annotation>< / semantics>< / com:Math> cycloalkyl. In some embodiments, <com:Math><semantics>R1b<annotation encoding="application / x-tex">R^{1b}< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>R1c<annotation encoding="application / x-tex">R^{1c}< / annotation>< / semantics>< / com:Math> are trifluoromethyl or cyclopropyl.
[0098] In some embodiments, provided herein are compounds according to Formula I, Formula A, or Formula B wherein R<com:Sup>1b< / com:Sup> and R<com:Sup>1c< / com:Sup> are independently C<com:Sub>1-4< / com:Sub> haloalkyl or <com:Math><semantics>C3−6<annotation encoding="application / x-tex">C_{3-6}< / annotation>< / semantics>< / com:Math> cycloalkyl, and <com:Math><semantics>R1a<annotation encoding="application / x-tex">R^{1a}< / annotation>< / semantics>< / com:Math> is hydrogen. In some embodiments, <com:Math><semantics>R1b<annotation encoding="application / x-tex">R^{1b}< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>R1c<annotation encoding="application / x-tex">R^{1c}< / annotation>< / semantics>< / com:Math> are trifluoromethyl or cyclopropyl, and R<com:Sup>1a< / com:Sup> is hydrogen.
[0099] In some embodiments, provided herein are compounds according to Formula I, Formula A, or Formula B wherein Z is O or CH<com:Sub>2< / com:Sub>; R<com:Sup>2a< / com:Sup> and R<com:Sup>2b< / com:Sup> are independently hydrogen or <com:Math><semantics>C1−4<annotation encoding="application / x-tex">C_{1-4}< / annotation>< / semantics>< / com:Math> alkyl; <com:Math><semantics>R1b<annotation encoding="application / x-tex">R^{1b}< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>R1c<annotation encoding="application / x-tex">R^{1c}< / annotation>< / semantics>< / com:Math> are independently selected <com:Math><semantics>C1−4<annotation encoding="application / x-tex">C_{1-4}< / annotation>< / semantics>< / com:Math> alkyl; and <com:Math><semantics>R1a<annotation encoding="application / x-tex">R^{1a}< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>C1−4<annotation encoding="application / x-tex">C_{1-4}< / annotation>< / semantics>< / com:Math> alkyl, halo-C<com:Sub>1-4< / com:Sub> alkyl, cyano-C<com:Sub>1-4< / com:Sub> alkyl, or cyclopropyl. In some such embodiments, Y is CR<com:Sup>4a< / com:Sup>R<com:Sup>4b< / com:Sup>; and R<com:Sup>3a< / com:Sup>, R<com:Sup>3b< / com:Sup>, R<com:Sup>4a< / com:Sup>, and R<com:Sup>4b< / com:Sup> are independently hydrogen or C<com:Sub>1-4< / com:Sub> alkyl.
[0100] In some embodiments, provided herein are compounds according to Formula I, Formula A, or Formula B wherein Z is O or CH<com:Sub>2< / com:Sub>; R<com:Sup>2a< / com:Sup> and R<com:Sup>2b< / com:Sup> are independently hydrogen or <com:Math><semantics>C1−4<annotation encoding="application / x-tex">C_{1-4}< / annotation>< / semantics>< / com:Math> alkyl; <com:Math><semantics>R1b<annotation encoding="application / x-tex">R^{1b}< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>R1c<annotation encoding="application / x-tex">R^{1c}< / annotation>< / semantics>< / com:Math> are independently selected <com:Math><semantics>C1−4<annotation encoding="application / x-tex">C_{1-4}< / annotation>< / semantics>< / com:Math> alkyl; and <com:Math><semantics>R1a<annotation encoding="application / x-tex">R^{1a}< / annotation>< / semantics>< / com:Math> is methyl, ethyl, difluoromethyl, cyanomethyl, 1,1-difluoroethyl, 2,2-difluoroethyl, or cyclopropyl. In some such embodiments, Y is CR<com:Sup>4a< / com:Sup>R<com:Sup>4b< / com:Sup>; and R<com:Sup>3a< / com:Sup>, R<com:Sup>3b< / com:Sup>, R<com:Sup>4a< / com:Sup>, and R<com:Sup>4b< / com:Sup> are independently hydrogen or <com:Math><semantics>C1−4<annotation encoding="application / x-tex">C_{1-4}< / annotation>< / semantics>< / com:Math> alkyl.
[0101] In some embodiments, provided herein are compounds according to Formula I, Formula A, or Formula B wherein Z is O or CH<com:Sub>2< / com:Sub>; R<com:Sup>2a< / com:Sup> and R<com:Sup>2b< / com:Sup> are independently hydrogen or <com:Math><semantics>C1−4<annotation encoding="application / x-tex">C_{1-4}< / annotation>< / semantics>< / com:Math> alkyl; <com:Math><semantics>R1b<annotation encoding="application / x-tex">R^{1b}< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>R1c<annotation encoding="application / x-tex">R^{1c}< / annotation>< / semantics>< / com:Math> are each methyl; and <com:Math><semantics>R1a<annotation encoding="application / x-tex">R^{1a}< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>C1−4<annotation encoding="application / x-tex">C_{1-4}< / annotation>< / semantics>< / com:Math> alkyl, halo-<com:Math><semantics>C1−4<annotation encoding="application / x-tex">C_{1-4}< / annotation>< / semantics>< / com:Math> alkyl, cyano-<com:Math><semantics>C1−4<annotation encoding="application / x-tex">C_{1-4}< / annotation>< / semantics>< / com:Math> alkyl, or cyclopropyl. In some such embodiments, Y is CR<com:Sup>4a< / com:Sup>R<com:Sup>4b< / com:Sup>; and R<com:Sup>3a< / com:Sup>, R<com:Sup>3b< / com:Sup>, R<com:Sup>4a< / com:Sup>, and R<com:Sup>4b< / com:Sup> are independently hydrogen or C<com:Sub>1-4< / com:Sub> alkyl.
[0102] In some embodiments, provided herein are compounds according to Formula I, Formula A, or Formula B wherein Z is O or CH<com:Sub>2< / com:Sub>; R<com:Sup>2a< / com:Sup> and R<com:Sup>2b< / com:Sup> are independently hydrogen or <com:Math><semantics>C1−4<annotation encoding="application / x-tex">C_{1-4}< / annotation>< / semantics>< / com:Math> alkyl; <com:Math><semantics>R1b<annotation encoding="application / x-tex">R^{1b}< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>R1c<annotation encoding="application / x-tex">R^{1c}< / annotation>< / semantics>< / com:Math> are each methyl; and <com:Math><semantics>R1a<annotation encoding="application / x-tex">R^{1a}< / annotation>< / semantics>< / com:Math> is methyl, ethyl, difluoromethyl, cyanomethyl, 1,1-difluoroethyl, 2,2-difluoroethyl, or cyclopropyl. In some such embodiments, Y is CR<com:Sup>4a< / com:Sup>R<com:Sup>4b< / com:Sup>; and R<com:Sup>3a< / com:Sup>, R<com:Sup>3b< / com:Sup>, R<com:Sup>4a< / com:Sup>, and R<com:Sup>4b< / com:Sup> are independently hydrogen or C<com:Sub>1-4< / com:Sub> alkyl.
[0103] In some embodiments, provided herein are compounds according to Formula I, Formula A, or Formula B wherein Z is O or CH<com:Sub>2< / com:Sub>; R<com:Sup>2a< / com:Sup> and R<com:Sup>2b< / com:Sup> are independently hydrogen or C<com:Sub>1-4< / com:Sub> alkyl; R<com:Sup>1b< / com:Sup> and R<com:Sup>1c< / com:Sup> are independently C<com:Sub>1-4< / com:Sub> haloalkyl or C<com:Sub>3-6< / com:Sub> cycloalkyl; and R<com:Sup>1a< / com:Sup> is hydrogen. In some such embodiments, Y is CR<com:Sup>4a< / com:Sup>R<com:Sup>4b< / com:Sup>; and R<com:Sup>3a< / com:Sup>, R<com:Sup>3b< / com:Sup>, R<com:Sup>4a< / com:Sup>, and R<com:Sup>4b< / com:Sup> are independently hydrogen or C<com:Sub>1-4< / com:Sub> alkyl.
[0104] In some embodiments, provided herein are compounds according to Formula I, Formula A, or Formula B wherein Z is O or CH<com:Sub>2< / com:Sub>; R<com:Sup>2a< / com:Sup> and R<com:Sup>2b< / com:Sup> are independently hydrogen or C<com:Sub>1-4< / com:Sub> alkyl; R<com:Sup>1b< / com:Sup> and R<com:Sup>1c< / com:Sup> are trifluoromethyl or cyclopropyl; and R<com:Sup>1a< / com:Sup> is hydrogen. In some such embodiments, Y is CR<com:Sup>4a< / com:Sup>R<com:Sup>4b< / com:Sup>; and R<com:Sup>3a< / com:Sup>, R<com:Sup>3b< / com:Sup>, R<com:Sup>4a< / com:Sup>, and R<com:Sup>4b< / com:Sup> are independently hydrogen or C<com:Sub>1-4< / com:Sub> alkyl.
[0105] In some embodiments, provided herein are compounds according to Formula I, Formula A, or Formula B wherein R<com:Sup>1b< / com:Sup> and R<com:Sup>1c< / com:Sup> are taken together to form 4- to 12-membered heterocyclyl.
[0106] In some embodiments, provided herein are compounds according to Formula I, Formula A, or Formula B wherein R<com:Sup>1a< / com:Sup> is absent, and wherein R<com:Sup>1b< / com:Sup> and R<com:Sup>1c< / com:Sup> are taken together to form <com:Math><semantics>C6−10<annotation encoding="application / x-tex">C_{6-10}< / annotation>< / semantics>< / com:Math> aryl or 5- to 12-membered heteroaryl.
[0107] In some embodiments, provided herein are compounds according to Formula I, Formula A, or Formula B wherein R<com:Sup>4a< / com:Sup> is hydrogen or methyl.
[0108] In some embodiments, provided herein are compounds according to Formula I, Formula A, or Formula B wherein Y is O.
[0109] In some embodiments, provided herein are compounds according to Formula I, Formula A, or Formula B wherein R<com:Sup>3a< / com:Sup> and R<com:Sup>3b< / com:Sup> are independently hydrogen or methyl.
[0110] In some embodiments, provided herein are compounds according to Formula I, Formula A, or Formula B wherein W<com:Sup>1< / com:Sup>, W<com:Sup>2< / com:Sup>, W<com:Sup>3< / com:Sup>, and W<com:Sup>4< / com:Sup> are CR<com:Sup>7< / com:Sup>.
[0111] In some embodiments, provided herein are compounds according to Formula I, Formula A, or Formula B wherein W<com:Sup>2< / com:Sup>, W<com:Sup>3< / com:Sup>, and W<com:Sup>4< / com:Sup> are CR<com:Sup>7< / com:Sup>; wherein at least one R<com:Sup>7< / com:Sup> in W<com:Sup>2< / com:Sup>, <com:Math><semantics>W3<annotation encoding="application / x-tex">W^3< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>W4<annotation encoding="application / x-tex">W^4< / annotation>< / semantics>< / com:Math> is hydrogen; and wherein <com:Math><semantics>W1<annotation encoding="application / x-tex">W^1< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>CR7<annotation encoding="application / x-tex">CR^7< / annotation>< / semantics>< / com:Math>, wherein <com:Math><semantics>R7<annotation encoding="application / x-tex">R^7< / annotation>< / semantics>< / com:Math> in <com:Math><semantics>W1<annotation encoding="application / x-tex">W^1< / annotation>< / semantics>< / com:Math> is halogen, -CN, -N3, -NO2, -SF5, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C1-8 heteroalkyl, C<com:Sub>3-8< / com:Sub> cycloalkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, 4- to 12-membered heterocyclyl, C<com:Sub>6-10< / com:Sub> aryl, 5- to 12- membered heteroaryl, <com:Math><semantics>−OR7a<annotation encoding="application / x-tex">-OR^{7a}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(O)R7b<annotation encoding="application / x-tex">-C(O)R^{7b}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−N(R7a)2<annotation encoding="application / x-tex">-N(R^{7a})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(O)OR7a<annotation encoding="application / x-tex">-C(O)OR^{7a}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(O)N(R7a)2<annotation encoding="application / x-tex">-C(O)N(R^{7a})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NR7aC(O)R7b<annotation encoding="application / x-tex">-NR^{7a}C(O)R^{7b}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NR7aC(O)N(R7a)2<annotation encoding="application / x-tex">-NR^{7a}C(O)N(R^{7a})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NR7aC(O)OR7a<annotation encoding="application / x-tex">-NR^{7a}C(O)OR^{7a}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−OC(O)N(R7a)2<annotation encoding="application / x-tex">-OC(O)N(R^{7a})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−OC(O)OR7a<annotation encoding="application / x-tex">-OC(O)OR^{7a}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−SR7a<annotation encoding="application / x-tex">-SR^{7a}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(O)R7b<annotation encoding="application / x-tex">-S(O)R^{7b}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(O)2R7b<annotation encoding="application / x-tex">-S(O)_2R^{7b}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(O)3R7a<annotation encoding="application / x-tex">-S(O)_3R^{7a}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(O)N(R7a)2<annotation encoding="application / x-tex">-S(O)N(R^{7a})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(O)2N(R7a)2<annotation encoding="application / x-tex">-S(O)_2N(R^{7a})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NR7aS(O)R7b<annotation encoding="application / x-tex">-NR^{7a}S(O)R^{7b}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NR7aS(O)2R7b<annotation encoding="application / x-tex">-NR^{7a}S(O)_2R^{7b}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NR7aS(O)N(R7a)2<annotation encoding="application / x-tex">-NR^{7a}S(O)N(R^{7a})_2< / annotation>< / semantics>< / com:Math>, or <com:Math><semantics>−NR7aS(O)2N(R7a)2<annotation encoding="application / x-tex">-NR^{7a}S(O)_2N(R^{7a})_2< / annotation>< / semantics>< / com:Math>, each of which is optionally and independently substituted with one or more (e.g., one to eight) <com:Math><semantics>ℝ8<annotation encoding="application / x-tex">\mathbb{R}^8< / annotation>< / semantics>< / com:Math>. In some such embodiments, <com:Math><semantics>ℝ7<annotation encoding="application / x-tex">\mathbb{R}^7< / annotation>< / semantics>< / com:Math> in <com:Math><semantics>𝕎1<annotation encoding="application / x-tex">\mathbb{W}^1< / annotation>< / semantics>< / com:Math> is halogen, -CN, -NO<com:Sub>2< / com:Sub>, -SF<com:Sub>5< / com:Sub>, C<com:Sub>1-8< / com:Sub> haloalkyl, -C(O)R<com:Sup>7b< / com:Sup>, -C(O)OR<com:Sup>7a< / com:Sup>, -S(O)R<com:Sup>7b< / com:Sup>, -S(O)<com:Sub>2< / com:Sub>R<com:Sup>7b< / com:Sup>, or <com:Math><semantics>−S(O)3R7a<annotation encoding="application / x-tex">-S(O)_3R^{7a}< / annotation>< / semantics>< / com:Math>.
[0112] In some embodiments, provided herein are compounds according to Formula I, Formula A, or Formula B wherein W<com:Sup>1< / com:Sup>, W<com:Sup>3< / com:Sup>, and W<com:Sup>4< / com:Sup> are CR<com:Sup>7< / com:Sup>; wherein at least one R<com:Sup>7< / com:Sup> in W<com:Sup>1< / com:Sup>, <com:Math><semantics>W3<annotation encoding="application / x-tex">W^3< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>W4<annotation encoding="application / x-tex">W^4< / annotation>< / semantics>< / com:Math> is hydrogen; and wherein <com:Math><semantics>W2<annotation encoding="application / x-tex">W^2< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>CR7<annotation encoding="application / x-tex">CR^7< / annotation>< / semantics>< / com:Math>, wherein <com:Math><semantics>R7<annotation encoding="application / x-tex">R^7< / annotation>< / semantics>< / com:Math> in <com:Math><semantics>W2<annotation encoding="application / x-tex">W^2< / annotation>< / semantics>< / com:Math> is halogen, -CN, -N<com:Sub>3< / com:Sub>, -NO<com:Sub>2< / com:Sub>, -SF<com:Sub>5< / com:Sub>, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>2-8< / com:Sub> alkenyl, C<com:Sub>2-8< / com:Sub> alkynyl, C<com:Sub>1-8< / com:Sub> heteroalkyl, C<com:Sub>3-8< / com:Sub> cycloalkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, 4- to 12-membered heterocyclyl, C<com:Sub>6-10< / com:Sub> aryl, 5- to 12-membered heteroaryl, <com:Math><semantics>−OR7a<annotation encoding="application / x-tex">-OR^{7a}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(O)R7b<annotation encoding="application / x-tex">-C(O)R^{7b}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−N(R7a)2<annotation encoding="application / x-tex">-N(R^{7a})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(O)OR7a<annotation encoding="application / x-tex">-C(O)OR^{7a}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(O)N(R7a)2<annotation encoding="application / x-tex">-C(O)N(R^{7a})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NR7aC(O)R7b<annotation encoding="application / x-tex">-NR^{7a}C(O)R^{7b}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NR7aC(O)N(R7a)2<annotation encoding="application / x-tex">-NR^{7a}C(O)N(R^{7a})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NR7aC(O)OR7a<annotation encoding="application / x-tex">-NR^{7a}C(O)OR^{7a}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−OC(O)N(R7a)2<annotation encoding="application / x-tex">-OC(O)N(R^{7a})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−OC(O)OR7a<annotation encoding="application / x-tex">-OC(O)OR^{7a}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−SR7a<annotation encoding="application / x-tex">-SR^{7a}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(O)R7b<annotation encoding="application / x-tex">-S(O)R^{7b}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(O)2R7b<annotation encoding="application / x-tex">-S(O)_2R^{7b}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(O)3R7a<annotation encoding="application / x-tex">-S(O)_3R^{7a}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(O)N(R7a)2<annotation encoding="application / x-tex">-S(O)N(R^{7a})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(O)2N(R7a)2<annotation encoding="application / x-tex">-S(O)_2N(R^{7a})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NR7aS(O)R7b<annotation encoding="application / x-tex">-NR^{7a}S(O)R^{7b}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NR7aS(O)2R7b<annotation encoding="application / x-tex">-NR^{7a}S(O)_2R^{7b}< / annotation>< / semantics>< / com:Math>, -NR<com:Sup>7a< / com:Sup>S(O)N(R<com:Sup>7a< / com:Sup>)<com:Sub>2< / com:Sub>, or -NR<com:Sup>7a< / com:Sup>S(O)<com:Sub>2< / com:Sub>N(R<com:Sup>7a< / com:Sup>)<com:Sub>2< / com:Sub>, each of which is optionally and independently substituted with one or more (e.g., one to eight) <com:Math><semantics>ℝ8<annotation encoding="application / x-tex">\mathbb{R}^8< / annotation>< / semantics>< / com:Math>. In some such embodiments, <com:Math><semantics>ℝ7<annotation encoding="application / x-tex">\mathbb{R}^7< / annotation>< / semantics>< / com:Math> in <com:Math><semantics>𝕎2<annotation encoding="application / x-tex">\mathbb{W}^2< / annotation>< / semantics>< / com:Math> is halogen, -CN, -NO<com:Sub>2< / com:Sub>, -SF<com:Sub>5< / com:Sub>, C<com:Sub>1-8< / com:Sub> haloalkyl, -C(O)R<com:Sup>7b< / com:Sup>, -C(O)OR<com:Sup>7a< / com:Sup>, -S(O)R<com:Sup>7b< / com:Sup>, -S(O)<com:Sub>2< / com:Sub>R<com:Sup>7b< / com:Sup>, or <com:Math><semantics>−S(O)3R7a<annotation encoding="application / x-tex">-S(O)_3R^{7a}< / annotation>< / semantics>< / com:Math>.
[0113] In some embodiments, provided herein are compounds according to Formula I, Formula A, or Formula B wherein W<com:Sup>1< / com:Sup>, W<com:Sup>2< / com:Sup>, and W<com:Sup>4< / com:Sup> are CR<com:Sup>7< / com:Sup>; wherein at least one R<com:Sup>7< / com:Sup> in W<com:Sup>1< / com:Sup>, W<com:Sup>2< / com:Sup>, and W<com:Sup>4< / com:Sup> is hydrogen; and wherein W<com:Sup>3< / com:Sup> is CR<com:Sup>7< / com:Sup>, wherein R<com:Sup>7< / com:Sup> in W<com:Sup>3< / com:Sup> is halogen, -CN, -N<com:Sub>3< / com:Sub>, -NO<com:Sub>2< / com:Sub>, -SF<com:Sub>5< / com:Sub>, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>2-8< / com:Sub> alkenyl, C<com:Sub>2-8< / com:Sub> alkynyl, C<com:Sub>1-8< / com:Sub> heteroalkyl, C<com:Sub>3-8< / com:Sub> cycloalkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, 4- to 12-membered heterocyclyl, C<com:Sub>6-10< / com:Sub> aryl, 5- to 12-membered heteroaryl, <com:Math><semantics>−OR7a<annotation encoding="application / x-tex">-OR^{7a}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(O)R7b<annotation encoding="application / x-tex">-C(O)R^{7b}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−N(R7a)2<annotation encoding="application / x-tex">-N(R^{7a})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(O)OR7a<annotation encoding="application / x-tex">-C(O)OR^{7a}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(O)N(R7a)2<annotation encoding="application / x-tex">-C(O)N(R^{7a})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NR7aC(O)R7b<annotation encoding="application / x-tex">-NR^{7a}C(O)R^{7b}< / annotation>< / semantics>< / com:Math>, -NR<com:Sup>7a< / com:Sup>C(O)N(R<com:Sup>7a< / com:Sup>)<com:Sub>2< / com:Sub>, -NR<com:Sup>7a< / com:Sup>C(O)OR<com:Sup>7a< / com:Sup>, -OC(O)N(R<com:Sup>7a< / com:Sup>)<com:Sub>2< / com:Sub>, -OC(O)OR<com:Sup>7a< / com:Sup>, -SR<com:Sup>7a< / com:Sup>, -S(O)R<com:Sup>7b< / com:Sup>, <com:Math><semantics>−S(O)2R7b<annotation encoding="application / x-tex">-S(O)_2R^{7b}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(O)3R7a<annotation encoding="application / x-tex">-S(O)_3R^{7a}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(O)N(R7a)2<annotation encoding="application / x-tex">-S(O)N(R^{7a})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(O)2N(R7a)2<annotation encoding="application / x-tex">-S(O)_2N(R^{7a})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NR7aS(O)R7b<annotation encoding="application / x-tex">-NR^{7a}S(O)R^{7b}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NR7aS(O)2R7b<annotation encoding="application / x-tex">-NR^{7a}S(O)_2R^{7b}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NR7aS(O)N(R7a)2<annotation encoding="application / x-tex">-NR^{7a}S(O)N(R^{7a})_2< / annotation>< / semantics>< / com:Math>, or <com:Math><semantics>−NR7aS(O)2N(R7a)2<annotation encoding="application / x-tex">-NR^{7a}S(O)_2N(R^{7a})_2< / annotation>< / semantics>< / com:Math>, each of which is optionally and independently substituted with one or more (e.g., one to eight) <com:Math><semantics>ℝ8<annotation encoding="application / x-tex">\mathbb{R}^8< / annotation>< / semantics>< / com:Math>. In some such embodiments, <com:Math><semantics>ℝ7<annotation encoding="application / x-tex">\mathbb{R}^7< / annotation>< / semantics>< / com:Math> in <com:Math><semantics>𝕎3<annotation encoding="application / x-tex">\mathbb{W}^3< / annotation>< / semantics>< / com:Math> is halogen, -CN, -NO<com:Sub>2< / com:Sub>, -SF<com:Sub>5< / com:Sub>, C<com:Sub>1-8< / com:Sub> haloalkyl, -C(O)R<com:Sup>7b< / com:Sup>, -C(O)OR<com:Sup>7a< / com:Sup>, -S(O)R<com:Sup>7b< / com:Sup>, -S(O)<com:Sub>2< / com:Sub>R<com:Sup>7b< / com:Sup>, or <com:Math><semantics>−S(O)3R7a<annotation encoding="application / x-tex">-S(O)_3R^{7a}< / annotation>< / semantics>< / com:Math>.
[0114] In some embodiments, provided herein are compounds according to Formula I, Formula A, or Formula B wherein W<com:Sup>1< / com:Sup>, W<com:Sup>2< / com:Sup>, and W<com:Sup>3< / com:Sup> are CR<com:Sup>7< / com:Sup>; wherein at least one R<com:Sup>7< / com:Sup> in W<com:Sup>1< / com:Sup>, <com:Math><semantics>W2<annotation encoding="application / x-tex">W^2< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>W3<annotation encoding="application / x-tex">W^3< / annotation>< / semantics>< / com:Math> is hydrogen; and wherein <com:Math><semantics>W4<annotation encoding="application / x-tex">W^4< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>CR7<annotation encoding="application / x-tex">CR^7< / annotation>< / semantics>< / com:Math>, wherein <com:Math><semantics>R7<annotation encoding="application / x-tex">R^7< / annotation>< / semantics>< / com:Math> in <com:Math><semantics>W4<annotation encoding="application / x-tex">W^4< / annotation>< / semantics>< / com:Math> is halogen, -CN, -N<com:Sub>3< / com:Sub>, -NO<com:Sub>2< / com:Sub>, -SF<com:Sub>5< / com:Sub>, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>2-8< / com:Sub> alkenyl, C<com:Sub>2-8< / com:Sub> alkynyl, C<com:Sub>1-8< / com:Sub> heteroalkyl, C<com:Sub>3-8< / com:Sub> cycloalkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, 4- to 12-membered heterocyclyl, C<com:Sub>6-10< / com:Sub> aryl, 5- to 12-membered heteroaryl, <com:Math><semantics>−OR7a<annotation encoding="application / x-tex">-OR^{7a}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(O)R7b<annotation encoding="application / x-tex">-C(O)R^{7b}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−N(R7a)2<annotation encoding="application / x-tex">-N(R^{7a})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(O)OR7a<annotation encoding="application / x-tex">-C(O)OR^{7a}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(O)N(R7a)2<annotation encoding="application / x-tex">-C(O)N(R^{7a})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NR7aC(O)R7b<annotation encoding="application / x-tex">-NR^{7a}C(O)R^{7b}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NR7aC(O)N(R7a)2<annotation encoding="application / x-tex">-NR^{7a}C(O)N(R^{7a})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NR7aC(O)OR7a<annotation encoding="application / x-tex">-NR^{7a}C(O)OR^{7a}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−OC(O)N(R7a)2<annotation encoding="application / x-tex">-OC(O)N(R^{7a})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−OC(O)OR7a<annotation encoding="application / x-tex">-OC(O)OR^{7a}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−SR7a<annotation encoding="application / x-tex">-SR^{7a}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(O)R7b<annotation encoding="application / x-tex">-S(O)R^{7b}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(O)2R7b<annotation encoding="application / x-tex">-S(O)_2R^{7b}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(O)3R7a<annotation encoding="application / x-tex">-S(O)_3R^{7a}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(O)N(R7a)2<annotation encoding="application / x-tex">-S(O)N(R^{7a})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(O)2N(R7a)2<annotation encoding="application / x-tex">-S(O)_2N(R^{7a})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NR7aS(O)R7b<annotation encoding="application / x-tex">-NR^{7a}S(O)R^{7b}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NR7aS(O)2R7b<annotation encoding="application / x-tex">-NR^{7a}S(O)_2R^{7b}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NR7aS(O)N(R7a)2<annotation encoding="application / x-tex">-NR^{7a}S(O)N(R^{7a})_2< / annotation>< / semantics>< / com:Math>, or <com:Math><semantics>−NR7aS(O)2N(R7a)2<annotation encoding="application / x-tex">-NR^{7a}S(O)_2N(R^{7a})_2< / annotation>< / semantics>< / com:Math>, each of which is optionally and independently substituted with one or more (e.g., one to eight) <com:Math><semantics>ℝ8<annotation encoding="application / x-tex">\mathbb{R}^8< / annotation>< / semantics>< / com:Math>. In some such embodiments, <com:Math><semantics>ℝ7<annotation encoding="application / x-tex">\mathbb{R}^7< / annotation>< / semantics>< / com:Math> in <com:Math><semantics>𝕎4<annotation encoding="application / x-tex">\mathbb{W}^4< / annotation>< / semantics>< / com:Math> is halogen, -CN, -NO<com:Sub>2< / com:Sub>, -SF<com:Sub>5< / com:Sub>, <com:Math><semantics>C1−8<annotation encoding="application / x-tex">C_{1-8}< / annotation>< / semantics>< / com:Math> haloalkyl, -C(O)<com:Math><semantics>R7b<annotation encoding="application / x-tex">R^{7b}< / annotation>< / semantics>< / com:Math>, -C(O)<com:Math><semantics>QR7a<annotation encoding="application / x-tex">QR^{7a}< / annotation>< / semantics>< / com:Math>, -S(O)<com:Math><semantics>QR7b<annotation encoding="application / x-tex">QR^{7b}< / annotation>< / semantics>< / com:Math>, -S(O)<com:Math><semantics>QR7b<annotation encoding="application / x-tex">QR^{7b}< / annotation>< / semantics>< / com:Math>, or <com:Math><semantics>−S(O)3R7a<annotation encoding="application / x-tex">-S(O)_3R^{7a}< / annotation>< / semantics>< / com:Math>.
[0115] In some embodiments, provided herein are compounds according to Formula I, Formula A, or Formula B wherein W<com:Sup>1< / com:Sup>, W<com:Sup>2< / com:Sup>, W<com:Sup>3< / com:Sup>, and W<com:Sup>4< / com:Sup> are CR<com:Sup>7< / com:Sup>; wherein each R<com:Sup>7< / com:Sup> in W<com:Sup>2< / com:Sup>, W<com:Sup>3< / com:Sup>, and W<com:Sup>4< / com:Sup> is independently hydrogen, halogen, -CN, -NO<com:Sub>2< / com:Sub>, -SF<com:Sub>5< / com:Sub>, C<com:Sub>1-8< / com:Sub> haloalkyl, -C(O)R<com:Sup>7b< / com:Sup>, <com:Math><semantics>−C(O)OR7a<annotation encoding="application / x-tex">-C(O)OR^{7a}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(O)R7b<annotation encoding="application / x-tex">-S(O)R^{7b}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(O)2R7b<annotation encoding="application / x-tex">-S(O)_2R^{7b}< / annotation>< / semantics>< / com:Math>, or <com:Math><semantics>−S(O)3R7a<annotation encoding="application / x-tex">-S(O)_3R^{7a}< / annotation>< / semantics>< / com:Math>; and wherein <com:Math><semantics>R7<annotation encoding="application / x-tex">R^7< / annotation>< / semantics>< / com:Math> is in <com:Math><semantics>W1<annotation encoding="application / x-tex">W^1< / annotation>< / semantics>< / com:Math> is halogen, <com:Math><semantics>−CN<annotation encoding="application / x-tex">-CN< / annotation>< / semantics>< / com:Math>, -NO<com:Sub>2< / com:Sub>, -SF<com:Sub>5< / com:Sub>, C<com:Sub>1-8< / com:Sub> haloalkyl, -C(O)<com:Math><semantics>R7b<annotation encoding="application / x-tex">R^{7b}< / annotation>< / semantics>< / com:Math>, -C(O)O<com:Math><semantics>R7a<annotation encoding="application / x-tex">R^{7a}< / annotation>< / semantics>< / com:Math>, -S(O)<com:Math><semantics>R7b<annotation encoding="application / x-tex">R^{7b}< / annotation>< / semantics>< / com:Math>, -S(O)<com:Sub>2< / com:Sub><com:Math><semantics>R7b<annotation encoding="application / x-tex">R^{7b}< / annotation>< / semantics>< / com:Math>, or -S(O)<com:Sub>3< / com:Sub><com:Math><semantics>R7a<annotation encoding="application / x-tex">R^{7a}< / annotation>< / semantics>< / com:Math>.
[0116] In some embodiments, provided herein are compounds according to Formula I, Formula A, or Formula B wherein W<com:Sup>1< / com:Sup>, W<com:Sup>2< / com:Sup>, W<com:Sup>3< / com:Sup>, and W<com:Sup>4< / com:Sup> are CR<com:Sup>7< / com:Sup>; wherein each R<com:Sup>7< / com:Sup> in W<com:Sup>1< / com:Sup>, W<com:Sup>3< / com:Sup>, and W<com:Sup>4< / com:Sup> is independently hydrogen, halogen, -CN, -NO<com:Sub>2< / com:Sub>, -SF<com:Sub>5< / com:Sub>, C<com:Sub>1-8< / com:Sub> haloalkyl, -C(O)R<com:Sup>7b< / com:Sup>, <com:Math><semantics>−C(O)OR7a<annotation encoding="application / x-tex">-C(O)OR^{7a}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(O)R7b<annotation encoding="application / x-tex">-S(O)R^{7b}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(O)2R7b<annotation encoding="application / x-tex">-S(O)_2R^{7b}< / annotation>< / semantics>< / com:Math>, or <com:Math><semantics>−S(O)3R7a<annotation encoding="application / x-tex">-S(O)_3R^{7a}< / annotation>< / semantics>< / com:Math>; and wherein <com:Math><semantics>R7<annotation encoding="application / x-tex">R^7< / annotation>< / semantics>< / com:Math> is in <com:Math><semantics>W2<annotation encoding="application / x-tex">W^2< / annotation>< / semantics>< / com:Math> is halogen, <com:Math><semantics>−CN<annotation encoding="application / x-tex">-CN< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NO2<annotation encoding="application / x-tex">-NO_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−SF5<annotation encoding="application / x-tex">-SF_5< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C1−8<annotation encoding="application / x-tex">C_{1-8}< / annotation>< / semantics>< / com:Math> haloalkyl, <com:Math><semantics>−C(O)R7b<annotation encoding="application / x-tex">-C(O)R^{7b}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(O)OR7a<annotation encoding="application / x-tex">-C(O)OR^{7a}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(O)R7b<annotation encoding="application / x-tex">-S(O)R^{7b}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(O)2R7b<annotation encoding="application / x-tex">-S(O)_2R^{7b}< / annotation>< / semantics>< / com:Math>, or <com:Math><semantics>−S(O)3R7a<annotation encoding="application / x-tex">-S(O)_3R^{7a}< / annotation>< / semantics>< / com:Math>.
[0117] In some embodiments, provided herein are compounds according to Formula I, Formula A, or Formula B wherein W<com:Sup>1< / com:Sup>, W<com:Sup>2< / com:Sup>, W<com:Sup>3< / com:Sup>, and W<com:Sup>4< / com:Sup> are CR<com:Sup>7< / com:Sup>; wherein each R<com:Sup>7< / com:Sup> in W<com:Sup>1< / com:Sup>, W<com:Sup>2< / com:Sup>, and W<com:Sup>4< / com:Sup> is independently hydrogen, halogen, -CN, -NO<com:Sub>2< / com:Sub>, -SF<com:Sub>5< / com:Sub>, C<com:Sub>1-8< / com:Sub> haloalkyl, -C(O)R<com:Sup>7b< / com:Sup>, <com:Math><semantics>−C(O)OR7a<annotation encoding="application / x-tex">-C(O)OR^{7a}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(O)R7b<annotation encoding="application / x-tex">-S(O)R^{7b}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(O)2R7b<annotation encoding="application / x-tex">-S(O)_2R^{7b}< / annotation>< / semantics>< / com:Math>, or <com:Math><semantics>−S(O)3R7a<annotation encoding="application / x-tex">-S(O)_3R^{7a}< / annotation>< / semantics>< / com:Math>; and wherein <com:Math><semantics>R7<annotation encoding="application / x-tex">R^7< / annotation>< / semantics>< / com:Math> is in <com:Math><semantics>W3<annotation encoding="application / x-tex">W^3< / annotation>< / semantics>< / com:Math> is halogen, <com:Math><semantics>−CN<annotation encoding="application / x-tex">-CN< / annotation>< / semantics>< / com:Math>, -NO<com:Sub>2< / com:Sub>, -SF<com:Sub>5< / com:Sub>, C<com:Sub>1-8< / com:Sub> haloalkyl, -C(O)<com:Math><semantics>R7b<annotation encoding="application / x-tex">R^{7b}< / annotation>< / semantics>< / com:Math>, -C(O)<com:Math><semantics>QR7a<annotation encoding="application / x-tex">QR^{7a}< / annotation>< / semantics>< / com:Math>, -S(O)<com:Math><semantics>QR7b<annotation encoding="application / x-tex">QR^{7b}< / annotation>< / semantics>< / com:Math>, -S(O)<com:Math><semantics>QR7b<annotation encoding="application / x-tex">QR^{7b}< / annotation>< / semantics>< / com:Math>, or -S(O)<com:Math><semantics>QR7a<annotation encoding="application / x-tex">QR^{7a}< / annotation>< / semantics>< / com:Math>.
[0118] In some embodiments, provided herein are compounds according to Formula I, Formula A, or Formula B wherein W<com:Sup>1< / com:Sup>, W<com:Sup>2< / com:Sup>, W<com:Sup>3< / com:Sup>, and W<com:Sup>4< / com:Sup> are CR<com:Sup>7< / com:Sup>; wherein each R<com:Sup>7< / com:Sup> in W<com:Sup>1< / com:Sup>, W<com:Sup>2< / com:Sup>, and W<com:Sup>3< / com:Sup> is independently hydrogen, halogen, -CN, -NO<com:Sub>2< / com:Sub>, -SF<com:Sub>5< / com:Sub>, C<com:Sub>1-8< / com:Sub> haloalkyl, -C(O)R<com:Sup>7b< / com:Sup>, <com:Math><semantics>−C(O)OR7a<annotation encoding="application / x-tex">-C(O)OR^{7a}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(O)R7b<annotation encoding="application / x-tex">-S(O)R^{7b}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(O)2R7b<annotation encoding="application / x-tex">-S(O)_2R^{7b}< / annotation>< / semantics>< / com:Math>, or <com:Math><semantics>−S(O)3R7a<annotation encoding="application / x-tex">-S(O)_3R^{7a}< / annotation>< / semantics>< / com:Math>; and wherein <com:Math><semantics>R7<annotation encoding="application / x-tex">R^7< / annotation>< / semantics>< / com:Math> is in <com:Math><semantics>W4<annotation encoding="application / x-tex">W^4< / annotation>< / semantics>< / com:Math> is halogen, <com:Math><semantics>−CN<annotation encoding="application / x-tex">-CN< / annotation>< / semantics>< / com:Math>, -NO<com:Sub>2< / com:Sub>, -SF<com:Sub>5< / com:Sub>, C<com:Sub>1-8< / com:Sub> haloalkyl, -C(O)<com:Math><semantics>R7b<annotation encoding="application / x-tex">R^{7b}< / annotation>< / semantics>< / com:Math>, -C(O)O<com:Math><semantics>R7a<annotation encoding="application / x-tex">R^{7a}< / annotation>< / semantics>< / com:Math>, -S(O)<com:Math><semantics>R7b<annotation encoding="application / x-tex">R^{7b}< / annotation>< / semantics>< / com:Math>, -S(O)<com:Sub>2< / com:Sub><com:Math><semantics>R7b<annotation encoding="application / x-tex">R^{7b}< / annotation>< / semantics>< / com:Math>, or -S(O)<com:Sub>3< / com:Sub><com:Math><semantics>R7a<annotation encoding="application / x-tex">R^{7a}< / annotation>< / semantics>< / com:Math>.
[0119] In some embodiments, provided herein are compounds according to Formula A or Formula B wherein W<com:Sup>1< / com:Sup> is N and W<com:Sup>2< / com:Sup>, W<com:Sup>3< / com:Sup>, and W<com:Sup>4< / com:Sup> are CR<com:Sup>7< / com:Sup>. In some such embodiments, R<com:Sup>7< / com:Sup> in each of W<com:Sup>2< / com:Sup>, W<com:Sup>3< / com:Sup>, and W<com:Sup>4< / com:Sup> is independently hydrogen, halogen, -CN, -NO<com:Sub>2< / com:Sub>, -SF<com:Sub>5< / com:Sub>, C<com:Sub>1-8< / com:Sub> haloalkyl, <com:Math><semantics>−C(O)R7b<annotation encoding="application / x-tex">-C(O)R^{7b}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(O)OR7a<annotation encoding="application / x-tex">-C(O)OR^{7a}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(O)R7b<annotation encoding="application / x-tex">-S(O)R^{7b}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(O)2R7b<annotation encoding="application / x-tex">-S(O)_2R^{7b}< / annotation>< / semantics>< / com:Math>, or <com:Math><semantics>−S(O)3R7a<annotation encoding="application / x-tex">-S(O)_3R^{7a}< / annotation>< / semantics>< / com:Math>.
[0120] In some embodiments, provided herein are compounds according to Formula I, Formula A, or Formula B wherein W<com:Sup>2< / com:Sup> is N and W<com:Sup>1< / com:Sup>, W<com:Sup>3< / com:Sup>, and W<com:Sup>4< / com:Sup> are CR<com:Sup>7< / com:Sup>. In some such embodiments, R<com:Sup>7< / com:Sup> in each of W<com:Sup>1< / com:Sup>, W<com:Sup>3< / com:Sup>, and W<com:Sup>4< / com:Sup> is independently hydrogen, halogen, -CN, -NO<com:Sub>2< / com:Sub>, -SF<com:Sub>5< / com:Sub>, C<com:Sub>1-8< / com:Sub> haloalkyl, -C(O)<com:Math><semantics>R7b<annotation encoding="application / x-tex">R^{7b}< / annotation>< / semantics>< / com:Math>, -C(O)<com:Math><semantics>QR7a<annotation encoding="application / x-tex">QR^{7a}< / annotation>< / semantics>< / com:Math>, -S(O)<com:Math><semantics>R7b<annotation encoding="application / x-tex">R^{7b}< / annotation>< / semantics>< / com:Math>, -S(O)<com:Sub>2< / com:Sub><com:Math><semantics>R7b<annotation encoding="application / x-tex">R^{7b}< / annotation>< / semantics>< / com:Math>, or -S(O)<com:Sub>3< / com:Sub><com:Math><semantics>R7a<annotation encoding="application / x-tex">R^{7a}< / annotation>< / semantics>< / com:Math>.
[0121] In some embodiments, provided herein are compounds according to Formula A or Formula B wherein W<com:Sup>3< / com:Sup> is N and W<com:Sup>1< / com:Sup>, W<com:Sup>2< / com:Sup>, and W<com:Sup>4< / com:Sup> are CR<com:Sup>7< / com:Sup>. In some such embodiments, R<com:Sup>7< / com:Sup> in each of W<com:Sup>1< / com:Sup>, W<com:Sup>2< / com:Sup>, and W<com:Sup>4< / com:Sup> is independently hydrogen, halogen, -CN, -NO<com:Sub>2< / com:Sub>, -SF<com:Sub>5< / com:Sub>, C<com:Sub>1-8< / com:Sub> haloalkyl, <com:Math><semantics>−C(O)R7b<annotation encoding="application / x-tex">-C(O)R^{7b}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(O)OR7a<annotation encoding="application / x-tex">-C(O)OR^{7a}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(O)R7b<annotation encoding="application / x-tex">-S(O)R^{7b}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(O)2R7b<annotation encoding="application / x-tex">-S(O)_2R^{7b}< / annotation>< / semantics>< / com:Math>, or <com:Math><semantics>−S(O)3R7a<annotation encoding="application / x-tex">-S(O)_3R^{7a}< / annotation>< / semantics>< / com:Math>.
[0122] In some embodiments, provided herein are compounds according to Formula A or Formula B wherein W<com:Sup>1< / com:Sup>, W<com:Sup>2< / com:Sup>, and W<com:Sup>3< / com:Sup> are CR<com:Sup>7< / com:Sup> and W<com:Sup>4< / com:Sup> is N. In some such embodiments, R<com:Sup>7< / com:Sup> in each of W<com:Sup>1< / com:Sup>, W<com:Sup>2< / com:Sup>, and W<com:Sup>3< / com:Sup> is independently hydrogen, halogen, -CN, -NO<com:Sub>2< / com:Sub>, -SF<com:Sub>5< / com:Sub>, C<com:Sub>1-8< / com:Sub> haloalkyl, <com:Math><semantics>−C(O)R7b<annotation encoding="application / x-tex">-C(O)R^{7b}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(O)OR7a<annotation encoding="application / x-tex">-C(O)OR^{7a}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(O)R7b<annotation encoding="application / x-tex">-S(O)R^{7b}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(O)2R7b<annotation encoding="application / x-tex">-S(O)_2R^{7b}< / annotation>< / semantics>< / com:Math>, or <com:Math><semantics>−S(O)3R7a<annotation encoding="application / x-tex">-S(O)_3R^{7a}< / annotation>< / semantics>< / com:Math>.
[0123] In some embodiments, provided herein are compounds according to Formula A or Formula B wherein W<com:Sup>4< / com:Sup> is CR<com:Sup>7< / com:Sup> and R<com:Sup>7< / com:Sup> of W<com:Sup>4< / com:Sup> is CN or halogen. In some such embodiments, W<com:Sup>4< / com:Sup> is C-CN. In some such embodiments, W<com:Sup>4< / com:Sup> is C-CN, and W<com:Sup>2< / com:Sup> is N. In some embodiments, W<com:Sup>4< / com:Sup> is C-CN, W<com:Sup>2< / com:Sup> is N, and Z is O or S. In some embodiments, W<com:Sup>4< / com:Sup> is C-X, wherein X is halogen; and W<com:Sup>2< / com:Sup> is N. In some embodiments, W<com:Sup>4< / com:Sup> is C-X, wherein X is halogen; W<com:Sup>2< / com:Sup> is N; and Z is O or S. In some such embodiments, Z is O.
[0124] In some such embodiments, W<com:Sup>4< / com:Sup> is C-CN; and W<com:Sup>2< / com:Sup> is CH or C-X, wherein X is halogen. In some embodiments, W<com:Sup>4< / com:Sup> is C-CN, W<com:Sup>2< / com:Sup> is CH or C-X, wherein X is halogen; and Z is O or S. In some embodiments, W<com:Sup>4< / com:Sup> is C-X, wherein X is halogen; and W<com:Sup>2< / com:Sup> is CH or C-X, wherein X is halogen. In some embodiments, W<com:Sup>4< / com:Sup> is C-X, wherein X is halogen; W<com:Sup>2< / com:Sup> is CH or C-X, wherein X is halogen; and Z is O or S. In some such embodiments, Z is O.
[0125] In some embodiments, provided herein are compounds according to Formula A or Formula B wherein W<com:Sup>1< / com:Sup> is N; R<com:Sup>1a< / com:Sup> is present; and at least two of R<com:Sup>1a< / com:Sup>, R<com:Sup>1b< / com:Sup>, and R<com:Sup>1c< / com:Sup> are other than hydrogen.
[0126] In some embodiments, provided herein are compounds according to Formula I wherein each R<com:Sup>7< / com:Sup> is independently hydrogen, halogen, cyano, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, or <com:Math><semantics>C1−8<annotation encoding="application / x-tex">C_{1-8}< / annotation>< / semantics>< / com:Math> alkoxy.
[0127] In some embodiments, provided herein is a compound which is selected from Table 1 or Examples 258-309, or a pharmaceutically acceptable salt, solvate, prodrug, isotopic analog, or isomer thereof. III. Synthesis of Compounds
[0128] The compounds may be prepared using the methods disclosed herein and routine modifications thereof, which will be apparent given the disclosure herein and methods well known in the art. Conventional and well-known synthetic methods may be used in addition to the teachings herein. The synthesis of typical compounds described herein may be accomplished as described in the following examples. If available, reagents may be purchased commercially, e.g., from Sigma Aldrich or other chemical suppliers. It will be appreciated that where typical or preferred process conditions (i.e., reaction temperatures, times, mole ratios of reactants, solvents, pressures, etc.) are given, other process conditions can also be used unless otherwise stated. Optimum reaction conditions may vary with the particular reactants or solvent used, but such conditions can be determined by one skilled in the art by routine optimization procedures.
[0129] Additionally, as will be apparent to those skilled in the art, conventional protecting groups may be necessary to prevent certain functional groups from undergoing undesired reactions. Suitable protecting groups for various functional groups as well as suitable conditions for protecting and deprotecting particular functional groups are well known in the art. For example, numerous protecting groups are described in Wuts, P. G. M., Greene, T. W., & Greene, T. W. (2006). Greene's protective groups in organic synthesis. Hoboken, N.J., Wiley-Interscience, and references cited therein.
[0130] Furthermore, the compounds of this disclosure may contain one or more chiral centers. Accordingly, if desired, such compounds can be prepared or isolated as pure stereoisomers, i.e., as individual enantiomers or diastereomers or as stereoisomer-enriched mixtures. All such stereoisomers (and enriched mixtures) are included within the scope of this disclosure, unless otherwise indicated. Pure stereoisomers (or enriched mixtures) may be prepared using, for example, optically active starting materials or stereoselective reagents well-known in the art. Alternatively, racemic mixtures of such compounds can be separated using, for example, chiral column chromatography, chiral resolving agents, and the like.
[0131] The starting materials for the following reactions are generally known compounds or can be prepared by known procedures or obvious modifications thereof. For example, many of the starting materials are available from commercial suppliers such as Aldrich Chemical Co. (Milwaukee, Wisconsin, USA), Bachem (Torrance, California, USA), Emka- Chemce or Sigma (St. Louis, Missouri, USA). Others may be prepared by procedures or obvious modifications thereof, described in standard reference texts such as Fieser and Fieser's Reagents for Organic Synthesis, Volumes 1-15 (John Wiley, and Sons, 1991), Rodd's Chemistry of Carbon Compounds, Volumes 1-5, and Supplementals (Elsevier Science Publishers, 1989) organic Reactions, Volumes 1-40 (John Wiley, and Sons, 1991), March's Advanced Organic Chemistry, (John Wiley, and Sons, 5th Edition, 2001), and Larock's Comprehensive Organic Transformations (VCH Publishers Inc., 1989).
[0132] The terms "solvent," "inert organic solvent" or "inert solvent" refer to a solvent inert under the conditions of the reaction being described in conjunction therewith (including, for example, benzene, toluene, acetonitrile, tetrahydrofuran ("THF"), dimethylformamide ("DMF"), chloroform, methylene chloride (or dichloromethane), diethyl ether, methanol, pyridine and the like). Unless specified to the contrary, the solvents used in the reactions of the present disclosure are inert organic solvents, and the reactions are carried out under an inert gas, preferably nitrogen.
[0133] Scheme 1 shows the synthesis of compounds of Formula I, wherein Q is hydroxy (i.e., -OH) or a leaving group (e.g., chloride) and W<com:Sup>1< / com:Sup>, W<com:Sup>2< / com:Sup>, W<com:Sup>3< / com:Sup>, W<com:Sup>4< / com:Sup>, Y, Z, R<com:Sup>1a< / com:Sup>, R<com:Sup>1b< / com:Sup>, R<com:Sup>1c< / com:Sup>, R<com:Sup>2a< / com:Sup>, <com:Math><semantics>R2b<annotation encoding="application / x-tex">R^{2b}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>R3a<annotation encoding="application / x-tex">R^{3a}< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>R3b<annotation encoding="application / x-tex">R^{3b}< / annotation>< / semantics>< / com:Math> are as defined herein. Scheme 1 [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] 1-a
[0134] As depicted in Scheme 1, the compounds of Formula I may be prepared by contacting a suitably substituted amine 1-a with compound 1-b, under standard amide bond forming reaction conditions. When Q is hydroxy, an activating agent may be used to facilitate the reaction. Suitable coupling agents (or activating agents) are known in the art and include for example, carbodimides (e.g., N,N'-dicyclohexylcarbodimide (DCC), N,N'- dicyclopentylcarbodiimide, N,N'-diisopropylcarbodiimide (DIC), 1-ethyl-3-(3- dimethylaminopropyl)carbodiimide (EDC), N-t-butyl-N-methylcarbodiimide (BMC), N-t- butyl-N-ethylcarbodiimide (BEC), 1,3-bis(2,2-dimethyl-1,3-dioxolan-4- ylmethyl)carbodiimide (BDDC), etc.), phosphonium salts (HOBt, PyBOP, HOAt, etc.), aminium / uronium salts (e.g., tetramethyl aminium salts, bispyrrolidino aminium salts, bispiperidino aminium salts, imidazolium uronium salts, pyrimidinium uronium salts, uronium salts derived from N,N,N'-trimethyl-N'-phenylurea, morpholino-based aminium / uronium coupling reagents, antimoniate uronium salts, etc.), organophosphorus reagents (e.g., phosphinic and phosphoric acid derivatives), organosulfur reagents (e.g., sulfonic acid derivatives), triazine coupling reagents (e.g., 2- chloro-4,6-dimethoxy-1,3,5- triazine, 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4 methylmorpholinium chloride, 4-(4,6- dimethoxy-1,3,5-triazin-2-yl)-4 methylmorpholinium tetrafluoroborate, etc.), pyridinium coupling reagents (e.g., Mukaiyama's reagent, pyridinium tetrafluoroborate coupling reagents, etc.), polymer-supported reagents (e.g., polymer-bound carbodiimide, polymer- bound TBTU, polymer-bound 2,4,6-trichloro-1,3,5-triazine, polymer-bound HOBt, polymer- bound HOSu, polymer-bound IIDQ, polymer-bound EEDQ, etc.), and the like (see, e.g., El- Faham, et al. Chem. Rev., 2011, 111(11): 6557–6602; Han, et al. Tetrahedron, 2004, 60:2447-2467). Caboxylic acids where Q is –OH can also be converted to activated derivatives wherein Q is a leaving group; activated derivatives include, but are not limited to, anhydrides (including symmetric, mixed, or cyclic anhydrides), activated esters (e.g., p- nitrophenyl esters, pentafluorophenyl esters, N-succinimidyl esters, and the like), acylazoles (e.g., acylimidazoles, prepared using carbonyl diimidazole, and the like), acyl azides, and acid halides (e.g., acid chlorides).
[0135] Compounds of formula 1-a and 1-b for use in Scheme 1 may be obtained as described in the schemes and Examples provided herein or from conventional synthetic methods known in the art using appropriate starting materials. A number of unsubstituted and substituted benzapine and benzoxazepine starting materials are commercially available and can be used in the methods described herein. Examples of such starting materials include, but are not limited to: 1,2,4,5-tetrahydro-3,2-benzoxazepine; 2,3,4,5-tetrahydro-1,4- benzoxazepine; 2,3,4,5-tetrahydro-1H-2-benzazepine; 2,3,4,5-tetrahydro-1,4- benzothiazepine; 2,3,4,5-tetrahydropyrido[3,4-f][1,4]oxazepine-9-carbonitrile; 2,3,4,5- tetrahydro-1,4-benzoxazepine-6-carbonitrile; 2,3,4,5-tetrahydro-1,4-benzoxazepine-9- carbonitrile; 2-methyl-2,3,4,5-tetrahydro-1,4-benzoxazepine; 3-methyl-2,3,4,5-tetrahydro- 1,4-benzoxazepine; 4-benzyl-9-bromo-6-fluoro-2,3-dihydro-1,4-benzoxazepin-5-one; 6- fluoro-2,3,4,5-tetrahydro-1,4-benzoxazepine; 7-chloro-2,3,4,5-tetrahydro-1,4-benzoxazepine; 7-fluoro-2,3,4,5-tetrahydro-1,4-benzoxazepine; 7-methyl-2,3,4,5-tetrahydro-1,4- benzoxazepine; 8-methoxy-2,3,4,5-tetrahydro-1,4-benzoxazepine; 9-bromo-7-fluoro-2,3,4,5- tetrahydro-1,4-benzoxazepine hydrochloride; 9-fluoro-2,3,4,5-tetrahydro-1,4-benzoxazepine; and salts thereof (e.g., hydrochloride salts and the like).
[0136] In some embodiments, bicyclic amines for acylation with compound 1-b are prepared as summarized in Scheme 2, wherein Q is hydroxy (i.e., -OH) or a leaving group (e.g., chloride); V is hydrogen or an amine protecting group; <com:Math><semantics>Z1<annotation encoding="application / x-tex">Z^1< / annotation>< / semantics>< / com:Math> is a first reactive functional group; Z<com:Sup>2< / com:Sup> is a second reactive functional group; and W<com:Sup>1< / com:Sup>, W<com:Sup>2< / com:Sup>, W<com:Sup>3< / com:Sup>, W<com:Sup>4< / com:Sup>, Y, Z, R<com:Sup>1a< / com:Sup>, R<com:Sup>1b< / com:Sup>, R<com:Sup>1c< / com:Sup>, R<com:Sup>2a< / com:Sup>, <com:Math><semantics>R2b<annotation encoding="application / x-tex">R^{2b}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>R3a<annotation encoding="application / x-tex">R^{3a}< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>R3b<annotation encoding="application / x-tex">R^{3b}< / annotation>< / semantics>< / com:Math> are as defined herein. Scheme 2 [Image disponible dans le document PDF, Image available in the PDF document]
[0137] A compound 2-a (e.g., a primary or secondary amine where Y is <com:Math><semantics>CR4aR4b<annotation encoding="application / x-tex">CR^{4a}R^{4b}< / annotation>< / semantics>< / com:Math>, or a hydroxylamine where Y is O) can be used for reductive amination with ketone or aldehyde 2- b to provide amine 2-c, or compound 2-a can be used for acylation with compound 2-e to provide amide 2-f. The reductive amination for formation of amine 2-c is typically conducted with sodium borohydride, sodium cyanoborohydride, or another suitable reducing agent. The acylation step for formation of amide 2-f can be conducted with a carboxylic acid 2-e (wherein Q is OH) or an activated carboxylic acid derivative 2-e (wherein Q is a leaving group) as described above for Scheme 1. Amide 2-f can then be reduced to provide amine 2- g using a reducing agent such as borane, lithium aluminum hydride, or a silane reagent (e.g., diethyl silane, 1,1,3,3-tetramethyldisiloxane, etc.) with or without a suitable catalyst (e.g., zinc acetate, diethyl zinc, tris(pentafluorophenyl)boron, etc.).
[0138] Amines 2-c and 2-g contain complementary reactive groups <com:Math><semantics>Z1<annotation encoding="application / x-tex">Z^1< / annotation>< / semantics>< / com:Math> and <com:Math><semantics>Z2<annotation encoding="application / x-tex">Z^2< / annotation>< / semantics>< / com:Math>, which can be reacted in a cyclization step to provide bicyclic amines 2-d and 2-h. For example, an alcohol <com:Math><semantics>Z1<annotation encoding="application / x-tex">Z^1< / annotation>< / semantics>< / com:Math> group can react with a halide <com:Math><semantics>Z2<annotation encoding="application / x-tex">Z^2< / annotation>< / semantics>< / com:Math> group (e.g., chloro) in the presence of a base (e.g., sodium hydride, lithium diisopropylamide, etc.). One of skill in the art will recognize that a <com:Math><semantics>Z1<annotation encoding="application / x-tex">Z^1< / annotation>< / semantics>< / com:Math> group can be protected with a suitable protecting group (e.g., as a silyl ether such as TBSO) to prevent unwanted reactions prior to the cyclization step. The protecting group can then be removed (e.g., with an acid such as HCl) before reaction with the <com:Math><semantics>Z2<annotation encoding="application / x-tex">Z^2< / annotation>< / semantics>< / com:Math> group. Similarly, amine 2-a can contain a protecting group V (e.g., benzyloxycarbonyl) to prevent unwanted reactions prior to acylation as shown in Scheme 1. The protecting group V can be removed (e.g., via hydrogenation) before acylation with a carboxylic acid or activated derivative thereof. Desired functional groups at W<com:Sup>1< / com:Sup>, W<com:Sup>2< / com:Sup>, W<com:Sup>3< / com:Sup>, W<com:Sup>4< / com:Sup>, Y, R<com:Sup>3a< / com:Sup>, and R<com:Sup>3b< / com:Sup> be installed prior to, or after, the cyclization step in Scheme 2 by employing conventional synthetic methods known in the art (e.g., via halogenation, reduction, oxidation, olefination, alkylation, etc.).
[0139] In some embodiments, a method for preparing a compound according to Formula A, or a salt thereof, is provided. [Image disponible dans le document PDF, Image available in the PDF document] <com:Math><semantics>(A)<annotation encoding="application / x-tex">(A)< / annotation>< / semantics>< / com:Math>, The method includes: contacting a compound according to Formula IIa [Image disponible dans le document PDF, Image available in the PDF document] (IIa) with a compound according to Formula IIb, [Image disponible dans le document PDF, Image available in the PDF document] (IIb) under conditions sufficient to form a compound according to Formula IIc [Image disponible dans le document PDF, Image available in the PDF document] (IIc); converting the compound of Formula IIc to a compound of Formula IId [Image disponible dans le document PDF, Image available in the PDF document] (IId); and contacting the compound of Formula IId with a compound of Formula IIe [Image disponible dans le document PDF, Image available in the PDF document] (IIe) under conditions sufficient to form the compound of Formula A; wherein: <com:Math><semantics>Z1<annotation encoding="application / x-tex">Z^1< / annotation>< / semantics>< / com:Math> is an optionally protected first reactive group; <com:Math><semantics>Z2<annotation encoding="application / x-tex">Z^2< / annotation>< / semantics>< / com:Math> is an optionally protected second reactive group; Q is -OH or a leaving group; and R<com:Sup>1a< / com:Sup>, R<com:Sup>1b< / com:Sup>, R<com:Sup>1c< / com:Sup>, R<com:Sup>2a< / com:Sup>, R<com:Sup>2b< / com:Sup>, R<com:Sup>3a< / com:Sup>, R<com:Sup>3b< / com:Sup>, W<com:Sup>1< / com:Sup>, W<com:Sup>2< / com:Sup>, W<com:Sup>3< / com:Sup>, W<com:Sup>4< / com:Sup>, Y, and Z are defined as set forth above.
[0140] In some embodiments, <com:Math><semantics>Z1<annotation encoding="application / x-tex">Z^1< / annotation>< / semantics>< / com:Math> is an optionally protected alcohol. In some embodiments, <com:Math><semantics>Z2<annotation encoding="application / x-tex">Z^2< / annotation>< / semantics>< / com:Math> is a halogen. In some embodiments, converting a compound of Formula IIc to a compound of Formula IId includes contacting the compound of Formula IIc with a base (e.g., sodium hydride, lithium diisopropylamide, potassium tert-butoxide, potassium carbonate, or the like). One of skill in the art will appreciate that methods for preparing compounds of Formula A can also be used for the preparation of compounds according to Formula B and / or Formula I.
[0141] Also provided herein are intermediates for the synthesis of kinase inhibitors, including compounds according to Formula IId as set forth above. In some embodiments, compounds of Formula IId are provided wherein W<com:Sup>2< / com:Sup> is N. In some such embodiments, W<com:Sup>1< / com:Sup>, W<com:Sup>3< / com:Sup>, and W<com:Sup>4< / com:Sup> are CR<com:Sup>7< / com:Sup>. In some embodiments, W<com:Sup>2< / com:Sup> is N, W<com:Sup>1< / com:Sup> is CH, W<com:Sup>3< / com:Sup> is CH, and W<com:Sup>4< / com:Sup> is CR<com:Sup>7< / com:Sup>. In some embodiments, compounds of Formula IId are provided wherein W<com:Sup>2< / com:Sup> is N, W<com:Sup>1< / com:Sup> is CH, W<com:Sup>3< / com:Sup> is CH, and W<com:Sup>4< / com:Sup> is C(CN); in some such embodiments, Y is CH<com:Sub>2< / com:Sub> and Z is O. In some embodiments, the compound of Formula IId is: [Image disponible dans le document PDF, Image available in the PDF document] or a salt thereof. In some embodiments, the salt is a hydrochloride salt. In some embodiments, the salt is a dihydrochloride salt. IV. Pharmaceutical compositions
[0142] Compounds provided herein are usually administered in the form of pharmaceutical compositions. Thus, provided herein are also pharmaceutical compositions that contain one or more of the compounds described herein or a pharmaceutically acceptable salt, tautomer, stereoisomer, mixture of stereoisomers, prodrug, or deuterated analog thereof and one or more pharmaceutically acceptable vehicles selected from carriers, adjuvants and excipients. Suitable pharmaceutically acceptable vehicles may include, for example, inert solid diluents and fillers, diluents, including sterile aqueous solution and various organic solvents, permeation enhancers, solubilizers and adjuvants. Such compositions are prepared in a manner well known in the pharmaceutical arts.
[0143] The pharmaceutical compositions of the present disclosure may be specially formulated for administration in solid or liquid form, including those adapted for the following: oral administration, for example, drenches (aqueous or non-aqueous solutions or suspensions), tablets, e.g., those targeted for buccal, sublingual and systemic absorption, boluses, powders, granules, pastes for application to the tongue; parenteral administration, for example, by subcutaneous, intramuscular, intravenous or epidural injection as, for example, a sterile solution or suspension or sustained-release formulation; topical application, for example, as a cream, ointment or a controlled-release patch or spray applied to the skin; intravaginally or intrarectally, for example, as a pessary, cream or foam; sublingually; ocularly; transdermally; or nasally, pulmonary and to other mucosal surfaces.
[0144] The phrase "pharmaceutically acceptable" is employed herein to refer to those compounds, materials, compositions and / or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response or other problem or complication, commensurate with a reasonable benefit / risk ratio.
[0145] The phrase "pharmaceutically-acceptable carrier" as used herein means a pharmaceutically acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient or solvent encapsulating material, involved in carrying or transporting the subject compound from one organ or portion of the body, to another organ or portion of the body. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. Some examples of materials which can serve as pharmaceutically-acceptable carriers include: sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; surfactants, such as polysorbate 80 (i.e., Tween<com:Sup>TM< / com:Sup> 80); powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol; pH buffered solutions; polyesters, polycarbonates and / or polyanhydrides; and other non-toxic compatible substances employed in pharmaceutical formulations. Examples of such formulations include, but are not limited to DMSO, 10 mM DMSO, 8% hydroxypropyl-beta-cyclodextrin in PBS, propylene glycol, etc. For example, in a certain embodiment the compounds of the disclosure can be used as 4 mM solution in 8% hydroxypropyl-beta-cyclodextrin in PBS for parenteral administration. In another certain embodiments, the compounds of the disclosure can be used as a suspension in 0.5% aqueous CMC containing 0.1% TWEEN 80.
[0146] As set out herein, certain embodiments of the present compounds may contain a basic functional group, such as amino or methylamino (NCH<com:Sub>3< / com:Sub>) and are, thus, capable of forming pharmaceutically acceptable salts with pharmaceutically-acceptable acids. The term "pharmaceutically-acceptable salts" in this respect refers to the relatively non-toxic, inorganic and organic acid addition salts of compounds of the present disclosure. These salts can be prepared in situ in the administration vehicle or the dosage form manufacturing process or by separately reacting a purified compound of the disclosure in its free base form with a suitable organic or inorganic acid and isolating the salt thus formed during subsequent purification. Representative salts include the hydrobromide, hydrochloride, sulfate, bisulfate, phosphate, nitrate, acetate, valerate, oleate, palmitate, stearate, laurate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, napthylate, mesylate, glucoheptonate, lactobionate and laurylsulphonate salts and the like.
[0147] The pharmaceutically acceptable salts of the subject compounds include the conventional nontoxic salts or quaternary ammonium salts of the compounds, e.g., from non- toxic organic or inorganic acids. For example, such conventional nontoxic salts include those derived from inorganic acids such as hydrochloride, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, palmitic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicyclic, sulfanilic, 2- acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isothionic and the like.
[0148] In other cases, the compounds of the present disclosure may contain one or more acidic functional groups and, thus, are capable of forming pharmaceutically-acceptable salts with pharmaceutically-acceptable bases. The term "pharmaceutically-acceptable salts" in these instances refers to the relatively non-toxic, inorganic and organic base addition salts of compounds of the present disclosure. These salts can likewise be prepared in situ in the administration vehicle or the dosage form manufacturing process or by separately reacting the purified compound in its free acid form with a suitable base, such as the hydroxide, carbonate or bicarbonate of a pharmaceutically-acceptable metal cation, with ammonia or with a pharmaceutically-acceptable organic primary, secondary or tertiary amine. Representative alkali or alkaline earth salts include the lithium, sodium, potassium, calcium, magnesium and aluminum salts and the like. Representative organic amines useful for the formation of base addition salts include ethylamine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine and the like.
[0149] Wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions.
[0150] Examples of pharmaceutically-acceptable antioxidants include: water soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like; oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol and the like; and metal chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid and the like.
[0151] Formulations of the present disclosure include those suitable for oral, nasal, topical (including buccal and sublingual), rectal, vaginal and / or parenteral administration. The formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will vary depending upon the host being treated, the particular mode of administration. The amount of active ingredient that can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound which produces a therapeutic effect. Generally, this amount will range from about 1% to about 99% of active ingredient, preferably from about 5% to about 70%, most preferably from about 10% to about 30%.
[0152] In certain embodiments, a formulation of the present disclosure comprises one or more of cyclodextrins, liposomes, micelle forming agents, e.g., bile acids and polymeric carriers, e.g., polyesters and polyanhydrides; and a compound of the present disclosure. In certain embodiments, an aforementioned formulation renders orally bioavailable a compound of the present disclosure.
[0153] Methods of preparing these formulations or compositions include the step of bringing into association a compound of the present disclosure with the carrier and, optionally, one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association a compound of the present disclosure with liquid carriers or finely divided solid carriers or both and then, if necessary, shaping the product.
[0154] Formulations of the disclosure suitable for oral administration may be in the form of capsules, cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), powders, granules or as a solution or a suspension in an aqueous or non-aqueous liquid or as an oil-in-water or water-in-oil liquid emulsion or as an elixir or syrup or as pastilles (using an inert base, such as gelatin and glycerin or sucrose and acacia) and / or as mouth washes and the like, each containing a predetermined amount of a compound of the present disclosure as an active ingredient. A compound of the present disclosure may also be administered as a bolus, electuary or paste.
[0155] In solid dosage forms of the disclosure for oral administration (capsules, tablets, pills, dragees, powders, granules and the like), the active ingredient is mixed with one or more pharmaceutically- acceptable carriers, such as sodium citrate or dicalcium phosphate and / or any of the following: fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol and / or silicic acid; binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and / or acacia; humectants, such as glycerol; disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates and sodium carbonate; solution retarding agents, such as paraffin; absorption accelerators, such as quaternary ammonium compounds; wetting agents, such as, for example, cetyl alcohol, glycerol monostearate and non-ionic surfactants; absorbents, such as kaolin and bentonite clay; lubricants, such a talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate and mixtures thereof; and coloring agents. In the case of capsules, tablets and pills, the pharmaceutical compositions may also comprise buffering agents. Solid compositions of a similar type may also be employed as fillers in soft and hard-shelled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.
[0156] A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface-active or dispersing agent. Molded tablets may be made in a suitable machine in which a mixture of the powdered compound is moistened with an inert liquid diluent.
[0157] The tablets and other solid dosage forms of the pharmaceutical compositions of the present disclosure, such as dragees, capsules, pills and granules, may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical formulating arts. They may also be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile, other polymer matrices, liposomes and / or microspheres. They may be formulated for rapid release, e.g., freeze-dried. They may be sterilized by, for example, filtration through a bacteria-retaining filter or by incorporating sterilizing agents in the form of sterile solid compositions that can be dissolved in sterile water or some other sterile injectable medium immediately before use. These compositions may also optionally contain opacifying agents and may be of a composition that they release the active ingredient(s) only or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. The active ingredient can also be in micro-encapsulated form, if appropriate, with one or more of the above- described excipients.
[0158] Liquid dosage forms for oral administration of the compounds of the disclosure include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active ingredient, the liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan and mixtures thereof.
[0159] Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.
[0160] Suspensions, in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth and mixtures thereof.
[0161] Formulations of the pharmaceutical compositions of the disclosure for rectal or vaginal administration may be presented as a suppository, which may be prepared by mixing one or more compounds of the disclosure with one or more suitable nonirritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the rectum or vaginal cavity and release the active compound.
[0162] Formulations of the present disclosure which are suitable for vaginal administration also include pessaries, tampons, creams, gels, pastes, foams or spray formulations containing such carriers as are known in the art to be appropriate.
[0163] Dosage forms for the topical or transdermal administration of a compound of this disclosure include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants. The active compound may be mixed under sterile conditions with a pharmaceutically-acceptable carrier and with any preservatives, buffers or propellants which may be required.
[0164] The ointments, pastes, creams and gels may contain, in addition to an active compound of this disclosure, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide or mixtures thereof.
[0165] Powders and sprays can contain, in addition to a compound of this disclosure, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder or mixtures of these substances. Sprays can additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.
[0166] Transdermal patches have the added advantage of providing controlled delivery of a compound of the present disclosure to the body. Dissolving or dispersing the compound in the proper medium can make such dosage forms. Absorption enhancers can also be used to increase the flux of the compound across the skin. Either providing a rate controlling membrane or dispersing the compound in a polymer matrix or gel can control the rate of such flux.
[0167] Ophthalmic formulations, eye ointments, powders, solutions and the like, are also contemplated as being within the scope of this disclosure.
[0168] Pharmaceutical compositions of this disclosure suitable for parenteral administration comprise one or more compounds of the disclosure in combination with one or more pharmaceutically-acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain sugars, alcohols, antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.
[0169] Examples of suitable aqueous and nonaqueous carriers, which may be employed in the pharmaceutical compositions of the disclosure include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol and the like) and suitable mixtures thereof, vegetable oils, such as olive oil and injectable organic esters, such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants.
[0170] These compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms upon the subject compounds may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenyl sorbic acid and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride and the like into the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin.
[0171] In some cases, in order to prolong the effect of a drug, it is desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material having poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution, which in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally-administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.
[0172] Injectable depot forms are made by forming microencapsulated matrices of the subject compounds in biodegradable polymers such as polylactide-polyglycolide. Depending on the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions, which are compatible with body tissue. V. Methods of treatment
[0173] In other embodiments, provided herein is a method of treating a receptor-interacting protein kinase 1-mediated disease or disorder. The method includes administering a therapeutically effective amount of a compound or pharmaceutical composition as described herein to a subject in need thereof. In some embodiments, the receptor-interacting protein kinase 1-mediated disease or disorder is trauma, ischemia, stroke, cardiac infarction, infection, Gaucher's disease, Krabbe disease, sepsis, Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, HIV-associated dementia, retinal degenerative disease, glaucoma, age-related macular degeneration, rheumatoid arthritis, psoriasis, psoriatic arthritis, or inflammatory bowel disease.
[0174] The term "trauma" as used herein refers to any physical damage to the body caused by violence, accident, fracture etc. The term "ischemia" refers to a cardiovascular disorder characterized by a low oxygen state usually due to the obstruction of the arterial blood supply or inadequate blood flow leading to hypoxia in the tissue. The term "stroke" refers to cardiovascular disorders caused by a blood clot or bleeding in the brain, most commonly caused by an interruption in the flow of blood in the brain as from clot blocking a blood vessel and in certain embodiments of the disclosure the term stroke refers to ischemic stroke or hemorrhagic stroke. The term "myocardial infarction" refers to a cardiovascular disorder characterized by localized necrosis resulting from obstruction of the blood supply.
[0175] The methods described herein may be applied to cell populations in vivo or ex vivo. "In vivo" means within a living individual, as within an animal or human. In this context, the methods described herein may be used therapeutically in an individual. "Ex vivo" means outside of a living individual. Examples of ex vivo cell populations include in vitro cell cultures and biological samples including fluid or tissue samples obtained from individuals. Such samples may be obtained by methods well known in the art. Exemplary biological fluid samples include blood, cerebrospinal fluid, urine, and saliva. In this context, the compounds and compositions described herein may be used for a variety of purposes, including therapeutic and experimental purposes. For example, the compounds and compositions described herein may be used ex vivo to determine the optimal schedule and / or dosing of administration of a compound of the present disclosure for a given indication, cell type, individual, and other parameters. Information gleaned from such use may be used for experimental purposes or in the clinic to set protocols for in vivo treatment. Other ex vivo uses for which the compounds and compositions described herein may be suited are described below or will become apparent to those skilled in the art. The selected compounds may be further characterized to examine the safety or tolerance dosage in human or non- human subjects. Such properties may be examined using commonly known methods to those skilled in the art.
[0176] Experiments with knockout animal models and Necrostatin 1, a receptor-interacting protein kinase 1 inhibitor, have demonstrated the effectiveness of receptor-interacting protein kinase 1 inhibition in protecting tissues from inflammatory bowel diseases (e.g., ulcerative colitis and Crohn's disease), psoriasis, retinal-detachment-induced photoreceptor necrosis, retinitis pigmentosa, cerulein-induced acute pancreatitis, and sepsis / systemic inflammatory response syndrome (SIRS), and alleviating ischemic brain injury, retinal ischemia / reperfusion injury, Huntington's disease, renal ischemia reperfusion injury, cisplatin induced kidney injury, traumatic brain injury, hematological and solid organ malignancies, bacterial infections and viral infections (e.g., tuberculosis and influenza) and lysosomal storage diseases. The receptor-interacting protein kinase 1 inhibitors of the present disclosure are therefore useful for treating diseases and conditions mediated by receptor-interacting protein kinase 1, including but not limited to inflammatory diseases or disorders, necrotic cell diseases, neurodegenerative diseases, central nervous system (CNS) diseases, ocular diseases, infections, and malignancies. In certain embodiments, the receptor-interacting protein kinase 1 inhibitors described herein can inhibit inflammation, protect tissue or cell from damage or undesired cell death (e.g., necrosis or apoptosis), ameliorate symptoms, and improve immune response or neuronal function in a patient suffering from any of the prescribed diseases or conditions. Moreover, the compounds may be suitable for treatment of immune-mediated disease, such as but not limited to, allergic diseases, autoimmune diseases, and prevention of transplant rejection.
[0177] Provided herein are compounds and compositions for use in medicine. In certain embodiments, the compounds and compositions are for use in the treatment of a receptor- interacting protein kinase 1- mediated disease or disorder. Also provided is a method of treating a receptor-interacting protein kinase 1-mediated disease or disorder comprising administering a therapeutically effective amount of a compound or pharmaceutical composition disclosed herein to a subject in need thereof. In certain embodiments, the disease or disorder is an inflammatory disease associated with A20 SNPs.
[0178] Various specific diseases and disorders are described below. In certain embodiments, the disease or disorder is necrotizing enterocolitis, tuberous sclerosis, Tangier's Disease, Wohlman's Syndrome, inflammatory bowel disease, Crohn's disease, ulcerative colitis, psoriasis, retinal detachment, retinitis pigmentosa, macular degeneration, pancreatitis (e.g., acute pancreatitis), atopic dermatitis, rheumatoid arthritis, spondyloarthritis, gout, SoJIA, systemic lupus erythematosus, Sjogren's syndrome, systemic scleroderma, anti- phospholipid syndrome, vasculitis, osteoarthritis, non-alcohol steatohepatitis, alcohol steatohepatitis, autoimmune hepatitis autoimmune hepatobiliary diseases, primary sclerosing cholangitis, nephritis, Celiac disease, autoimmune ITP, transplant rejection, ischemia reperfusion injury of solid organs, sepsis, systemic inflammatory response syndrome, cerebrovascular accident, myocardial infarction, Huntington's disease, Alzheimer's disease, Parkinson's disease, allergic diseases, asthma, atopic dermatitis, multiple sclerosis, type I diabetes, Wegener's granulomatosis, pulmonary sarcoidosis, Behçet's disease, interleukin-1 converting enzyme associated fever syndrome, chronic obstructive pulmonary disease, tumor necrosis factor receptor-associated periodic syndrome, periodontitis, bacterial infection, staphylococcus infection, mycobacterium infection, retinitis pigmentosa, influenza, transplant rejection, burns or hypoxia. In certain embodiments, the disease or disorder is trauma, ischemia, stroke, cardiac infarction, infection, lysosomal storage disease, Niemann-Pick disease, Gaucher's disease, Krabbe disease, sepsis, Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis (ALS / Lou Gehrig's Disease), Huntington's disease, HIV- associated dementia, encephalopathy, retinal degenerative disease, glaucoma, age-related macular degeneration, rheumatoid arthritis, psoriasis, psoriatic arthritis or inflammatory bowel disease. In certain embodiments, the disease or disorder is Alzheimer's disease, ALS, Friedreich's ataxia, Huntington's disease, Lewy body disease, Parkinson's disease, Huntington's disease, multiple sclerosis, diabetic neuropathy, polyglutamine (polyQ) diseases, stroke, Fahr disease, Menke's disease, Wilson's disease, cerebral ischemia, lysosomal storage disease or a prion disorder. In certain embodiments, the disease is ALS. In certain embodiments, the disease is Alzheimer's disease. In certain embodiments, the disease is lysosomal storage disease. In certain embodiments, the disease is Parkinson's disease. In certain embodiments the disorder is an ischemic disease of organs including but not limited to brain, heart, kidney and liver. In some different embodiments, the disorder is an ocular disorder such as retinal degenerative disease, glaucoma or age-related macular degeneration. In some different embodiments, the disorder is a central nervous system (CNS) disorder.
[0179] In certain embodiments, the compounds and compositions are useful for treating psoriasis.
[0180] In certain embodiments, the disorder is an inflammatory disease of the intestines such as Crohn's disease or ulcerative colitis (both generally known together as inflammatory bowel disease). In certain embodiments, the mammal is a primate, canine or feline subject. In certain embodiments, the mammal is a human subject. While not wishing to be bound by theory, it is believed that inhibition of receptor interacting protein kinase 1 by the presently disclosed compounds is responsible, at least in part, for their anti-inflammatory activity. Accordingly, embodiments of the disclosure also include methods for inhibiting receptor interacting protein kinase 1, either in vitro or in a subject in need thereof, the method comprises contacting a receptor interacting protein kinase 1 with a compound disclosed herein. In some of these embodiments, inhibiting receptor interacting protein kinase 1 is effective to block (partially or fully) the release of inflammatory mediators such as TNF and / or IL6.
[0181] In certain embodiments, provided is a method of treating rheumatoid arthritis, systemic onset juvenile idiopathic arthritis (SoJIA), spondyloarthritis, osteoarthritis, psoriasis, Crohn's disease, ulcerative colitis, or multiple sclerosis, comprising administering a therapeutically effective amount of a compound as provided herein to a subject in need thereof. In certain embodiments, provided is a method of treating autoimmune hepatitis, atherosclerosis, neutrophilic dermatoses, or a rare disease driven by A20, NEMO, and / or LUBAC mutations, comprising administering a therapeutically effective amount of a compound as provided herein to a subject in need thereof. In certain embodiments, the compound is of Formula I (or any Formula described herein or tautomer thereof), wherein A is triazole. In certain embodiments, the compound is of Formula V or Va. In certain embodiments, the method comprises administering Compound 42 or tautomer thereof. Inflammatory Diseases or Disorders
[0182] The receptor interacting protein kinase 1 inhibitors described herein may be used to treat inflammatory diseases and disorders. Inflammatory diseases and disorders typically exhibit high levels of inflammation in the connective tissues or degeneration of these tissues.
[0183] Non-limiting examples of inflammatory diseases and disorders include Alzheimer's disease, ankylosing spondylitis, arthritis including osteoarthritis, rheumatoid arthritis (RA), psoriasis, asthma, atherosclerosis, Crohn's disease, colitis, dermatitis, diverticulitis, fibromyalgia, hepatitis, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), systemic lupus erythematous (SLE), nephritis, Parkinson's disease and ulcerative colitis. In certain embodiments, the compounds and compositions of the present disclosure are useful for treating an autoimmune disorder, such as rheumatoid arthritis, psoriasis, psoriatic arthritis, encephalitis, allograft rejection, autoimmune thyroid diseases (such as Graves' disease and Hashimoto's thyroiditis), autoimmune uveoretinitis, giant cell arteritis, inflammatory bowel diseases (including Crohn's disease, ulcerative colitis, regional enteritis, granulomatous enteritis, distal ileitis, regional ileitis, and terminal ileitis), insulin-dependent diabetes mellitus, multiple sclerosis, pernicious anemia, sarcoidosis, scleroderma, and systemic lupus erythematosus. In an embodiment, the receptor interacting protein kinase 1 inhibitors described herein are useful for treating autoimmune encephalitis.
[0184] In certain embodiments, the compounds and compositions are useful for treating rheumatoid arthritis (RA). In certain embodiments, the compounds and compositions are useful for treating ulcerative colitis. In certain embodiments, the compounds and compositions are useful for treating psoriasis.
[0185] In certain embodiments, the disorder is an inflammatory disease of the intestines such as Crohn's disease or ulcerative colitis (both generally known together as inflammatory bowel disease). In certain embodiments, the mammal is a primate, canine or feline subject. In certain embodiments, the mammal is a human subject. While not wishing to be bound by theory, it is believed that inhibition of receptor interacting protein kinase 1 by the presently disclosed compounds is responsible, at least in part, for their anti-inflammatory activity. Accordingly, embodiments of the disclosure also include methods for inhibiting receptor interacting protein kinase 1, either in vitro or in a subject in need thereof, the method comprises contacting a receptor interacting protein kinase 1 with a compound disclosed herein. In some of these embodiments, inhibiting receptor interacting protein kinase 1 is effective to block (partially or fully) the release of inflammatory mediators such as TNF and / or IL6. Necrotic Cell Diseases
[0186] The compounds described herein may be used for the treatment of diseases / disorders caused or otherwise associated with cellular necrosis. In particular, the disclosure provides methods for preventing or treating a disorder associated with cellular necrosis in a mammal, comprising the step of administering to said mammal a therapeutically effective amount of a compound or composition described herein. The term "necrotic cell disease" refers to diseases associated with or caused by cellular necrosis, for example trauma, ischemia, stroke, cardiac infarction, infection, Gaucher's disease, Krabbe disease, sepsis, Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, HIV-associated dementia, retinal degenerative disease, glaucoma, age-related macular degeneration, rheumatoid arthritis, psoriasis, psoriatic arthritis or inflammatory bowel disease.
[0187] The necrotic cell diseases can be acute diseases such as trauma, ischemia, stroke, cardiac infarction, anthrax lethal toxin induced septic shock, sepsis, cell death induced by LPS and HIV induced T-cell death leading to immunodeficiency. In certain embodiments the disorder is an ischemic disease of organs including but not limited to brain, heart, kidney and liver.
[0188] The necrotic cell diseases also include chronic neurodegenerative diseases, such as Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, Alzheimer's disease, infectious encephalopathies, dementia such as HIV associated dementia.
[0189] In some different embodiments, the disorder is an ocular disorder such as retinal degenerative disease, glaucoma or age-related macular degeneration. In some different embodiments, the disorder is a central nervous system (CNS) disorder. Neurodegenerative and CNS Diseases
[0190] The receptor-interacting protein kinase 1 inhibitors described herein may also be used to treat neurodegenerative diseases. Neurodegenerative diseases can affect many of the body's activities, such as balance, movement, talking, breathing, and heart function. Neurodegenerative diseases can be genetic or caused by medical conditions such as alcoholism, tumors, strokes, toxins, chemicals, and viruses.
[0191] Non-limiting examples of neurodegenerative diseases include Alzheimer's disease, amyotrophic lateral sclerosis (ALS), Friedreich's ataxia, Huntington's disease, Lewy body disease, Parkinson's disease, and spinal muscular atrophy. In certain embodiments, neurodegenerative diseases and CNS diseases include Niemann–Pick disease, type C1 (NPC1), Alzheimer's disease, amyotrophic lateral sclerosis (ALS), Friedreich's ataxia, Huntington's disease, Lewy body disease, Parkinson's disease, and spinal muscular atrophy.
[0192] In certain embodiments, the receptor interacting protein kinase 1 inhibitors described herein may be used to treat NPC1 via inhibiting necroptosis that causes neuronal loss. In certain embodiments, the compounds and compositions of the present disclosure are useful for treating Alzheimer's disease. In certain embodiments, the compounds and compositions of the present disclosure are useful for treating Parkinson's disease. In certain embodiments, the compounds and compositions of the present disclosure are useful for treating amyotrophic lateral sclerosis (ALS).
[0193] More generally, the receptor-interacting protein kinase 1 inhibitors described herein can be used to preserve neuron viability and promote axon growth and nerve functions within the central nervous system (CNS). Accordingly, the compounds may be used to reduce or even reverse the loss of cognitive, motor, and sensory functions associated with a CNS disease or disorder, by preserving neuron viability and / or promoting axon regeneration and / or nerve functions.
[0194] The receptor-interacting protein kinase 1 inhibitors described herein can be used in a method for promoting axon regeneration in a CNS neuron, such as a CNS sensory neuron, a motor neuron, a cortical neuron, a cerebellar neuron, a hippocampal neuron, and a midbrain neuron. The receptor interacting protein kinase 1 inhibitors described herein can be used in a method for promoting nerve function or preserving the viability following injury to a CNS neuron. In another embodiments, these compounds can be used to promote regeneration of an axon in a CNS neuron that is degenerated in the CNS disease or disorder. The RIP receptor- interacting protein kinase 1 inhibitors may be administered by any conventional means, such as locally to the neuron or applied ex vivo before re-implantation.
[0195] Accordingly, in one aspect, the disclosure provides a method of treating a CNS disorder in a subject in need thereof, wherein a symptom of the CNS disorder is axon degeneration or injury within a CNS neuron. The method comprises administering to the subject an effective amount of a compound or composition disclosed herein thereby to promote regeneration of an axon in a CNS neuron affected by the CNS disorder. Following administration, neural functions may be measured, for example, as an indication of axon regeneration. It is also contemplated that, following administration of the compound or composition, the neuron function of the CNS neuron is preserved or improved relative to the neuron function prior to administration.
[0196] Non-limiting examples of CNS diseases or disorders include brain injury, spinal cord injury, dementia, stroke, Alzheimer's disease, amyotrophic lateral sclerosis (ALS / Lou Gehrig's Disease), Parkinson's disease, Huntington's disease, multiple sclerosis, diabetic neuropathy, polyglutamine (polyQ) diseases, stroke, Fahr disease, Menke's disease, Wilson's disease, cerebral ischemia, and a prion disorder.
[0197] In exemplary embodiments, the CNS disorder is brain injury or spinal cord injury.
[0198] Also provided herein are methods for promoting neuron survival and axon regeneration in the CNS. CNS disorders characterized by impaired or failing axon growth or axon degeneration may arise from CNS neuron injury (e.g., trauma, surgery, nerve compression, nerve contusion, nerve transection, neurotoxicity or other physical injury to the brain or spinal cord) or neurodegenerative CNS disease, wherein a symptom of the disorder is axon degeneration (e.g., Alzheimer's disease, amyotrophic lateral sclerosis (ALS / Lou Gehrig's Disease), Parkinson's disease, multiple sclerosis, diabetic neuropathy, polyglutamine (polyQ) diseases, stroke, Fahr disease, Menke's disease, Wilson's disease, cerebral ischemia, prion disorder (e.g., Creutzfeldt-Jakob disease). In certain embodiments, the CNS disorder is brain injury (e.g., traumatic brain injury) or spinal cord injury (e.g., chronic, acute or traumatic spinal cord injury). In certain embodiments, the CNS disorder affects a subject's basic vital life functions such as breathing, heart beat and blood pressure, e.g., an injury to or aneurysm in the brain stem.
[0199] In certain embodiments, the CNS disease or disorder affects a subject's cognitive ability. In certain embodiments, the CNS disease or disorder affects a subject's movement and / or strength. In certain embodiments, the CNS disease or disorder affects a subject's coordination.
[0200] In certain embodiments, the CNS disorder affects a subject's cognitive ability, such as, brain injury to the cerebral cortex or a neurodegenerative CNS disorder, such as, Alzheimer's disease, frontotemporal dementia, dementia with Lewy bodies, corticobasal degeneration, progressive supranuclear palsy and prion disorders.
[0201] In certain embodiments, the CNS disorder affects a subject's movement and / or strength, such as injury to the brain or spinal cord or a neurodegenerative CNS disorder such as Parkinson's disease, frontotemporal dementia, dementia with Lewy bodies, corticobasal degeneration, progress supranuclear palsy, Huntington's disease, multiple system atrophy, amyotrophic lateral sclerosis and hereditary spastic paresis.
[0202] In certain embodiments, the CNS disorder affects a subject's coordination, such as brain injury to the cerebellum or a neurodegenerative CNS disorder such as spinocerebellar atrophies, Friedreich's ataxia and prion disorders.
[0203] In each of the foregoing methods, the CNS disorder includes, but is not limited to, brain injury, spinal cord injury, Alzheimer's disease, amyotrophic lateral sclerosis (ALS / Lou Gehrig's Disease), Parkinson's disease, multiple sclerosis, diabetic neuropathy, polyglutamine (polyQ) diseases, stroke, Fahr disease, Menke's disease, Wilson's disease, cerebral ischemia, a prion disorder (e.g., Creutzfeldt-Jakob disease), dementia (e.g., frontotemporal dementia, dementia with Lewy bodies), corticobasal degeneration, progressive supranuclear palsy, multiple system atrophy, hereditary spastic paraparesis and spinocerebellar atrophies.
[0204] Non-limiting examples of neurodegenerative diseases include Alzheimer's disease, lysosomal storage diseases, amyotrophic lateral sclerosis (ALS), Friedreich's ataxia, Huntington's disease, Lewy body disease, Parkinson's disease, and spinal muscular atrophy.
[0205] In certain embodiments, the compounds and compositions of the present disclosure are useful for treating Alzheimer's disease. In certain embodiments, the compounds and compositions of the present disclosure are useful for treating Parkinson's disease. In certain embodiments, the compounds and compositions of the present disclosure are useful for treating amyotrophic lateral sclerosis (ALS). In certain embodiments, the compounds and compositions of the present disclosure are useful for treating lysosomal storage diseases.
[0206] In certain embodiments, the disorder is a brain disorders, such as, but not limited to, Alzheimer's disease, ALS, frontotemporal dementias, vascular dementia, Huntington's disease, Parkinson's disease, Lewy Body dementia, Progressive Supranuclear Palsy, multiple sclerosis, neuromyelitis optica, ischemic brain damage (stroke), hypoxic brain damage, traumatic brain injury, spinal cord injury, sepsis-induced brain damage, CNS infections, CNS abscesses, glioblastoma multiforme, epilepsy, neuropathic pain, major depression, bipolar depression, schizophrenia, autism, Niemann-Pick disease, neuro-Behçet's disease.
[0207] In certain embodiments, provided is a method of treating a CNS disease or disorder, comprising administering a therapeutically effective amount of a compound as provided herein to a subject in need thereof. In certain embodiments, the disease or disorder is Alzheimer's disease or amyotrophic lateral sclerosis (ALS). In certain embodiments, the compound is of Formula I (or any Formula described herein), wherein A is other than triazole. In certain embodiments, the compound is of Formula VI. Ocular Conditions
[0208] The receptor-interacting protein kinase 1 inhibitors described herein can also be used to treat ocular conditions, for example to reduce or prevent the loss of photoreceptor and / or retinal pigment epithelial cell viability.
[0209] In certain embodiments, the disclosure provides a method of preserving the visual function of an eye of a subject with an ocular condition, wherein a symptom of the ocular condition is the loss of photoreceptor cell viability in the retina of the eye with the condition. The method comprises administering to the eye of the subject an effective amount of a compound or composition described herein, thereby preserving the viability of the photoreceptor cells disposed within the retina of the eye. After administration, the visual function (e.g., visual acuity) of the eye may be preserved or improved relative to the visual function of the eye prior to administration.
[0210] The ocular condition may be age-related macular degeneration (AMD), retinosis pigmentosa (RP), macular edema, diabetic retinopathy, central areolar choroidal dystrophy, BEST disease, adult vitelliform disease, pattern dystrophy, myopic degeneration, central serous retinopathy, Stargardt's disease, Cone-Rod dystrophy, North Carolina dystrophy, infectious retinitis, inflammatory retinitis, uveitis, toxic retinitis, or light-induced toxicity. AMD may be the neovascular or the dry form of AMD. Retinal detachment may be a rhegmatogenous, a serous, and a tractional retinal detachment. In certain embodiments, the ocular condition may be geographic atrophy, glaucoma, or another ischemic eye disease.
[0211] In certain embodiments, the disclosure provides a method of preserving the viability of retinal pigment epithelial (RPE) cells within the retina of a subject with an ocular condition with administration of a compound of the present disclosure. The subject being treated may have a loss of retinal pigment epithelial cells in the retina of the eye with the condition and the ocular condition may be age-related macular degeneration (AMD), BEST disease, myopic degeneration, Stargardt's disease, uveitis, adult foveomacular dystrophy, fundus falvimaculatus, multiple evanescent white dot syndrome, serpiginous choroidopathy, acute multifocal posterior placoid epitheliopathy (AMPPE), or another uveitis disorder. In certain embodiments, the method comprises administering to the eye of the subject an effective amount of a compound or composition described herein, thereby preserving the viability of the retinal pigment epithelial cells.
[0212] Provided in another embodiment is a method of preserving the viability of photoreceptor cells disposed within a retina of a subject with age-related macular degeneration (AMD), retinosis pigmentosa (RP), macular edema, diabetic retinopathy, central areolar choroidal dystrophy, BEST disease, adult vitelliform disease, pattern dystrophy, myopic degeneration, central serous retinopathy, Stargardt's disease, Cone-Rod dystrophy, North Carolina dystrophy, infectious retinitis, inflammatory retinitis, uveitis, toxic retinitis, or light-induced toxicity. Therefore, in certain embodiments, the method comprises administering to the eye an effective amount of a compound or composition described herein, thereby preserving the viability of the photoreceptor cells disposed within the retina of the subject with a condition.
[0213] Provided in another embodiment is a method of preserving the viability of photoreceptor cells disposed within a retina of a mammalian eye following retinal detachment. The retinal detachment may be a rhegmatogenous retinal detachment, tractional retinal detachment, or serous retinal detachment. In other embodiments, the retinal detachment may occur as a result of a retinal tear, retinoblastoma, melanoma or other cancers, diabetic retinopathy, uveitis, choroidal neovascularization, retinal ischemia, pathologic myopia, or trauma. In certain embodiments, the method comprises administering a compound or composition described herein to the eye in which a region of the retina has been detached in amounts sufficient to preserve the viability of photoreceptor cells disposed within the region of the detached retina.
[0214] Provided in another embodiment is a method of preserving visual function of an eye of a subject with age-related macular degeneration (AMD), retinosis pigmentosa (RP), macular edema, central areolar choroidal dystrophy, retinal detachment, diabetic retinopathy, BEST disease, adult vitelliform disease, pattern dystrophy, myopic degeneration, central serous retinopathy, Stargardt's disease, Cone-Rod dystrophy, North Carolina dystrophy, infectious retinitis, inflammatory retinitis, uveitis, toxic retinitis, or light-induced toxicity, wherein a symptom of the ocular condition is the loss of photoreceptor cells viability in the retina of the eye, wherein the method comprises treating the subject with a compound or composition described herein to the subject.
[0215] In another aspect, the disclosure provides a method of preserving the visual function of an eye of a subject with an ocular condition, wherein a symptom of the ocular condition is the loss of photoreceptor cell viability and / or RPE viability in the retina of the eye wherein the method comprises treating the subject with a compound or composition described herein to the subject.
[0216] In certain embodiments, provided a method of preserving the visual function of an eye of a subject with ocular conditions, wherein a symptom of the ocular condition is the loss of retinal ganglion cell viability in the retina of the eye with the conditions. The method comprises administering to the eye of the subject an effective amount of a compound or composition, thereby preserving the viability of the retinal ganglion cells disposed within the retina of the eye. After administration of the compound or composition, the visual function of the eye may be preserved or improved relative to the visual function of the eye prior to administration. Further, after the administration, the preserved retinal ganglion cell is capable of supporting axonal regeneration.
[0217] Non-limiting examples of symptoms associated with the ocular conditions include the loss of retinal ganglion cell viability in the retina of the eye, glaucoma, optic nerve injury, optic neuritis, optic neuropathies, diabetic retinopathy, central retinal artery occlusion, and central retinal vein occlusion.
[0218] The compounds described herein may also be used for the treatment of optic neuropathies such as ischemic optic neuropathy (e.g., arteritic or non-arteritic anterior ischemic neuropathy and posterior ischemic optic neuropathy), compressive optic neuropathy, infiltrative optic neuropathy, traumatic optic neuropathy, mitochondrial optic neuropathy (e.g., Leber's optic neuropathy), nutritional optic neuropathy, toxic optic neuropathy, and hereditary optic neuropathy (e.g., Leber's optic neuropathy, Dominant Optic Atrophy, Behr's syndrome).
[0219] Also disclosed is a method of preserving the visual function of an eye of a subject with glaucoma, optic nerve injury, optic neuropathies, diabetic retinopathy, central retinal artery occlusion, or central retinal vein occlusion. The method comprises administering to the eye of the subject an effective amount of a compound or composition described herein, thereby preserving the viability of the retinal ganglion cells disposed within the retina of the eye and the visual function of the eye.
[0220] In another aspect, disclosed herein is a method of preserving the viability of retinal ganglion cells disposed within a retina of a mammalian eye affected by, for example, glaucoma, optic nerve injury, optic neuritis, optic neuropathies, diabetic retinopathy, central retinal artery occlusion and central retinal vein occlusion. The method comprises administering a compound or composition described herein to the eye in which a region of the retina has been affected in amounts sufficient to preserve the viability of retinal ganglion cells disposed within the region of the affected retina. The preserved retinal ganglion cell is capable of supporting axonal regeneration.
[0221] Also disclosed is a method for promoting axon regeneration in an eye of a subject with an ocular condition, wherein a symptom of the ocular condition is the loss of retinal ganglion cell viability in the retina of the eye with the condition. The method comprises administering to the eye of the subject an effective amount of a compound or composition described herein, thereby promoting axon regeneration of the retinal ganglion cell within the retina of the eye.
[0222] In each of the foregoing embodiments, it is understood that the methods and compositions described herein can be used to preserve the viability and / or promote axon regeneration of retinal ganglion cells during treatment of the underlying conditions including, but not limited to, glaucoma, optic nerve injury, optic neuritis, optic neuropathies, diabetic retinopathy, central retinal artery occlusion and central retinal vein occlusion. Tissue Injuries or Damages
[0223] The ability of the compounds described herein to inhibit inflammation and cell death makes them suitable for ameliorating tissue injuries or damages. The tissue injuries or damages may be a result of any of the diseases or conditions described above. For example, the compounds may be used for amelioration of brain tissue injury or damage following ischemic brain injury or traumatic brain injury, or for amelioration of heart tissue injury or damage following myocardial infarction, or for amelioration of brain tissue injury or damage associated with Huntington's disease, Alzheimer's disease or Parkinson's disease, or for amelioration of liver tissue injury or damage associated with non-alcohol steatohepatitis, alcohol steatohepatitis, autoimmune hepatitis autoimmune hepatobiliary diseases, or primary sclerosing cholangitis, or for the amelioration of liver tissue injury or damage associated with overdose of acetaminophen, or for amelioration of kidney tissue injury or damage following renal transplant or the administration of nephrotoxic drugs or substances. In certain embodiments, the For example, the compounds may be used for amelioration of brain tissue injury or damage following pulmonary injury or damage.
[0224] Non-limiting examples of brain injury or damage include stroke (e.g., hemorrhagic and nonhemorrhagic), traumatic brain injury (TBI), cerebral hemorrhage, subarachnoid hemorrhage, intracranial hemorrhage secondary to cerebral arterial malformation, cerebral infarction, perinatal brain injury, non-traumatic brain injury, Alzheimer's disease, Parkinson's disease, Huntington's disease, multiple sclerosis, amyotrophic lateral sclerosis, brain hemorrhage, brain infections, brain tumor, subclinical brain injury, spinal cord injury, anoxic- ischemic brain injury, focal cerebral ischemia, global cerebral ischemia, and hypoxic hypoxia.
[0225] In an embodiment, the compounds and compositions of the present disclosure may be used to treat peritoneal tissue injury. Non-limiting examples of peritoneal tissue injury include peritoneal deterioration, peritoneal sclerosis, and peritoneal cancer. For example, the receptor interacting protein kinase 1 inhibitors described herein may be used to treat peritoneal damage caused by peritoneal dialysis fluid (PDF) and PD-related side effects. Liver Injury and Diseases
[0226] In an embodiment, the compounds and compositions of the present disclosure may be used to treat liver injury and diseases. Non-limiting examples of liver injury or damage include not only degeneration or necrosis of liver parenchyma cells which results from injury caused by a certain factor, but also undesirable phenomena caused by biological reactions to the injury, such as mobilization, infiltration, activation of Kupffer cells, leukocytes and the like, fibrosis of the liver tissue, etc., which reactions occur alone or in combination. In certain embodiments, the receptor interacting protein kinase 1 inhibitors described herein may be used to treat steatohepatitis and hepatocellular carcinoma via inhibiting receptor interacting protein kinase 1 activity-dependent apoptosis of hepatocytes and hepatocarcinogenesis. In an embodiment, the receptor interacting protein kinase 1 inhibitors described herein may be used to treat alcoholic hepatitis, autoimmune hepatitis, fulminent hepatic failure, acute cholestasis and liver injury. Kidney Injury and Diseases
[0227] In an embodiment, the compounds and compositions of the present disclosure may be used to treat kidney injury and diseases. Non-limiting examples of kidney diseases include chronic kidney disease (CKD) (e.g., glomerular diseases, tubulointerstitial diseases, obstruction, polycystic kidney disease), acute kidney injury (AKI), diabetic nephropathy, fibrosis, glomerulonephritis, focal glomerulosclerosis, immune complex nephropathy, crystalline nephropathy, or lupus nephritis. Kidney disease may be caused by drug-induced renal injury or kidney graft rejection. Kidney disease may be characterized as nephrotic syndrome or renal insufficiency. In an embodiment, the receptor interacting protein kinase 1 inhibitors described herein may be used to treat kidney diseases (e.g., AKI) via inhibiting cell death pathway in kidney diseases. In an embodiment, the receptor interacting protein kinase 1 inhibitors described herein may be used to treat patient with kidney stones and to prevent crystal-induced cytotoxicity and acute kidney injury via inhibiting receptor interacting protein kinase 3-MLKL-mediated necroptosis. Skin Diseases
[0228] In an embodiment, the compounds and compositions of the present disclosure may be used to treat dermal (or skin) diseases, including but not limited to, inflammatory skin diseases or neutrophilic dermatosis. Malignancies
[0229] In an embodiment, the compounds and compositions of the present disclosure are useful for treating malignancies / cancers such as carcinoma, sarcoma, melanoma, lymphoma or leukemia. Nonlimiting examples of malignancies suitably treated by the receptor interacting protein kinase 1 inhibitors described herein include lung cancer (e.g., non-small cell lung cancer, small-cell lung cancer), hepatocellular cancer, melanoma, pancreatic cancer, urological cancer, bladder cancer, colorectal cancer, colon cancer, breast cancer, prostate cancer, renal cancer, thyroid cancer, gall bladder cancer, peritoneal cancer, ovarian cancer, cervical cancer, gastric cancer, endometrial cancer, esophageal cancer, head and neck cancer, neuroendocrine cancer, CNS cancer, brain tumors (e.g., glioma, anaplastic oligodendroglioma, adult glioblastoma multiforme, and adult anaplastic astrocytoma), bone cancer, soft tissue sarcoma, retinoblastomas, neuroblastomas, peritoneal effusions, malignant pleural effusions, mesotheliomas, Wilms tumors, trophoblastic neoplasms, hemangiopericytomas, Kaposi's sarcomas, myxoid carcinoma, round cell carcinoma, squamous cell carcinomas, esophageal squamous cell carcinomas, oral carcinomas, vulval cancer, cancers of the adrenal cortex, ACTH producing tumors, lymphoma, and leukemia. Infectious Diseases
[0230] In an embodiment, the compounds and compositions of the present disclosure are useful for treating infectious diseases resulting from the presence of pathogenic agents, including pathogenic viruses, pathogenic bacteria, fungi, protozoa, multicellular parasites and aberrant proteins known as prions. Non-limiting examples of infectious diseases suitably treated by the receptor interacting protein kinase 1 inhibitors described herein include virus infectious diseases and bacterial infectious diseases. The virus infectious disease is not particularly limited and includes, for example, infectious diseases with respiratory infectious viruses (e.g., infectious diseases due to respiratory infectious viruses such as influenza virus, rhino virus, corona virus, parainfluenza virus, RS virus, adeno virus, reo virus and the like), Staphylococcus aureus (MRSA) pneumonia, Serratia marcescens hemorrhagic pneumonia, herpes zoster caused by herpes virus, diarrhea caused by rotavirus, viral hepatitis, AIDS and the like. The bacterial infectious disease is not particularly limited and includes, for example, infectious diseases caused by Bacillus cereus, Vibrio parahaemolyticus, Enterohemorrhagic Escherichia coli, Staphylococcus aureus, MRSA, Salmonella, Botulinus, Candida and the like. Bone Diseases
[0231] In an embodiment, the compounds and compositions of the present disclosure are useful for treating bone diseases that may result from a bone remodeling disorder whereby the balance between bone formation and bone resorption is shifted. Non-limiting examples of bone remodeling disorders include osteoporosis, Paget's disease, osteoarthritis, rheumatoid arthritis, achondroplasia, osteochondritis, hyperparathyroidism, osteogenesis imperfecta, congenital hypophosphatasia, fribromatous lesions, fibrous displasia, multiple myeloma, abnormal bone turnover, osteolytic bone disease and periodontal disease. Additional examples of bone diseases suitably treated by the receptor interacting protein kinase 1 inhibitors described herein include bone fracture, bone trauma, or a bone deficit condition associated with post-traumatic bone surgery, post-prosthetic joint surgery, post-plastic bone surgery, post-dental surgery, bone chemotherapy treatment or bone radiotherapy treatment. Additional examples of diseases affecting bone or bone joints suitably treated by the receptor interacting protein kinase 1 inhibitors described herein include metastatic bone cancer, rheumatic diseases such as rheumatoid arthritis, osteoarthritis and other inflammatory arthropathies. In an embodiment, the receptor interacting protein kinase 1 inhibitors described herein may be used to treat postmenopausal osteoporosis via inhibiting osteocyte necroptosis and trabecular deterioration. Cardiovascular Diseases
[0232] In an embodiment, the compounds and compositions of the present disclosure are useful for treating cardiovascular diseases that may be relate to the cardiovascular disorders of fragile plaque disorder, occlusive disorder and stenosis. Non-limiting cardiovascular diseases include coronary artery disorders and peripheral arterial disorders, including, among others, atherosclerosis, arterial occlusion, aneurysm formation, thrombosis, post-traumatic aneurysm formation, restenosis, and post-operative graft occlusion. It is believed that atherosclerosis results from maladaptive inflammation driven primarily by macrophages. Thus, the compounds and compositions of the present disclosure may be used to treat atherosclerosis via inhibiting macrophage necroptosis. Transplantation
[0233] In an embodiment, the compounds and compositions of the present disclosure are useful for treating transplant patients. Non-limiting examples of transplant patient suitably treated by the receptor interacting protein kinase 1 inhibitors described herein include patients with solid and non-solid organ and tissue transplantations and transplants, such as liver, heart, kidney, and heterologous and autologous bone marrow transplantations / transplants. Typically, immunosuppressive therapy is used to avoid graft rejection in recipients of solid organ transplants. Recipients of bone marrow transplants are usually subjected to extensive irradiation and chemotherapy prior to transplantation. It is believed that receptor interacting protein kinase 1 and NF-κB signaling in dying cells determines cross-priming of CD8+ T cells. Thus, the receptor interacting protein kinase 1 inhibitors described herein may be used to treat transplant patient and avoid graft rejection by modulating cross-priming of CD8+ T cells. Other Diseases and Conditions
[0234] Additional examples of diseases and disorders suitably treated by the receptor interacting protein kinase 1 inhibitors described herein include Gaucher disease, organ failure, pancreatitis, atopic dermatitis, spondyloarthritis, gout, systemic onset juvenile idiopathic arthritis (SoJIA), systemic lupus erythematosus (SLE), Sjogren's syndrome, systemic scleroderma, anti-phospholipid syndrome (APS), vasculitis, primary sclerosing cholangitis (PSC), acetaminophen toxicity, kidney damage / injury (nephritis, renal transplant, surgery, administration of nephrotoxic drugs <com:Math><semantics>e.g.<annotation encoding="application / x-tex">e.g.< / annotation>< / semantics>< / com:Math>, cisplatin, acute kidney injury(AKI)), Celiac disease, autoimmune idiopathic thrombocytopenic purpura (autoimmune ITP), cerebrovascular accident (CVA, stroke), myocardial infarction (MI), allergic diseases (including asthma), diabetes, Wegener's granulomatosis, pulmonary sarcoidosis, Behcet's disease, interleukin-1 converting enzyme (ICE / caspase-1) associated fever syndrome, chronic obstructive pulmonary disease (COPD), tumor necrosis factor receptor-associated periodic syndrome (TRAPS), peridontitis, NEMO-deficiency syndrome (F-kappa-B essential modulator gene (also known as IKK gamma or IKKG) deficiency syndrome), HOIL-1 deficiency ((also known as RBCKI) heme-oxidized IRP2 ubiquitin ligase-1 deficiency), linear ubiquitin chain assembly complex (LUBAC) deficiency syndrome, hematological and solid organ malignancies, bacterial infections and viral infections (e.g., tuberculosis and influenza) and lysosomal storage diseases.
[0235] Non-limiting examples of lysosomal storage diseases include Gaucher disease, GM2 Gangliosidosis, alpha-mannosidosis, aspartylglucosaminuria, cholesteryl ester storage disease, chronic hexosaminidase A deficiency, cystinosis, Danon disease, Fabry disease, Farber disease, fucosidosis, galactosialidosis, GM1 gangliosidosis, mucolipidosis, infantile free sialic acid storage disease, juvenile hexosaminidase A deficiency, Krabbe disease, lysosomal acid lipase deficiency, metachromatic leukodystrophy, mucopolysaccharidoses disorders, multiple sulfatase deficiency, Niemann-Pick disease, neuronal ceroid lipofuscinoses, Pompe disease, pycnodysostosis, Sandhoff disease, Schindler disease, sialic acid storage disease, Tay-Sachs and Wolman disease.
[0236] In certain embodiments, provided are compounds and compositions for use in medicine. In certain embodiments, the compounds and compositions are for use in the treatment of a receptor interacting protein kinase 1-mediated disease or disorder. Also provided is a method of treating a receptor interacting protein kinase 1-mediated disease or disorder comprising administering a therapeutically effective amount of a compound or pharmaceutical composition disclosed herein to a subject in need thereof.
[0237] In another embodiment, the present disclosure provides a method of inhibiting receptor-interacting protein kinase 1. The method includes contacting the receptor- interacting protein kinase 1 with an effective amount of a compound as described herein. Inhibiting the receptor-interacting protein kinase 1 generally include contacting the receptor- interacting protein kinase 1 with an amount of the compound sufficient to reduce the activity of the receptor-interacting protein kinase 1 as compared to the receptor-interacting protein kinase 1 activity in the absence of the compound. For example, contacting the receptor- interacting protein kinase 1 with the compound can result in from about 1% to about 99% receptor-interacting protein kinase 1 inhibition (i.e., the activity of the inhibited enzyme ranges from 99% to 1% of the enzyme activity in the absence of the compound). The level of receptor-interacting protein kinase 1 inhibition can range from about 1% to about 10%, or from about 10% to about 20%, or from about 20% to about 30%, or from about 30% to about 40%, or from about 40% to about 50%, or from about 50% to about 60%, or from about 60% to about 70%, or from about 70% to about 80%, or from about 80% to about 90%, or from about 90% to about 99%. The level of receptor-interacting protein kinase 1 inhibition can range from about 5% to about 95%, or from about 10% to about 90%, or from about 20% to about 80%, or from about 30% to about 70%, or from about 40% to about 60%. In some embodiments, contacting the receptor-interacting protein kinase 1 with a compound as described herein will result in complete (i.e., 100%) inhibition. Dosing
[0238] The phrases "parenteral administration" and "administered parenterally" as used herein means modes of administration other than enteral and topical administration, usually by injection and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal and intrasternal injection and infusion.
[0239] The phrases "systemic administration," "administered systemically," "peripheral administration" and "administered peripherally" as used herein mean the administration of a compound, drug or other material other than directly into the central nervous system, such that it enters the patient's system and, thus, is subject to metabolism and other like processes, for example, subcutaneous administration.
[0240] These compounds may be administered to humans and other animals for therapy by any suitable route of administration, including orally, nasally, as by, for example, a spray, rectally, intravaginally, parenterally, intracistemally and topically, as by powders, ointments or drops, including buccally and sublingually.
[0241] Regardless of the route of administration selected, the compounds of the present disclosure, which may be used in a suitable hydrated form and / or the pharmaceutical compositions of the present disclosure, are formulated into pharmaceutically-acceptable dosage forms by conventional methods known to those of skill in the art.
[0242] Actual dosage levels of the active ingredients in the pharmaceutical compositions of this disclosure may be varied so as to obtain an amount of the active ingredient that is effective to achieve the desired therapeutic response for a particular patient, composition and mode of administration, without being toxic to the patient.
[0243] The selected dosage level will depend upon a variety of factors including the activity of the particular compound of the present disclosure employed or the ester, salt or amide thereof, the route of administration, the time of administration, the rate of excretion or metabolism of the particular compound being employed, the duration of the treatment, other drugs, compounds and / or materials used in combination with the particular compound employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated and like factors well known in the medical arts. A daily, weekly or monthly dosage (or other time interval) can be used.
[0244] A physician or veterinarian having ordinary skill in the art can readily determine and prescribe the effective amount of the pharmaceutical composition required. For example, the physician or veterinarian could start doses of the compounds of the disclosure employed in the pharmaceutical composition at levels lower than that required to achieve the desired therapeutic effect and then gradually increasing the dosage until the desired effect is achieved.
[0245] In general, a suitable daily dose of a compound of the disclosure will be that amount of the compound that is the lowest dose effective to produce a therapeutic effect (e.g., inhibit necrosis). Such an effective dose will generally depend upon the factors described above. Generally doses of the compounds of this disclosure for a patient, when used for the indicated effects, will range from about 0.0001 to about 100 mg per kg of body weight per day. Preferably the daily dosage will range from 0.001 to 50 mg of compound per kg of body weight and even more preferably from 0.01 to 10 mg of compound per kg of body weight.
[0246] If desired, the effective daily dose of the active compound may be administered as two, three, four, five, six or more sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms.
[0247] In certain embodiments, the present disclosure relates to compounds for inhibiting cell death, wherein the compounds are represented by structures (I). In certain embodiments, the compounds of the present disclosure are inhibitors of cell death. In any event, the compounds of the present disclosure preferably exert their effect on inhibiting cell death at a concentration less than about 50 micromolar, more preferably at a concentration less than about 10 micromolar and most preferably at a concentration less than 1 micromolar.
[0248] The compounds of the disclosure can be tested in standard animal models of stroke and standard protocols such as described by Hara, H., et al. Proc. Natl. Acad. Sci. USA, 1997. 94(5): 2007-12.
[0249] When the compounds of the present disclosure are administered as pharmaceuticals, to humans and animals, they can be given per se or as a pharmaceutical composition containing, for example, 0.1% to 99.5% (more preferably, 0.5% to 90%) of active ingredient in combination with a pharmaceutically acceptable carrier.
[0250] The compounds of the present application or the compositions thereof may be administered once, twice, three or four times daily, using any suitable mode described above. Also, administration or treatment with the compounds may be continued for a number of days; for example, commonly treatment would continue for at least 7 days, 14 days or 28 days, for one cycle of treatment. Treatment cycles are well known and are frequently alternated with resting periods of about 1 to 28 days, commonly about 7 days or about 14 days, between cycles. The treatment cycles, in certain embodiments, may also be continuous.
[0251] When administered orally, the total daily dosage for a human subject may be between 1 mg and 1,000 mg, between about 1,000-2,000 mg / day, between about 10-500 mg / day, between about 50-300 mg / day, between about 75-200 mg / day or between about 100- 150 mg / day.
[0252] The daily dosage may also be described as a total amount of a compound described herein administered per dose or per day. Daily dosage of a compound may be between about 1 mg and 4,000 mg, between about 2,000 to 4,000 mg / day, between about 1 to 2,000 mg / day, between about 1 to 1,000 mg / day, between about 10 to 500 mg / day, between about 20 to 500 mg / day, between about 50 to 300 mg / day, between about 75 to 200 mg / day or between about 15 to 150 mg / day.
[0253] In certain embodiments, the method comprises administering to the subject an initial daily dose of about 1 to 800 mg of a compound described herein and increasing the dose by increments until clinical efficacy is achieved. Increments of about 5, 10, 25, 50 or 100 mg can be used to increase the dose. The dosage can be increased daily, every other day, twice per week or once per week.
[0254] In certain embodiments, a compound or pharmaceutical preparation is administered orally. In certain embodiments, the compound or pharmaceutical preparation is administered intravenously. Alternative routes of administration include sublingual, intramuscular and transdermal administrations.
[0255] The preparations of the present disclosure may be given orally, parenterally, topically or rectally. They are of course given in forms suitable for each administration route. For example, they are administered in tablets or capsule form, by injection, inhalation, eye lotion, ointment, suppository, etc. administration by injection, infusion or inhalation; topical by lotion or ointment; and rectal by suppositories. In certain embodiments, the administration is oral. VI. Examples
[0256] All solvents used were commercially available and were used without further purification. Reactions were typically run using anhydrous solvents under an inert atmosphere of nitrogen. Abbreviations: aq. (aqueous), EtOAc (ethyl acetate), DCM (dichloromethane), TFA (trifluoroacetic acid), HATU (1-[bis(dimethylamino)methylene]-1H- 1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate), TEA (triethylamine), DMF (dimethylformamide), THF (tetrahydrofuran), MeTHF (2-methyltetrahydrofuran), PE (petroleum ether), T3P (propylphosphonic anhydride), AcOH (acetic acid), hex (hexane), DIAD (diisopropyl azodicarboxylate), IPA (isopropylalcohol), MTBE (methyl tert-butyl ether), MsCl (methanesulfonylchloride), Boc<com:Sub>2< / com:Sub>O (di-tert-butyl dicarbonate), DMP (Dess- Martin periodinane), LDA (lithium diisopropylamide), DAST ((diethylamino)sulfur trifluoride), i-PrOH (isopropylalcohol), TBAF (tetrabutylammonium fluoride), DIEA (diisopropylethylamine), EtOH (ethanol), DMPU (1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)- pyrimidinone), BAST (bis(2-methoxyethyl)aminosulfur trifluoride), XPhos (2- dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl), BINAP ((2,2'-bis(diphenylphosphino)- 1,1'-binaphthyl), LHMDS (lithium bis(trimethylsilyl)amide), Select F (Selectfluor, 1- chloromethyl-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate)), DCE (1,2- dichloroethane), TMSCF<com:Sub>3< / com:Sub> ((trifluoromethyl)trimethylsilane), ACN (acetonitrile, methyl cyanide), NaHMDS (sodium hexamethyldisilazide), NMI (N-methylimidazole), equiv. (equivalent), M (molar), mM (millimolar), μM (micromolar), h (hour), min. (minute), mm (millimeter) mL (milliliter), µL (microliter), N (normal), RT (room temperature), mol (mole), mmol (millimol), g (gram), mg (milligram), sat. (saturated) v / v (volume / volume), i.d. (internal diameter), psi (pounds per square inch), LC-MS (liquid chromatography mass spectroscopy), HPLC (high performance liquid chromatography), TLC (thin layer chromatograph), SFC (supercritical fluid chromatograph).
[0257] NMR Spectroscopy. <com:Sup>1< / com:Sup>H Nuclear magnetic resonance (NMR) spectroscopy was carried out using a Bruker Avance III equipped with a BBFO 300 MHz probe operating at 300 MHz or one of the following instruments: a Bruker Avance 400 instrument equipped with probe DUAL 400 MHz S1, a Bruker Avance 400 instrument equipped with probe 6 S1 400 MHz 5mm <com:Sup>1< / com:Sup>H-<com:Sup>13<...
Claims
CLAIMS:
1. A compound according to Formula I: [Image disponible dans le document PDF, Image available in the PDF document] (I), or a pharmaceutically acceptable salt, solvate, isotopic analog, or stereoisomer thereof, wherein <com:Math><semantics>W1<annotation encoding="application / x-tex">W^1< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>W3<annotation encoding="application / x-tex">W^3< / annotation>< / semantics>< / com:Math>, and <com:Math><semantics>W4<annotation encoding="application / x-tex">W^4< / annotation>< / semantics>< / com:Math> are <com:Math><semantics>CR7<annotation encoding="application / x-tex">CR^7< / annotation>< / semantics>< / com:Math>; <com:Math><semantics>W2<annotation encoding="application / x-tex">W^2< / annotation>< / semantics>< / com:Math> is N or <com:Math><semantics>CR7<annotation encoding="application / x-tex">CR^7< / annotation>< / semantics>< / com:Math>; provided that when W<com:Sup>2< / com:Sup> is CR<com:Sup>7< / com:Sup>, then either a) W<com:Sup>4< / com:Sup> is C-CN or b) R<com:Sup>1a< / com:Sup> is not hydrogen and R<com:Sup>1b< / com:Sup> and R<com:Sup>1c< / com:Sup> together form a piperidin-4-yl ring substituted by <com:Math><semantics>(R5)n<annotation encoding="application / x-tex">(R^5)_n< / annotation>< / semantics>< / com:Math> and n is 1-9; R<com:Sup>1a< / com:Sup>, R<com:Sup>1b< / com:Sup>, and R<com:Sup>1c< / com:Sup> are independently hydrogen, halogen, -CN, -N<com:Sub>3< / com:Sub>, -NO<com:Sub>2< / com:Sub>, -OH, -SF<com:Sub>5< / com:Sub>, -SCF<com:Sub>3< / com:Sub>, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>2-8< / com:Sub> alkenyl, C<com:Sub>2-8< / com:Sub> alkynyl, C<com:Sub>1-8< / com:Sub> heteroalkyl, C<com:Sub>3-8< / com:Sub> cycloalkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, C<com:Sub>1-8< / com:Sub> alkoxy, C<com:Sub>1-8< / com:Sub> haloalkoxy, 4- to 12-membered heterocyclyl, <com:Math><semantics>C6−10<annotation encoding="application / x-tex">C_{6-10}< / annotation>< / semantics>< / com:Math> aryl, 5- to 12-membered heteroaryl, <com:Math><semantics>−N(R1d)2<annotation encoding="application / x-tex">-N(R^{1d})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(O)R1e<annotation encoding="application / x-tex">-C(O)R^{1e}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(O)OR1d<annotation encoding="application / x-tex">-C(O)OR^{1d}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(O)N(R1d)2<annotation encoding="application / x-tex">-C(O)N(R^{1d})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NR1dC(O)R1e<annotation encoding="application / x-tex">-NR^{1d}C(O)R^{1e}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NR1dC(O)N(R1d)2<annotation encoding="application / x-tex">-NR^{1d}C(O)N(R^{1d})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NR1dC(O)OR1d<annotation encoding="application / x-tex">-NR^{1d}C(O)OR^{1d}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−OC(O)N(R1d)2<annotation encoding="application / x-tex">-OC(O)N(R^{1d})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−OC(O)OR1d<annotation encoding="application / x-tex">-OC(O)OR^{1d}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−SR1d<annotation encoding="application / x-tex">-SR^{1d}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(O)R1e<annotation encoding="application / x-tex">-S(O)R^{1e}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(O)2R1e<annotation encoding="application / x-tex">-S(O)_2R^{1e}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(O)3R1d<annotation encoding="application / x-tex">-S(O)_3R^{1d}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(O)N(R1d)2<annotation encoding="application / x-tex">-S(O)N(R^{1d})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(O)2N(R1d)2<annotation encoding="application / x-tex">-S(O)_2N(R^{1d})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NR1dS(O)R1e<annotation encoding="application / x-tex">-NR^{1d}S(O)R^{1e}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NR1dS(O)2R1e<annotation encoding="application / x-tex">-NR^{1d}S(O)_2R^{1e}< / annotation>< / semantics>< / com:Math>, -NR<com:Sup>1d< / com:Sup>S(O)N(R<com:Sup>1d< / com:Sup>)<com:Sub>2< / com:Sub>, or -NR<com:Sup>1d< / com:Sup>S(O)<com:Sub>2< / com:Sub>N(R<com:Sup>1d< / com:Sup>)<com:Sub>2< / com:Sub>, wherein each of R<com:Sup>1a< / com:Sup>, R<com:Sup>1b< / com:Sup>, and R<com:Sup>1c< / com:Sup> is optionally and independently substituted with one to eight R<com:Sup>5< / com:Sup> and at least one of R<com:Sup>1a< / com:Sup>, R<com:Sup>1b< / com:Sup>, and R<com:Sup>1c< / com:Sup> is other than hydrogen; or R<com:Sup>1b< / com:Sup> and R<com:Sup>1c< / com:Sup> are optionally taken together to form C<com:Sub>3-10< / com:Sub> cycloalkyl or 4- to 12-membered heterocyclyl, each of which is optionally substituted with one to eight R<com:Sup>5< / com:Sup>; or R<com:Sup>1a< / com:Sup>, R<com:Sup>1b< / com:Sup>, and R<com:Sup>1c< / com:Sup> are optionally taken together to form C<com:Sub>5-10< / com:Sub> cycloalkyl or 6- to 8-membered heterocyclyl, each of which is optionally substituted with one to eight R<com:Sup>5< / com:Sup>; each R<com:Sup>1d< / com:Sup> is independently hydrogen, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, C<com:Sub>3-10< / com:Sub> cycloalkyl, or [Image disponible dans le document PDF, Image available in the PDF document] two R<com:Sup>1d< / com:Sup> on the same atom are optionally taken together to form a 4- to 8-membered heterocyclyl optionally substituted by oxo, halo, or C<com:Sub>1-6< / com:Sub> alkyl, wherein said alkyl is optionally substituted with one to eight R<com:Sup>5< / com:Sup>; each R<com:Sup>1e< / com:Sup> is independently C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, C<com:Sub>3-10< / com:Sub> cycloalkyl, or 4- to 12-membered heterocyclyl; R<com:Sup>2a< / com:Sup> and R<com:Sup>2b< / com:Sup> are independently hydrogen, halogen, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, C<com:Sub>2-8< / com:Sub> alkenyl, or C<com:Sub>2-8< / com:Sub> alkynyl, or R<com:Sup>2a< / com:Sup> and R<com:Sup>2b< / com:Sup> are optionally taken together to form C<com:Sub>3-6< / com:Sub> cycloalkyl or 4- to 6-membered heterocyclyl, each of which is optionally substituted with one to eight R<com:Sup>6< / com:Sup>; R<com:Sup>3a< / com:Sup> and R<com:Sup>3b< / com:Sup> are independently hydrogen, halogen, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>2-8< / com:Sub> alkenyl, C<com:Sub>2-8< / com:Sub> alkynyl, C<com:Sub>1-8< / com:Sub> haloalkyl, C<com:Sub>3-6< / com:Sub> cycloalkyl, or 4- to 6-membered heterocyclyl, wherein said cycloalkyl and said heterocyclyl are optionally substituted with one to eight R<com:Sup>6< / com:Sup>, or R<com:Sup>3a< / com:Sup> and R<com:Sup>3b< / com:Sup> are optionally taken together to form oxo, C<com:Sub>3-6< / com:Sub> cycloalkyl, or 4- to 6-membered heterocyclyl, wherein said cycloalkyl and said heterocyclyl are optionally substituted with one to eight R<com:Sup>6< / com:Sup>; Y is O, C(O), S, S(O), S(O)<com:Sub>2< / com:Sub>, <com:Math><semantics>CR4aR4b<annotation encoding="application / x-tex">CR^{4a}R^{4b}< / annotation>< / semantics>< / com:Math>, or <com:Math><semantics>NR4c<annotation encoding="application / x-tex">NR^{4c}< / annotation>< / semantics>< / com:Math>; R<com:Sup>4a< / com:Sup> and R<com:Sup>4b< / com:Sup> are independently hydrogen, halogen, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>2-8< / com:Sub> alkenyl, C<com:Sub>2-8< / com:Sub> alkynyl, C<com:Sub>1-8< / com:Sub> haloalkyl, C<com:Sub>3-6< / com:Sub> cycloalkyl, or 4- to 6-membered heterocyclyl, wherein said cycloalkyl and said heterocyclyl are optionally substituted with one to eight R<com:Sup>6< / com:Sup>, or R<com:Sup>4a< / com:Sup> and R<com:Sup>4b< / com:Sup> are optionally taken together to form C<com:Sub>3-6< / com:Sub> cycloalkyl or 4- to 6-membered heterocyclyl, wherein said cycloalkyl and said heterocyclyl are optionally substituted with one to eight R<com:Sup>6< / com:Sup>, or R<com:Sup>4a< / com:Sup> and R<com:Sup>1b< / com:Sup> are optionally taken together to form 4- to 12-membered heterocyclyl, which is optionally substituted with one to eight R<com:Sup>6< / com:Sup>, or R<com:Sup>4a< / com:Sup> and R<com:Sup>3a< / com:Sup> are optionally taken together to form C<com:Sub>3-8< / com:Sub> cycloalkyl or 4- to 12-membered heterocyclyl, each of which is optionally substituted with one to eight R<com:Sup>6< / com:Sup>, or R<com:Sup>4c< / com:Sup> is hydrogen, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, C<com:Sub>3-10< / com:Sub> cycloalkyl, or 4- to 12-membered heterocyclyl; each R<com:Sup>5< / com:Sup> is independently halogen, -CN, -OH, -SF<com:Sub>5< / com:Sub>, -SCF<com:Sub>3< / com:Sub>, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>2-8< / com:Sub> alkenyl, C<com:Sub>2-8< / com:Sub> alkynyl, C<com:Sub>1-8< / com:Sub> heteroalkyl, C<com:Sub>3-8< / com:Sub> cycloalkyl, C<com:Sub>1-8< / com:Sub> alkoxy, 4- to 12-membered heterocyclyl, C<com:Sub>6-10< / com:Sub> aryl, 5- to 12-membered heteroaryl, (4- to 12-membered heterocyclyl)(<com:Math><semantics>C1−8<annotation encoding="application / x-tex">C_{1-8}< / annotation>< / semantics>< / com:Math> heteroalkyl), (<com:Math><semantics>C6−10<annotation encoding="application / x-tex">C_{6-10}< / annotation>< / semantics>< / com:Math> aryl)(<com:Math><semantics>C1−8<annotation encoding="application / x-tex">C_{1-8}< / annotation>< / semantics>< / com:Math> heteroalkyl), (5- to 12-membered heteroaryl)(<com:Math><semantics>C1−8<annotation encoding="application / x-tex">C_{1-8}< / annotation>< / semantics>< / com:Math> heteroalkyl), <com:Math><semantics>−N(R5a)2<annotation encoding="application / x-tex">-N(R^{5a})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(O)R5b<annotation encoding="application / x-tex">-C(O)R^{5b}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(O)OR5a<annotation encoding="application / x-tex">-C(O)OR^{5a}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(O)N(R5a)2<annotation encoding="application / x-tex">-C(O)N(R^{5a})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NR5aC(O)R5b<annotation encoding="application / x-tex">-NR^{5a}C(O)R^{5b}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NR5aC(O)N(R5a)2<annotation encoding="application / x-tex">-NR^{5a}C(O)N(R^{5a})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NR5aC(O)OR5a<annotation encoding="application / x-tex">-NR^{5a}C(O)OR^{5a}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−OC(O)N(R5a)2<annotation encoding="application / x-tex">-OC(O)N(R^{5a})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−OC(O)OR5a<annotation encoding="application / x-tex">-OC(O)OR^{5a}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−SR5a<annotation encoding="application / x-tex">-SR^{5a}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(O)R5b<annotation encoding="application / x-tex">-S(O)R^{5b}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(O)2R5b<annotation encoding="application / x-tex">-S(O)_2R^{5b}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(O)3R5a<annotation encoding="application / x-tex">-S(O)_3R^{5a}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(O)N(R5a)2<annotation encoding="application / x-tex">-S(O)N(R^{5a})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(O)2N(R5a)2<annotation encoding="application / x-tex">-S(O)_2N(R^{5a})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NR5aS(O)R5b<annotation encoding="application / x-tex">-NR^{5a}S(O)R^{5b}< / annotation>< / semantics>< / com:Math>, -NR<com:Sup>5a< / com:Sup>S(O)<com:Sub>2< / com:Sub>R<com:Sup>5b< / com:Sup>, -NR<com:Sup>5a< / com:Sup>S(O)N(R<com:Sup>5a< / com:Sup>)<com:Sub>2< / com:Sub>, or -NR<com:Sup>5a< / com:Sup>S(O)<com:Sub>2< / com:Sub>N(R<com:Sup>5a< / com:Sup>)<com:Sub>2< / com:Sub>, each of which is optionally substituted with one to eight R<com:Sup>5c< / com:Sup>, or two R<com:Sup>5< / com:Sup> are optionally taken together to form oxo; each R<com:Sup>5a< / com:Sup> is independently hydrogen, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, C<com:Sub>3-10< / com:Sub> cycloalkyl, or 4- to 12-membered heterocyclyl, and each R<com:Sup>5b< / com:Sup> is independently C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, C<com:Sub>3-10< / com:Sub> cycloalkyl, 4- to 12-membered heterocyclyl, or 5- to 12-membered heteroaryl; each R<com:Sup>5c< / com:Sup> is independently halogen, cyano, C<com:Sub>1-8< / com:Sub> haloalkyl, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>1-8< / com:Sub> alkoxy, [Image disponible dans le document PDF, Image available in the PDF document] <Formule mathématique disponible dans le document PDF, Math available in the PDF document>N(R^{5d})_2(C_{1-8} \text{ alkoxy}), C_{3-10} \text{ cycloalkyl, or 4- to 12-membered heterocyclyl, or 4- two R<com:Sup>5c< / com:Sup> are optionally taken together to form oxo; each R<com:Sup>5d< / com:Sup> is independently hydrogen, C<com:Sub>1-8< / com:Sub> alkyl, or C<com:Sub>1-8< / com:Sub> haloalkyl; each R<com:Sup>6< / com:Sup> is halogen, -CN, -OH, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>1-8< / com:Sub> heteroalkyl, C<com:Sub>3-8< / com:Sub> cycloalkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] two R<com:Sup>6< / com:Sup> are taken together to form oxo; each R<com:Sup>6a< / com:Sup> is independently hydrogen, C<com:Sub>1-8< / com:Sub> alkyl, or C<com:Sub>1-8< / com:Sub> haloalkyl, or two R<com:Sup>6a< / com:Sup> on the same atom are optionally taken together to form 4- to 6-membered heterocyclyl; each R<com:Sup>6b< / com:Sup> is independently C<com:Sub>1-8< / com:Sub> alkyl or C<com:Sub>1-8< / com:Sub> haloalkyl; each R<com:Sup>7< / com:Sup> is independently hydrogen, halogen, -CN, -N<com:Sub>3< / com:Sub>, -NO<com:Sub>2< / com:Sub>, -SF<com:Sub>5< / com:Sub>, -SCF<com:Sub>3< / com:Sub>, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>2-8< / com:Sub> alkenyl, C<com:Sub>2-8< / com:Sub> alkynyl, C<com:Sub>1-8< / com:Sub> heteroalkyl, C<com:Sub>3-8< / com:Sub> cycloalkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, 4- to 12-membered heterocyclyl, C<com:Sub>6-10< / com:Sub> aryl, 5- to 12-membered [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] -NR<com:Sup>7a< / com:Sup>S(O)<com:Sub>2< / com:Sub>N(R<com:Sup>7a< / com:Sup>)<com:Sub>2< / com:Sub>, each of which is optionally and independently substituted with one to eight R<com:Sup>8< / com:Sup>; each R<com:Sup>7a< / com:Sup> is independently hydrogen, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, C<com:Sub>3-10< / com:Sub> cycloalkyl, or [Image disponible dans le document PDF, Image available in the PDF document] two R<com:Sup>7a< / com:Sup> on the same atom are optionally taken together to form a 4- to 8-membered heterocyclyl optionally substituted by oxo, halo, or C<com:Sub>1-6< / com:Sub> alkyl, wherein said alkyl is optionally substituted with one to eight R<com:Sup>8< / com:Sup>; each R<com:Sup>7b< / com:Sup> is independently C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, C<com:Sub>3-10< / com:Sub> cycloalkyl, or 4- to 12-membered heterocyclyl; each R<com:Sup>8< / com:Sup> is halogen, -CN, -OH, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>2-8< / com:Sub> alkenyl, C<com:Sub>2-8< / com:Sub> alkynyl, C<com:Sub>1-8< / com:Sub> heteroalkyl, <com:Math><semantics>C3−8<annotation encoding="application / x-tex">C_{3-8}< / annotation>< / semantics>< / com:Math> cycloalkyl, <com:Math><semantics>C1−8<annotation encoding="application / x-tex">C_{1-8}< / annotation>< / semantics>< / com:Math> haloalkyl, <com:Math><semantics>C1−8<annotation encoding="application / x-tex">C_{1-8}< / annotation>< / semantics>< / com:Math> alkoxy, 4- to 12-membered heterocyclyl, <com:Math><semantics>C6−10<annotation encoding="application / x-tex">C_{6-10}< / annotation>< / semantics>< / com:Math> aryl, 5- to 12-membered heteroaryl, <com:Math><semantics>−N(R8a)2<annotation encoding="application / x-tex">-N(R^{8a})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(O)R8b<annotation encoding="application / x-tex">-C(O)R^{8b}< / annotation>< / semantics>< / com:Math>, or <com:Math><semantics>−C(O)OR8a<annotation encoding="application / x-tex">-C(O)OR^{8a}< / annotation>< / semantics>< / com:Math>, or two R<com:Sup>8< / com:Sup> are optionally taken together to form oxo; each R<com:Sup>8a< / com:Sup> is independently hydrogen, C<com:Sub>1-8< / com:Sub> alkyl, or C<com:Sub>1-8< / com:Sub> haloalkyl; each R<com:Sup>8b< / com:Sup> is independently C<com:Sub>1-8< / com:Sub> alkyl or C<com:Sub>1-8< / com:Sub> haloalkyl; Z is <com:Math><semantics>C(R9)2<annotation encoding="application / x-tex">C(R^9)_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>C(O)<annotation encoding="application / x-tex">C(O)< / annotation>< / semantics>< / com:Math>, O, S, <com:Math><semantics>S(O)<annotation encoding="application / x-tex">S(O)< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>S(O)2<annotation encoding="application / x-tex">S(O)_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>S(O)NR9<annotation encoding="application / x-tex">S(O)NR^9< / annotation>< / semantics>< / com:Math>, or <com:Math><semantics>NR9<annotation encoding="application / x-tex">NR^9< / annotation>< / semantics>< / com:Math>; provided that when Z is N, then R<com:Sup>3a< / com:Sup> and R<com:Sup>3b< / com:Sup> are not oxo; each R<com:Sup>9< / com:Sup> is independently hydrogen, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>2-8< / com:Sub> alkenyl, C<com:Sub>2-8< / com:Sub> alkynyl, C<com:Sub>1-8< / com:Sub> haloalkyl, <com:Math><semantics>C3−8<annotation encoding="application / x-tex">C_{3-8}< / annotation>< / semantics>< / com:Math> cycloalkyl, 4- to 8-membered heterocyclyl, or <com:Math><semantics>−C(O)R9a<annotation encoding="application / x-tex">-C(O)R^{9a}< / annotation>< / semantics>< / com:Math>; and R<com:Sup>9a< / com:Sup> is C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, C<com:Sub>3-8< / com:Sub> cycloalkyl, or 4- to 12-membered heterocyclyl, or R<com:Sup>9< / com:Sup> and R<com:Sup>3a< / com:Sup> are optionally taken together to form C<com:Sub>3-8< / com:Sub> cycloalkyl or 4- to 12-membered heterocyclyl, each of which is optionally substituted with one to eight R<com:Sup>6< / com:Sup>.
2. A compound of claim 1, wherein W<com:Sup>2< / com:Sup> is N.
3. A compound of claim 2, wherein Z is O; Y is CR<com:Sup>4a< / com:Sup>R<com:Sup>4b< / com:Sup>; R<com:Sup>2a< / com:Sup>, R<com:Sup>2b< / com:Sup>, R<com:Sup>3a< / com:Sup>, R<com:Sup>3b< / com:Sup>, R<com:Sup>4a< / com:Sup>, and R<com:Sup>4b< / com:Sup> are H; and R<com:Sup>1a< / com:Sup>, R<com:Sup>1b< / com:Sup>, R<com:Sup>1c< / com:Sup>, R<com:Sup>5< / com:Sup>, R<com:Sup>7< / com:Sup>, and R<com:Sup>8< / com:Sup> are as defined for Formula I.
4. A compound of claim 1, according to Formula la: [Image disponible dans le document PDF, Image available in the PDF document] (la), 211 or a pharmaceutically acceptable salt, solvate, isotopic analog, or stereoisomer thereof, wherein R<com:Sup>1a< / com:Sup>, R<com:Sup>2a< / com:Sup>, R<com:Sup>2b< / com:Sup>, R<com:Sup>3a< / com:Sup>, R<com:Sup>3b< / com:Sup>, R<com:Sup>5< / com:Sup>, R<com:Sup>7< / com:Sup>, W<com:Sup>1< / com:Sup>, W<com:Sup>2< / com:Sup>, W<com:Sup>3< / com:Sup>, W<com:Sup>4< / com:Sup>, Y, and Z are as defined for Formula I; and n is 1-9; provided that when W<com:Sup>1< / com:Sup>, W<com:Sup>2< / com:Sup>, W<com:Sup>3< / com:Sup>, and W<com:Sup>4< / com:Sup> are CR<com:Sup>7< / com:Sup>, then R<com:Sup>1a< / com:Sup> is not hydrogen.
5. A compound of claim 4, wherein at least one of R<com:Sup>5< / com:Sup> is attached to the piperidine nitrogen atom.
6. A compound of claim 1, according to Formula lb: [Image disponible dans le document PDF, Image available in the PDF document] (lb), or a pharmaceutically acceptable salt, solvate, isotopic analog, or stereoisomer thereof, wherein R<com:Sup>1a< / com:Sup>, R<com:Sup>1b< / com:Sup>, R<com:Sup>1c< / com:Sup>, R<com:Sup>2a< / com:Sup>, R<com:Sup>2b< / com:Sup>, R<com:Sup>3a< / com:Sup>, R<com:Sup>3b< / com:Sup>, W<com:Sup>1< / com:Sup>, W<com:Sup>2< / com:Sup>, W<com:Sup>3< / com:Sup>, Y, and Z are as defined for Formula ١.
7. A compound of any one of claims 1 to 6, wherein W<com:Sup>2< / com:Sup> is N and W<com:Sup>1< / com:Sup>, W<com:Sup>3< / com:Sup>, W<com:Sup>4< / com:Sup> are CR<com:Sup>7< / com:Sup>.
8. A compound of any one of claims 1 to 6, wherein W<com:Sup>2< / com:Sup> is N and W<com:Sup>3< / com:Sup> is CH.
9. A compound of any one of claims 1 to 6, wherein W<com:Sup>2< / com:Sup> is N and each R<com:Sup>7< / com:Sup> is independently hydrogen, halogen, cyano, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, or C<com:Sub>1-8< / com:Sub> alkoxy.
10. A compound of any one of claims 1 and 4 to 6, wherein W<com:Sup>2< / com:Sup> is CR<com:Sup>7< / com:Sup>.
11. A compound of any one of claims 1 to 10, wherein each R<com:Sup>7< / com:Sup> is independently hydrogen, halogen, cyano, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, or C<com:Sub>1-8< / com:Sub> alkoxy.
12. A compound of any one of claims 1 to 10, wherein at least one R<com:Sup>7< / com:Sup> is halo, C<com:Sub>1-6< / com:Sub> alkyl, C<com:Sub>1-6< / com:Sub> alkoxy, or cyano.
13. A compound of any one of claims 1 to 10, wherein at least one R<com:Sup>7< / com:Sup> is chloro, fluoro, methyl, methoxy, cyano, or bromo.
14. A compound of any one of claims 1 to 10, wherein one or two of R<com:Sup>7< / com:Sup> is 7-chloro, 7-methyl, 8-methoxy, 9-fluoro, 6-fluoro, 6-fluoro-9-cyano, 7-fluoro-9-cyano, 9-cyano, 6-cyano, 8-cyano, 7- fluoro-, or 9-bromo-7-fluoro-.
15. A compound of any one of claims 1 to 14, wherein W<com:Sup>1< / com:Sup> is CH, CF, or CCN.
16. A compound of any one of claims 1 to 15, wherein W<com:Sup>2< / com:Sup> is CH, CCl, CF, or CCH<com:Sub>3< / com:Sub>.
17. A compound of any one of claims 1 to 16, wherein W<com:Sup>3< / com:Sup> is CH, COCH<com:Sub>3< / com:Sub>, CCN, CF, CCl, or CCF<com:Sub>3< / com:Sub>.
18. A compound of any one of claims 1 to 17, wherein W<com:Sup>4< / com:Sup> is CH, CCN, CF, Br, Cl, CCl, or CCF<com:Sub>3< / com:Sub>.
19. A compound of any one of claims 1 to 18, wherein Z is CH<com:Sub>2< / com:Sub>.
20. A compound of any one of claims 1 to 18, wherein Z is O.
21. A compound of any one of claims 1 to 20, wherein Y is CR<com:Sup>4a< / com:Sup>R<com:Sup>4b< / com:Sup>.
22. A compound of any one of claims 1 to 20, wherein Y is O.
23. A compound of any one of claims 1 to 22, wherein R<com:Sup>1a< / com:Sup> is hydrogen, C<com:Sub>1-8< / com:Sub> alkyl, <com:Math><semantics>C1−8<annotation encoding="application / x-tex">C_{1-8}< / annotation>< / semantics>< / com:Math> haloalkyl, or <com:Math><semantics>C3−8<annotation encoding="application / x-tex">C_{3-8}< / annotation>< / semantics>< / com:Math> cycloalkyl, each of which is optionally substituted with halogen and -CN.
24. A compound of any one of claims 1 to 22, wherein R<com:Sup>1b< / com:Sup> and R<com:Sup>1c< / com:Sup> are independently C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, or C<com:Sub>3-8< / com:Sub> cycloalkyl, each of which is optionally substituted with halogen and -CN.
25. A compound of any one of claims 1 to 22, wherein at least one of R<com:Sup>1a< / com:Sup>, R<com:Sup>1b< / com:Sup>, and R<com:Sup>1c< / com:Sup> is chloro, methyl, -CD<com:Sub>3< / com:Sub>, ethyl, difluoromethyl, cyanomethyl, cyclopropyl, cyclopropylmethyl, trifluoromethyl, methoxy, trifluoromethoxymethyl, 2,2,2-trifluoroethyl, 1,1-difluoroethyl, 2- fluoroethyl, trifluoromethoxy, 1-cyanoethyl, fluoromethyl, 1-hydroxycyclopropyl, difluoromethylcyclopropyl, cyanocyclopropyl, 3,3-difluorocyclobutyl, 1,1,2,2,2-pentafluoroethyl, 1-methylethyl, methylsulfanyl, methoxymethyl, 5-fluoropyrimidin-2-ylsulfanyl, azetidin-3-yl, pyrroldin-3-yl, cyano, or hydroxyl.
26. A compound of any one of claims 1 to 22, wherein R<com:Sup>1b< / com:Sup> and R<com:Sup>1c< / com:Sup> are taken together to form 4- to 12-membered heterocyclyl, which is optionally substituted with one to eight R<com:Sup>5< / com:Sup>.
27. A compound of any one of claims 1 to 22, wherein R<com:Sup>1b< / com:Sup> and R<com:Sup>1c< / com:Sup> are taken together to form a 4, 5, 6, or 7 membered heterocyclyl containing a nitrogen ring atom and optionally substituted with one to eight R<com:Sup>5< / com:Sup>.
28. A compound of claim 26 or claim 27, wherein the heterocyclyl is substituted with one to four R<com:Sup>5< / com:Sup>.
29. A compound of any one of claims 1 to 28, wherein at least one of R<com:Sup>5< / com:Sup> is C<com:Sub>1-8< / com:Sub> alkyl, <com:Math><semantics>C1−8<annotation encoding="application / x-tex">C_{1-8}< / annotation>< / semantics>< / com:Math> haloalkyl, halogen, <com:Math><semantics>C1−8<annotation encoding="application / x-tex">C_{1-8}< / annotation>< / semantics>< / com:Math> haloalkyl, <com:Math><semantics>C1−8<annotation encoding="application / x-tex">C_{1-8}< / annotation>< / semantics>< / com:Math> alkoxy, -OH, or cyano.
30. A compound of any one of claims 1 to 28, wherein at least one of R<com:Sup>5< / com:Sup> is methyl, ethyl, fluoro, chloro, difluoromethyl, fluoromethyl, methoxy, hydroxyl, C<com:Sub>1-8< / com:Sub> haloalkyl, halogen, <com:Math><semantics>C1−8<annotation encoding="application / x-tex">C_{1-8}< / annotation>< / semantics>< / com:Math> haloalkyl, <com:Math><semantics>C1−8<annotation encoding="application / x-tex">C_{1-8}< / annotation>< / semantics>< / com:Math> alkoxy, or cyano.
31. A compound of any one of claims 1 to 28, wherein at least one of R<com:Sup>5< / com:Sup> is 4- to 12-membered heterocyclyl or 5- to 12-membered heteroaryl, each of which is optionally substituted with one to eight R<com:Sup>5c< / com:Sup>.
32. A compound of claim 31, wherein at least one of R<com:Sup>5< / com:Sup> is a 5- to 12-membered heteroaryl optionally substituted with one to eight R<com:Sup>5c< / com:Sup>.
33. A compound of claim 32, wherein the 5- to 12-membered heteroaryl is selected from pyrimidin-2-yl, pyrimidin-4-yl, pyrazin-2-yl, [1,2,4]triazolo[1,5-a]pyrazin-8-yl, [1,2,4]triazolo[1,5- c]pyrimidin-5-yl, pyrazolo[1,5-a][1,3,5]triazin-4-yl, pyrazolo[1,5-a]pyrimidin-7-yl, pyridazin-4-yl, quinazolin-2-yl, imidazo[1,2-a]pyrazin-8-yl, pyrazolo[4,3-c]pyridin-6-yl, pyrrolo[3,2-d]pyrimidin-2- yl, imidazo[1,2-b]pyridazin-6-yl, pyrazolo[1,5-a]pyrimidin-7-yl, 6,7-dihydro-5H- cyclopenta[d]pyrimidin-2-yl, pyrid-2-yl, pyrid-3-yl, methoxypyridazin-3-yl, 5,7-dihydrofuro[3,4- d]pyrimidin-2-yl, purin-2-yl, quinazolin-2-yl, quinoxalin-2-yl, isoquinol-3-yl, quinol-2-yl, and 1,3,5- triazin-2-yl, and imidazo[2,1-f][1,2,4]triazin-4-yl, each of which is optionally substituted with one to eight R<com:Sup>5c< / com:Sup>.
34. A compound of claims 32 or 33, wherein the heterocyclyl is substituted with one to three <com:Math><semantics>R5c<annotation encoding="application / x-tex">R^{5c}< / annotation>< / semantics>< / com:Math>.
35. A compound of claim 34, wherein R<com:Sup>5c< / com:Sup> is independently fluoro, methoxy, difluoromethoxy, methyl, methylamino, cyclopropylamino, 2,2-difluoroethoxy, methylsulfanyl, dimethylaminopropoxy, chloro, 2-methoxyethoxy, dimethylaminoethoxy, cyano, trifluoromethyl, ethoxy, difluoromethyl, cyclopropyl, and oxo.
36. A compound of any one of claims 1 to 23 and 29 to 35, wherein R<com:Sup>1b< / com:Sup> and R<com:Sup>1c< / com:Sup> are taken together to form 2,2-difluorocyclobutyl, 3,3-difluorocyclobutyl, (5-fluoropyrimidin-2-yl)piperidin-4- yl, tetrahydropyran-4-yl, tetrahydropyran-3-yl, tetrahydrofuran-3-yl, cyclopropyl, or cyclobutyl.
37. A compound of any one of claims 1 to 36, wherein R<com:Sup>1a< / com:Sup> is hydrogen.
38. A compound of any one of claims 1 to 36, wherein R<com:Sup>1a< / com:Sup> is chloro, fluoro, methyl, ethyl, difluoromethyl, fluoromethyl, cyano, or hydroxyl.
39. A compound of any one of claims 1 to 22 and 29 to 35, wherein R<com:Sup>1a< / com:Sup>, R<com:Sup>1b< / com:Sup>, and R<com:Sup>1c< / com:Sup> are taken together to form bicyclo[1.1.1]pentane, azabicyclo[4.1.0]heptane, azepan-4-yl, 1,4- oxepane-7-yl, tetrahydropyran-2-yl, or 3,6-dihydro-2H-pyridin-4-yl.
40. A compound of any one of claims 1 to 39, wherein <com:Math><semantics>R2a<annotation encoding="application / x-tex">R^{2a}< / annotation>< / semantics>< / com:Math> is hydrogen and <com:Math><semantics>R2b<annotation encoding="application / x-tex">R^{2b}< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>C1−8<annotation encoding="application / x-tex">C_{1-8}< / annotation>< / semantics>< / com:Math> alkyl.
41. A compound of any one of claims 1 to 39, wherein R<com:Sup>2a< / com:Sup> and R<com:Sup>2b< / com:Sup> are hydrogen.
42. A compound of any one of claims 1 to 41, wherein R<com:Sup>4a< / com:Sup> is hydrogen or methyl.
43. A compound of any one of claims 1 to 42, wherein R<com:Sup>3a< / com:Sup> and R<com:Sup>3b< / com:Sup> are independently hydrogen or methyl.
44. A compound, or a pharmaceutically acceptable salt, solvate, isotopic analog, or stereoisomer thereof, selected from: [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] • 45. A compound selected from [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] .
46. The compound 4-(3,3-difluoro-2,2-dimethyl-propanoyl)-3,5-dihydro-2H-pyrido[3,4- f][1,4]oxazepine-9-carbonitrile.
47. A pharmaceutically acceptable salt of the compound 4-(3,3-difluoro-2,2-dimethyl- 262 propanoyl)-3,5-dihydro-2H-pyrido[3,4-f][1,4]oxazepine-9-carbonitrile.
48. A pharmaceutical composition comprising a compound according to any one of claims 1- 46, or a pharmaceutically acceptable salt, solvate, isotopic analog, or stereoisomer thereof, and a pharmaceutically acceptable excipient.
49. A method for preparing a compound according to Formula A: [Image disponible dans le document PDF, Image available in the PDF document] (A), or a salt thereof, the method comprising: contacting a compound according to Formula IIa [Image disponible dans le document PDF, Image available in the PDF document] (lla) with a compound according to Formula IIb, [Image disponible dans le document PDF, Image available in the PDF document] (IIb) under conditions sufficient to form a compound according to Formula IIc [Image disponible dans le document PDF, Image available in the PDF document] (IIc); converting the compound of Formula IIc to a compound of Formula IId [Image disponible dans le document PDF, Image available in the PDF document] (IId); and contacting the compound of Formula IId with a compound of Formula IIe [Image disponible dans le document PDF, Image available in the PDF document] (lle) under conditions sufficient to form the compound of Formula A; wherein: Z<com:Sup>1< / com:Sup> is an optionally protected first reactive group; <com:Math><semantics>Z2<annotation encoding="application / x-tex">Z^2< / annotation>< / semantics>< / com:Math> is an optionally protected second reactive group; Q is -OH or a leaving group; and W<com:Sup>1< / com:Sup>, W<com:Sup>2< / com:Sup>, W<com:Sup>3< / com:Sup>, and W<com:Sup>4< / com:Sup> are independently N or CR<com:Sup>7< / com:Sup>; provided that when W<com:Sup>2< / com:Sup> is CR<com:Sup>7< / com:Sup>, then either a) W<com:Sup>4< / com:Sup> is C-CN or b) R<com:Sup>1a< / com:Sup> is not hydrogen and R<com:Sup>1b< / com:Sup> and R<com:Sup>1c< / com:Sup> together form a piperidin-4-yl ring substituted by <com:Math><semantics>(R5)n<annotation encoding="application / x-tex">(R^5)_n< / annotation>< / semantics>< / com:Math> and n is 1-9; R<com:Sup>1a< / com:Sup>, R<com:Sup>1b< / com:Sup>, and R<com:Sup>1c< / com:Sup> are independently hydrogen, halogen, -CN, -N<com:Sub>3< / com:Sub>, -NO<com:Sub>2< / com:Sub>, -OH, -SF<com:Sub>5< / com:Sub>, -SCF<com:Sub>3< / com:Sub>, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>2-8< / com:Sub> alkenyl, <com:Math><semantics>C2−8<annotation encoding="application / x-tex">C_{2-8}< / annotation>< / semantics>< / com:Math> alkynyl, <com:Math><semantics>C1−8<annotation encoding="application / x-tex">C_{1-8}< / annotation>< / semantics>< / com:Math> heteroalkyl, <com:Math><semantics>C3−8<annotation encoding="application / x-tex">C_{3-8}< / annotation>< / semantics>< / com:Math> cycloalkyl, <com:Math><semantics>C1−8<annotation encoding="application / x-tex">C_{1-8}< / annotation>< / semantics>< / com:Math> haloalkyl, <com:Math><semantics>C1−8<annotation encoding="application / x-tex">C_{1-8}< / annotation>< / semantics>< / com:Math> alkoxy, <com:Math><semantics>C1−8<annotation encoding="application / x-tex">C_{1-8}< / annotation>< / semantics>< / com:Math> haloalkoxy, 4- to 12-membered heterocyclyl, <com:Math><semantics>C6−10<annotation encoding="application / x-tex">C_{6-10}< / annotation>< / semantics>< / com:Math> aryl, 5- to 12- membered heteroaryl, <com:Math><semantics>−N(R1d)2<annotation encoding="application / x-tex">-N(R^{1d})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(O)R1e<annotation encoding="application / x-tex">-C(O)R^{1e}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(O)OR1d<annotation encoding="application / x-tex">-C(O)OR^{1d}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(O)N(R1d)2<annotation encoding="application / x-tex">-C(O)N(R^{1d})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NR1dC(O)R1e<annotation encoding="application / x-tex">-NR^{1d}C(O)R^{1e}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NR1dC(O)N(R1d)2<annotation encoding="application / x-tex">-NR^{1d}C(O)N(R^{1d})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NR1dC(O)OR1d<annotation encoding="application / x-tex">-NR^{1d}C(O)OR^{1d}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−OC(O)N(R1d)2<annotation encoding="application / x-tex">-OC(O)N(R^{1d})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−OC(O)OR1d<annotation encoding="application / x-tex">-OC(O)OR^{1d}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−SR1d<annotation encoding="application / x-tex">-SR^{1d}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(O)R1e<annotation encoding="application / x-tex">-S(O)R^{1e}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(O)2R1e<annotation encoding="application / x-tex">-S(O)_2R^{1e}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(O)3R1d<annotation encoding="application / x-tex">-S(O)_3R^{1d}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(O)N(R1d)2<annotation encoding="application / x-tex">-S(O)N(R^{1d})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−S(O)2N(R1d)2<annotation encoding="application / x-tex">-S(O)_2N(R^{1d})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NR1dS(O)R1e<annotation encoding="application / x-tex">-NR^{1d}S(O)R^{1e}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NR1dS(O)2R1e<annotation encoding="application / x-tex">-NR^{1d}S(O)_2R^{1e}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−NR1dS(O)N(R1d)2<annotation encoding="application / x-tex">-NR^{1d}S(O)N(R^{1d})_2< / annotation>< / semantics>< / com:Math>, or -NR<com:Sup>1d< / com:Sup>S(O)<com:Sub>2< / com:Sub>N(R<com:Sup>1d< / com:Sup>)<com:Sub>2< / com:Sub>, wherein each of R<com:Sup>1a< / com:Sup>, R<com:Sup>1b< / com:Sup>, and R<com:Sup>1c< / com:Sup> is optionally and independently substituted with one to eight R<com:Sup>5< / com:Sup> and at least one of R<com:Sup>1a< / com:Sup>, R<com:Sup>1b< / com:Sup>, and R<com:Sup>1c< / com:Sup> is other than hydrogen; or R<com:Sup>1b< / com:Sup> and R<com:Sup>1c< / com:Sup> are optionally taken together to form C<com:Sub>3-10< / com:Sub> cycloalkyl or 4- to 12- membered heterocyclyl, each of which is optionally substituted with one to eight R<com:Sup>5< / com:Sup>; or R<com:Sup>1a< / com:Sup>, R<com:Sup>1b< / com:Sup>, and R<com:Sup>1c< / com:Sup> are optionally taken together to form C<com:Sub>5-10< / com:Sub> cycloalkyl or 5- to 12-membered heterocyclyl, each which is optionally substituted with one to eight R<com:Sup>5< / com:Sup>; each R<com:Sup>1d< / com:Sup> is independently hydrogen, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, C<com:Sub>3-10< / com:Sub> cycloalkyl, or 4- to 12-membered heterocyclyl, or two R<com:Sup>1d< / com:Sup> on the same atom are optionally taken together to form a 4- to 8- membered heterocyclyl optionally substituted by oxo, halo, or C<com:Sub>1-6< / com:Sub> alkyl, wherein said alkyl is optionally substituted with one to eight R<com:Sup>5< / com:Sup>; each R<com:Sup>1e< / com:Sup> is independently C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, C<com:Sub>3-10< / com:Sub> cycloalkyl, or 4- to 12-membered heterocyclyl; R<com:Sup>2a< / com:Sup> and R<com:Sup>2b< / com:Sup> are independently hydrogen, halogen, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, <com:Math><semantics>C2−8<annotation encoding="application / x-tex">C_{2-8}< / annotation>< / semantics>< / com:Math> alkenyl, or <com:Math><semantics>C2−8<annotation encoding="application / x-tex">C_{2-8}< / annotation>< / semantics>< / com:Math> alkynyl, or R<com:Sup>2a< / com:Sup> and R<com:Sup>2b< / com:Sup> are optionally taken together to form C<com:Sub>3-6< / com:Sub> cycloalkyl or 4- to 6-membered heterocyclyl, each of which is optionally substituted with one to eight R<com:Sup>6< / com:Sup>; R<com:Sup>3a< / com:Sup> and R<com:Sup>3b< / com:Sup> are independently hydrogen, halogen, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>2-8< / com:Sub> alkenyl, <com:Math><semantics>C2−8<annotation encoding="application / x-tex">C_{2-8}< / annotation>< / semantics>< / com:Math> alkynyl, <com:Math><semantics>C1−8<annotation encoding="application / x-tex">C_{1-8}< / annotation>< / semantics>< / com:Math> haloalkyl, <com:Math><semantics>C3−6<annotation encoding="application / x-tex">C_{3-6}< / annotation>< / semantics>< / com:Math> cycloalkyl, or 4- to 6-membered heterocyclyl, wherein said cycloalkyl and said heterocyclyl are optionally substituted with one to eight R<com:Sup>6< / com:Sup>, or R<com:Sup>3a< / com:Sup> and R<com:Sup>3b< / com:Sup> are optionally taken together to form oxo, C<com:Sub>3-6< / com:Sub> cycloalkyl, or 4- to 6-membered heterocyclyl, wherein said cycloalkyl and said heterocyclyl are optionally substituted with one to eight R<com:Sup>6< / com:Sup>; Y is O, C(O), S, S(O), S(O)<com:Sub>2< / com:Sub>, <com:Math><semantics>CR4aR4b<annotation encoding="application / x-tex">CR^{4a}R^{4b}< / annotation>< / semantics>< / com:Math>, or <com:Math><semantics>NR4c<annotation encoding="application / x-tex">NR^{4c}< / annotation>< / semantics>< / com:Math>; R<com:Sup>4a< / com:Sup> and R<com:Sup>4b< / com:Sup> are independently hydrogen, halogen, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>2-8< / com:Sub> alkenyl, C<com:Sub>2-8< / com:Sub> alkynyl, C<com:Sub>1-8< / com:Sub> haloalkyl, C<com:Sub>3-6< / com:Sub> cycloalkyl, or 4- to 6-membered heterocyclyl, wherein said cycloalkyl and said heterocyclyl are optionally substituted with one to eight R<com:Sup>6< / com:Sup>, or R<com:Sup>4a< / com:Sup> and R<com:Sup>4b< / com:Sup> are optionally taken together to form C<com:Sub>3-6< / com:Sub> cycloalkyl or 4- to 6-membered heterocyclyl, wherein said cycloalkyl and said heterocyclyl are optionally substituted with one to eight R<com:Sup>6< / com:Sup>, or R<com:Sup>4a< / com:Sup> and R<com:Sup>1b< / com:Sup> are optionally taken together to form 4- to 12-membered heterocyclyl, which is optionally substituted with one to eight R<com:Sup>6< / com:Sup>, or R<com:Sup>4a< / com:Sup> and R<com:Sup>3a< / com:Sup> are optionally taken together to form C<com:Sub>3-8< / com:Sub> cycloalkyl or 4- to 12-membered heterocyclyl, each of which is optionally substituted with one to eight R<com:Sup>6< / com:Sup>, or R<com:Sup>4c< / com:Sup> is hydrogen, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, C<com:Sub>3-10< / com:Sub> cycloalkyl, or 4- to 12-membered heterocyclyl; each R<com:Sup>5< / com:Sup> is independently halogen, -CN, -OH, -SF<com:Sub>5< / com:Sub>, -SCF<com:Sub>3< / com:Sub>, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>2-8< / com:Sub> alkenyl, <com:Math><semantics>C2−8<annotation encoding="application / x-tex">C_{2-8}< / annotation>< / semantics>< / com:Math> alkynyl, <com:Math><semantics>C1−8<annotation encoding="application / x-tex">C_{1-8}< / annotation>< / semantics>< / com:Math> haloalkyl, <com:Math><semantics>C1−8<annotation encoding="application / x-tex">C_{1-8}< / annotation>< / semantics>< / com:Math> heteroalkyl, <com:Math><semantics>C3−8<annotation encoding="application / x-tex">C_{3-8}< / annotation>< / semantics>< / com:Math> cycloalkyl, <com:Math><semantics>C1−8<annotation encoding="application / x-tex">C_{1-8}< / annotation>< / semantics>< / com:Math> haloalkyl, <com:Math><semantics>C1−8<annotation encoding="application / x-tex">C_{1-8}< / annotation>< / semantics>< / com:Math> alkoxy, <com:Math><semantics>C1−8<annotation encoding="application / x-tex">C_{1-8}< / annotation>< / semantics>< / com:Math> haloalkoxy, 4- to 12-membered heterocyclyl, <com:Math><semantics>C6−10<annotation encoding="application / x-tex">C_{6-10}< / annotation>< / semantics>< / com:Math> aryl, 5- to 12-membered heteroaryl, (4- to 12-membered heterocyclyl)(<com:Math><semantics>C1−8<annotation encoding="application / x-tex">C_{1-8}< / annotation>< / semantics>< / com:Math> heteroalkyl), (<com:Math><semantics>C6−10<annotation encoding="application / x-tex">C_{6-10}< / annotation>< / semantics>< / com:Math> aryl)(<com:Math><semantics>C1−8<annotation encoding="application / x-tex">C_{1-8}< / annotation>< / semantics>< / com:Math> heteroalkyl), (5- to 12- membered heteroaryl)(C<com:Sub>1-8< / com:Sub> heteroalkyl), -N(R<com:Sup>5a< / com:Sup>)<com:Sub>2< / com:Sub>, -C(O)R<com:Sup>5b< / com:Sup>, -C(O)OR<com:Sup>5a< / com:Sup>, [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] substituted with one to eight R<com:Sup>5c< / com:Sup>, or two R<com:Sup>5< / com:Sup> are optionally taken together to form oxo; each R<com:Sup>5a< / com:Sup> is independently hydrogen, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, C<com:Sub>3-10< / com:Sub> cycloalkyl, or 4- to 12-membered heterocyclyl, and each R<com:Sup>5b< / com:Sup> is independently C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, C<com:Sub>3-10< / com:Sub> cycloalkyl, 4- to 12-membered heterocyclyl, or 5- to 12-membered heteroaryl; each R<com:Sup>5c< / com:Sup> is independently halogen, cyano, C<com:Sub>1-8< / com:Sub> haloalkyl, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>1-8< / com:Sub> alkoxy, [Image disponible dans le document PDF, Image available in the PDF document] <com:Math><semantics>N(R5d)2(C1−8 alkoxy),C3−10 cycloalkyl, and 4- to 12-membered heterocyclyl,<annotation encoding="application / x-tex">N(R^{5d})_2(C_{1-8} \text{ alkoxy}), C_{3-10} \text{ cycloalkyl, and 4- to 12-membered heterocyclyl,}< / annotation>< / semantics>< / com:Math> or two R<com:Sup>5c< / com:Sup> are optionally taken together to form oxo; each R<com:Sup>5d< / com:Sup> is independently hydrogen, C<com:Sub>1-8< / com:Sub> alkyl, or C<com:Sub>1-8< / com:Sub> haloalkyl; each R<com:Sup>6< / com:Sup> is halogen, -CN, -OH, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>1-8< / com:Sub> heteroalkyl, C<com:Sub>3-8< / com:Sub> cycloalkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, C<com:Sub>1-8< / com:Sub> alkoxy, 4- to 12-membered heterocyclyl, C<com:Sub>6-10< / com:Sub> aryl, 5- to 12-membered heteroaryl, <com:Math><semantics>−N(R6a)2<annotation encoding="application / x-tex">-N(R^{6a})_2< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(O)R6b<annotation encoding="application / x-tex">-C(O)R^{6b}< / annotation>< / semantics>< / com:Math>, <com:Math><semantics>−C(O)N(R6a)2<annotation encoding="application / x-tex">-C(O)N(R^{6a})_2< / annotation>< / semantics>< / com:Math>, or [Image disponible dans le document PDF, Image available in the PDF document] two R<com:Sup>6< / com:Sup> are taken together to form oxo; each R<com:Sup>6a< / com:Sup> is independently hydrogen, C<com:Sub>1-8< / com:Sub> alkyl, or C<com:Sub>1-8< / com:Sub> haloalkyl, or two R<com:Sup>6a< / com:Sup> on the same atom are optionally taken together to form 4- to 6-membered heterocyclyl; each R<com:Sup>6b< / com:Sup> is independently C<com:Sub>1-8< / com:Sub> alkyl or C<com:Sub>1-8< / com:Sub> haloalkyl; each R<com:Sup>7< / com:Sup> is independently hydrogen, halogen, -CN, -N<com:Sub>3< / com:Sub>, -NO<com:Sub>2< / com:Sub>, -SF<com:Sub>5< / com:Sub>, -SCF<com:Sub>3< / com:Sub>, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>2-8< / com:Sub> alkenyl, C<com:Sub>2-8< / com:Sub> alkynyl, C<com:Sub>1-8< / com:Sub> heteroalkyl, C<com:Sub>3-8< / com:Sub> cycloalkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, 4- to 12-membered heterocyclyl, C<com:Sub>6-10< / com:Sub> aryl, 5- to 12-membered [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] [Image disponible dans le document PDF, Image available in the PDF document] substituted with one to eight R<com:Sup>8< / com:Sup>; each R<com:Sup>7a< / com:Sup> is independently hydrogen, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, C<com:Sub>3-10< / com:Sub> cycloalkyl, or [Image disponible dans le document PDF, Image available in the PDF document] two R<com:Sup>7a< / com:Sup> on the same atom are optionally taken together to form a 4- to 8- membered heterocyclyl optionally substituted by oxo, halo, or C<com:Sub>1-6< / com:Sub> alkyl, wherein said alkyl is optionally substituted with one to eight R<com:Sup>8< / com:Sup>; each R<com:Sup>7b< / com:Sup> is independently C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>1-8< / com:Sub> haloalkyl, C<com:Sub>3-10< / com:Sub> cycloalkyl, or 4- to 12-membered heterocyclyl; each R<com:Sup>8< / com:Sup> is halogen, -CN, -OH, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>2-8< / com:Sub> alkenyl, C<com:Sub>2-8< / com:Sub> alkynyl, [Image disponible dans le document PDF, Image available in the PDF document] 4- to 12-membered heterocyclyl, C<com:Sub>6-10< / com:Sub> aryl, 5- to 12-membered [Image disponible dans le document PDF, Image available in the PDF document] two R<com:Sup>8< / com:Sup> are optionally taken together to form oxo; each R<com:Sup>8a< / com:Sup> is independently hydrogen, C<com:Sub>1-8< / com:Sub> alkyl, or C<com:Sub>1-8< / com:Sub> haloalkyl; each R<com:Sup>8b< / com:Sup> is independently C<com:Sub>1-8< / com:Sub> alkyl or C<com:Sub>1-8< / com:Sub> haloalkyl; [Image disponible dans le document PDF, Image available in the PDF document] each R<com:Sup>9< / com:Sup> is independently hydrogen, C<com:Sub>1-8< / com:Sub> alkyl, C<com:Sub>2-8< / com:Sub> alkenyl, C<com:Sub>2-8< / com:Sub> alkynyl, C<com:Sub>1-8< / com:Sub> haloalkyl, C<com:Sub>3-8< / com:Sub> cycloalkyl, 4- to 8-membered heterocyclyl, or – <com:Math><semantics>C(O)R9a<annotation encoding="application / x-tex">C(O)R^{9a}< / annotation>< / semantics>< / com:Math>; and <com:Math><semantics>R9a<annotation encoding="application / x-tex">R^{9a}< / annotation>< / semantics>< / com:Math> is <com:Math><semantics>C1−8<annotation encoding="application / x-tex">C_{1-8}< / annotation>< / semantics>< / com:Math> alkyl, <com:Math><semantics>C1−8<annotation encoding="application / x-tex">C_{1-8}< / annotation>< / semantics>< / com:Math> haloalkyl, <com:Math><semantics>C3−8<annotation encoding="application / x-tex">C_{3-8}< / annotation>< / semantics>< / com:Math> cycloalkyl, or 4- to 12-membered heterocyclyl, or R<com:Sup>9< / com:Sup> and R<com:Sup>3a< / com:Sup> are optionally taken together to form C<com:Sub>3-8< / com:Sub> cycloalkyl or 4- to 12-membered heterocyclyl, each of which is optionally substituted with one to eight R<com:Sup>6< / com:Sup>.
50. Use of a compound according to any one of claims 1-46, or a pharmaceutically acceptable salt, solvate, isotopic analog, or stereoisomer thereof, for inhibiting receptor- interacting protein kinase 1 in a subject in need thereof.
51. Use of a compound according to any one of claims 1-46, or a pharmaceutically acceptable salt, solvate, isotopic analog, or steroisomer thereof, for treating a receptor- interacting protein kinase 1-mediated disease or disorder in a subject in need thereof.
52. The use of claim 51, wherein the receptor-interacting protein kinase 1-mediated disease or disorder is chosen from necrotizing enterocolitis, tuberous sclerosis, Tangier's Disease, Wohlman's Syndrome, inflammatory bowel disease, Crohn's disease, ulcerative colitis, psoriasis, retinal detachment, retinitis pigmentosa, macular degeneration, pancreatitis, acute pancreatitis, atopic dermatitis, rheumatoid arthritis, psoriatic arthritis, spondyloarthritis, gout, SoJIA, systemic lupus erythematosus, Sjogren's syndrome, systemic scleroderma, anti- phospholipid syndrome, vasculitis, osteoarthritis, non-alcohol steatohepatitis, alcohol steatohepatitis, autoimmune hepatitis autoimmune hepatobiliary diseases, primary sclerosing cholangitis, nephritis, Celiac disease, autoimmune ITP, transplant rejection, ischemia, ischemia reperfusion injury of solid organs, cerebral ischemia, sepsis, systemic inflammatory response syndrome, cerebrovascular accident, myocardial infarction, Huntington's disease, Alzheimer's disease, Parkinson's disease, allergic diseases, asthma, atopic dermatitis, multiple sclerosis, type I diabetes, Wegener's granulomatosis, pulmonary sarcoidosis, Behçet's disease, interleukin-1 converting enzyme associated fever syndrome, chronic obstructive pulmonary disease, tumor necrosis factor receptor-associated periodic syndrome, periodontitis, infection, bacterial infection, staphylococcus infection, mycobacterium infection, influenza, transplant rejection, burns, hypoxia, trauma, stroke, cardiac infarction, lysosomal storage disease, Niemann-Pick disease, Gaucher's disease, Krabbe disease, amyotrophic lateral sclerosis, ALS, Lou Gehrig's Disease, HIV-associated dementia, encephalopathy, retinal degenerative disease, glaucoma, age-related macular degeneration, Friedreich's ataxia, Lewy body disease, diabetic neuropathy, polyglutamine diseases, polyQ diseases, Fahr disease, Menke's disease, Wilson's disease, a prion disorder, atherosclerosis, Guillain-Barre syndrome, chronic inflammatory demyelinating polyneuropathy, major depressive disorder, bipolar disorder, delirium, post- operative cognitive impairment, autism, schizophrenia, and hidradenitis suppurativa.
